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INTRODUCTION 
Cancer is a devastating malignancy and it is one of the principal causes of death in the World 
affecting 8.2 million people in 2012 (WHO data). Currently tumors are the second leading cause of 
death in industrialized countries, preceded only by cardiovascular diseases. Surgical excision, 
radiation therapy and cancer chemotherapy are the three main therapeutic approaches on which it is 
based anticancer therapy. Although for some types of tumor surgery and radiotherapy are the 
elective therapeutic choice, chemotherapy is increasingly used. 
The ability to treat tumors with a chemotherapy drug approach goes back to the first half of the 
twentieth century, when it was discovered the cytotoxic effect of nitrogen mustards on 
hematopoietic cells. Since the continuous search for new molecules with antineoplastic action, the 
better understanding of their molecular mechanisms, resulted in continuous improvements in the 
prognosis and quality of life of cancer patients. 
But the heterogeneity and complexity of neoplastic diseases are a limit to the efficacy of classical 
chemotherapy, based on the effect cytostatic / cytotoxic of the drugs, basically due to mechanisms 
that interfere with DNA synthesis, required for the proliferation. 
The occurrence of serious side effects common to most “Classic” antineoplastic drugs is due to the 
mechanism of action. They are cytotoxic against not only the malignant cells, but also against all 
those in active proliferation; in some cases the cytotoxic action depends on the phase of the cell 
cycle in which the cell is located (cycle specific drugs) while in others it is entirely independent (not 
cycle specific drugs). In the first case, the antineoplastic effect will be influenced by the interval of 
exposure of tumor cells to the drug and the route of administration chosen will be the continuous 
infusion. In the second case, the antineoplastic effect will be due to the maximum reachable 
concentration and the drug administration will preferably be in bolus. 
Furthermore, the neoplastic cells may be more or less sensitive to anticancer agents, but above all 
they can develop resistance that in some cases affect the clinical outcome of therapy. 
Notwithstanding the difficulties mentioned, cancer chemotherapy continues to progress and to 
induce encouraging clinical results: the better understanding of the mechanisms of action, the 
pharmacokinetic studies and the identification of analogues of classical chemotherapy less toxic, 
have allowed an improvement of prognosis of patients with cancer. For these reasons the search for 
new anticancer drugs is one of the main objectives of scientific research [1]. 
Anticancer drugs can be generally divided in (Fig.1) [1]:  
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 Alkylating agents: (nitrosoureas, nitrogen mustards, alkyl sulfonate, ethylenimine, triazenes) 
they act via a reactive alkyl group that form covalent bonds with nucleic acids. There 
follows cross-linkings of the two strands of DNA, preventing replication or DNA breakage.  
 Platinum coordination complexes: (cisplatin, carboplatin, oxaliplatin) they act through the 
cross linking of DNA molecules. The DNA adducts formed by the platinum-containing 
complexes inhibit DNA replication and lead to strand breaks, causing apoptosis, inhibition 
of RNA and protein synthesis. 
 Antimetabolites: (antifolates, purine and pyrimidine analogues) molecules, similar to the 
nucleotides, that interfere with one or more enzymes or their reactions that are necessary for 
DNA synthesis. They affect DNA synthesis by acting as a substitute to the actual 
metabolites that would be used in the normal metabolic pathway causing alterations or 
block. 
 Microtubule damaging agents: (vincristine, vinblastine, paclitaxel, docetaxel) molecules that 
interfere with microtubule functions. They prevent the proper functioning of the mitotic 
spindle resulting in a non-cell division and subsequent apoptosis. 
 Topoisomerase inhibitors: agents designed to interfere with the action 
of  topoisomerase enzymes  (topoisomerase I and II), which are involved in the changes in 
DNA structure by catalyzing the breaking and rejoining of the phosphodiester backbone of 
DNA strands during replication and transcriptase. Topoisomerase inhibitors are divided 
according to which type of enzyme is inhibited: topoisomerase I inhibitors such as 
irinotecan and topotecan; topoisomerase II inhibitors such as etoposide. 
 Antibiotics: (antracicyclines, mitomycin) their activity is related to DNA intercalation, 
blocking synthesis of DNA and RNA, alteration of membrane fluidity and ion transport, 
semiquinone free radical an oxygen radical generation. 
 Proteasome inhibitors: (bortezomib) they block the chymotrypsin-like activity of 26S, 
cellular complexes that break down proteins. The inhibition of proteasome alters the 
homeostatic mechanism of the cellular protein catabolism, resulting in cell death. 
 Unarmed monoclonal antibody: (tastuzumab, rituximab) they bind only to cancer cell-
specific antigens and induce an immunological response against the target cancer cell. Some 
monoclonal antibody can be used for the delivery of a toxin or radioisotopes. Monoclonal 
antibody therapy can be used only for type of tumors in which antigens (and the respective 
antibodies) have been recognized. 
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 Tyrosine protein-kinase inhibitors: (imatinib, gefitinib) they are a class of chemotherapeutic 
agents that inhibit or block the enzyme tyrosine kinase. This is can be done in two different 
ways: competitive ATP inhibition at the catalytic binding site of tyrosine kinase, preventing 
the autophosphorylation of tyrosine residues; occupation of the extracellular site of the 
ligand with a monoclonal antibody, preventing the activation of the receptor. 
 Hormonal drugs: they are used for some kind of cancers that are hormone sensitive or 
hormone dependent and need hormones to grow or develop. Cancers that can be hormone 
sensitive are breast, prostate, ovarian and endometrial cancer. 
. 
 
Figure 1. Anticancer drug classification. 
One of the rarest forms of cancer is mesothelioma (or malignant mesothelioma) a tumor type that 
develops from cells of the mesothelium. About 43.000 people worldwide die from this cancer every 
year.  
The mesothelium is a thin layer that covers and lines several internal organs of the body. This 
membrane protects them thanks to the production of a particular liquid lubricant that facilitates the 
movements. The mesothelium has different names depending on the different localization: in the 
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chest is called pleura, in the abdominal cavity is called peritoneum and it is called pericardium in 
the heart sac.  
Mesothelioma is an extremely aggressive primary neoplasia of the serosal lining of the pleura, 
peritoneum, pericardium or tunica vaginalis [2]. It is a slow-growing solid tumor and it is classified 
into three classes in relation to its histological morphology: epithelial, biphasic and sarcomatoid. [3] 
There are four types of mesothelioma, each named for the area of the body where the cancer forms. 
There are pleural (lungs), peritoneal (abdomen), pericardial (heart) and testicular mesothelioma 
(Fig.2). Pleural and peritoneal are the most common types, comprising nearly 90 percent of all 
diagnoses.  
 
Figure 2. Types of mesothelioma.  
Pleural mesothelioma, is an aggressive type of cancer that develops in the lining of the lungs and it 
is often diagnosed at a very advanced stage. Peritoneal mesothelioma develops in the peritoneum, 
the membrane that lines the abdominal cavity and it is the second-most predominant type (Fig.3).  
 
Figure 3. Peritoneal mesothelioma. 
 Pleural Mesothelioma 75% 
 Testicular Mesothelioma < 1% 
 Pericardial Mesothelioma 1% 
 Peritoneal Mesothelioma 10-20% 
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The rarest types of the cancer are pericardial and testicular mesothelioma. Pericardial mesothelioma 
develops in the lining of the heart, while testicular mesothelioma starts in the lining of the testicles.  
Several papers showed a strong relationship between a prolonged exposure to asbestos (usually in 
the workplace), erionite, simian virus 40 (SV40), several genes (p16
INK4a
, p14
ARF
, NF2, LATS2, 
SAV, CTNNB1) and the development of mesothelioma [3].  
Diffuse Malignant Peritoneal Mesothelioma (DMPM) is a rare, aggressive and lethal form of 
mesothelioma that was first recognized and described a century ago. It is a diffuse primary 
malignant condition arising from mesothelial cells that line the peritoneal cavity and accounts for 
approximately 10-30 % of all forms of malignant mesothelioma [4]. It is characterized by a difficult 
diagnosis, different presentations and variable course. In spite of different therapeutic approaches, 
such as palliative surgery, systemic or intra-peritoneal chemotherapy [5], DMPM has a poor 
prognosis with a median overall survival that usually does not go beyond 1 year. The failure of 
conventional therapies towards the neoplastic cells has motivated the exploration of alternative 
therapeutic protocols. 
Prognosis depends on clinical presentation, the completeness of cytoreduction and gender (female 
patients survive longer than male patients). The practice of intraperitoneal chemotherapy may 
improve the life expectancy of the patients. In recent years, treatment of these patients was similar 
to that of patients with ovarian cancer and now includes cytoreductive surgery, heated 
intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin, and early postoperative 
intraperitoneal paclitaxel. Adjuvant intraperitoneal paclitaxel and second-look cytoreduction follow 
these perioperative treatments. This combined treatment approach with debulking surgery and 
intraperitoneal chemotherapy has resulted in a median survival of 50 to 60 months [6]. 
 In selected series, the introduction of an innovative strategy combining aggressive cytoreductive 
surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin or 
mitomycin C has improved median survival up to 40-92 months [7, 8, 9].  
The median survival was improved between 8.7 and 26.7 months in patients that have received 
systemic pemetrexed with platinum compounds or gemcitabine [10, 11].  
Recent studies on the molecular biology of DMPM have revealed new understandings about the 
potentially important role of the phosphatidylinositol 3-kinase/mammalian target of rapamycin and 
epidermal growth factor receptor pathways in this type of cancer, which can evolve into new 
therapeutic opportunities for patients with DMPM [9].  
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For patients who do not respond to treatment, lack of therapeutic options leads to a poor prognosis 
[11]. Furthermore, not much is known about the pathogenesis of this disease. These considerations 
have moved the exploration of novel effective therapeutic strategies which are able to halt the 
disease progression.  
 
In recent years, attention has been paid to the discovery of new bioactive compounds based on 
natural products scaffolds as possible novel cancer therapeutic agents. The application of natural 
compounds is having particular success mainly due to biotechnological advances and novel 
approaches such as high-throughput screening and combinatorial synthesis, although the clinical use 
of natural compounds was known, as reported in the medical scripts since ancient Egypt [12]. This 
is due to the wide diversity of structural features of the natural compounds and their potent panel of 
biological properties.  
There are many organisms in the ocean that produce a huge variety of compounds to help them 
survive extreme conditions of temperature and pressure and to defend them against predators. 
Several screenings were carried out for the identification of numerous of anti-cancer alkaloids from 
cyanobacteria, fungi, sponges, algae and tunicates [13].  
However, the limited number of drugs that have reached clinical trials or employed in clinical use is 
due to the considerable difficulties that occur in the development of drugs from marine sources. 
Nevertheless these difficulties, the two alkaloids aplidin 1 and trabectedin 2 have reached phase II 
clinical trials for the cure of many solid and hematologic tumors [12, 13].  
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Marine organisms are an exceptional source of compounds and metabolites having useful biological 
activities, such as antimicrobial, anti-inflammatory, antimalarial, antioxidant, anti-HIV and 
anticancer activity and they can be considered as potential new drug suitable for the treatment of 
human diseases (Fig.4) [14].  
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Figure 4. Marine drugs biological activities.  
 
Marine alkaloids include pyridoacridine, indole, pyrrole, pyridine, isoquinoline, guanidine, 
macrocyclic and steroidal alkaloids [15].  
Dibromophakellstatin 3, a tetracyclic pyrrole-imidazole alkaloid isolated from the marine sponge 
Phakellia mauritiana, displayed inhibitory activity against a panel of human cancer cell lines: ovary 
(OVCAR-3), brain (SF-295), kidney (A-498), lung (H-460), colon (KM20L2) and melanoma (SK-
MEL-5) with ED50 values of 0.46, 1.5, 0.21, 0.62, 0.11 and 0.11 μg/mL, respectively [16]. 
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Jorumycin 4, isoquinoline alkaloid, was isolated from the mantle and the mucus of the pacific 
nudibranch Jorunna funebris and was active against NIH 3T3 tumor cells (100% of inhibition at 50 
ng/mL) and also revealed cytotoxic activity against P388, A-549, HT-29 and MEL-28 cells with 
GI50 value of 12.5 μg/mL each [17].  
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Motuporamines A-C 5-7, macrocyclic alkaloids isolated from the marine sponge Xestospongia 
exigua, showed anti-invasive and anti-angiogenic activity because repressed in vitro invasion of 
basement membranes by many tumor cells such as MDA-231 breast carcinoma and PC-3 prostate 
carcinoma cells [12].   
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Hytriocarboline 8, 1-imidazoyl-3-carboxy-6-hydroxy-β-carboline alkaloid, isolated from a marine 
sponge Hyrtios reticulates, exhibited selective activity against non-small cell lung (H522-T1), 
melanoma (MDA-MB-435) and lymphoma (U937) with GI50 values of 1.2, 3.0 and 1.5 μg/mL, 
respectively. It also causes 57% inhibition of HeLa cells at 230 μM [18].  
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In particular, marine bisindole alkaloids, consisting of 2 indole units connected to each other, 
through their 3 position, by a spacer such as carbocycles, heterocycles differently sized or linear 
10 
 
chains, have received considerable attention because of their broad spectrum of biological activities 
as antitumor, antiviral, antimicrobial and anti-inflammatory agent. 
Asterriquinone 9, characterized by a quinone moiety, is an antitumor metabolite isolated from 
Aspergillus terreus IFO 6123, and showed an inhibitory affect against Ehrlich carcinoma, ascites 
hepatoma AH13 and mouse P-338 leukemia [19, 20].  
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9  
 
Topsentin 10 and bromotopsentin 11, isolated from the Mediterranean sponge Topsentia genitrix, 
containing 2-acyl imidazole moiety between two indole units, showed antitumor properties. 
Topsentin 10 showed antiproliferative activity against cultured human and murine tumor cells. It 
presented in vitro activity against P388 with GI50 value of 3 μg/mL, human tumor cell (HCT-8, A-
549, T47D) with GI50 value of 20 μg/mL and in vivo activity against P388 and B16 melanoma. 
Bromotopsentin 11 showed anti-proliferative activity against human non small cell 
bronchopulmonary carcinoma cells (NSCLC-N6) with GI50 value of 12 μg/mL [15]. 
 
N
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10 Topsentin  R1= R2 = H,  R3 = OH
11  Bromotopsentin  R1 = Br, R2 = H,  R3 = OH
R2
 
Dragmacidins, isolated from deep-water sponges, including Dragmacidon, Halicortex, Spongsorites 
and Hexadela, are composed by different spacers and different related properties. Dragmacidin 12, 
dragmacidins A-C 13-15, having a saturated six-membered heterocyclic link piperazine, showed 
modest antifungal, antiviral and cytotoxic activity.  
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12 Dragmacidin   R = H, R1 = Me, R2 = Br, R3 = OH
13 Dragmacidin A R = R2 = R3 = H, R1 = Me
14 Dragmacidin B R = R1 = Me, R2 = R3 = H
15 Dragmacidin C R = R1 = R2 = R3 = H  
Dragmacidin D 16, structurally composed by a pyrazinone moiety, showed a potent inhibition 
against protein phosphates, in particular against protein phosphatase 1 (PP1) and was a selective 
inhibitor of neural oxide synthase (nNOS), which is involved in neurodegegenerative diseases [21]. 
It was found to be active against human lung tumor cell lines and inhibited in vitro growth of the P-
388 murine and A-549 with GI50 values of 1.4 and 4.5 g/ml, respectively [15]. 
N
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Dragmacidin D
16  
Nortopsentins A-C 17-19, group of bisindole alkaloids having a characteristic five membered ring 
as spacer, the imidazole, were first isolated by Howard from Spongosorites ruetzleri and 
Halichondria. The subsequent catalytic hydrogenation of nortopsentine A-C 17-19 led to 
nortopsentin D 20, while the methylation of nortopsentine B 18 with dimethyl sulfate in the 
presence of potassium carbonate in acetone afforded trimethyl and tetramethyl nortopsentins B 21-
22, as MeSO4
- 
salt. Nortopsentin A-C exhibited in vitro cytotoxicity against P388 leukemia cells 
with GI50 of 7.6, 7.8, 1.7, g/ml, respectively. They also showed antifungal activity against Candida 
albicans (MIC 3.1, 6.2, 12.5 g/ml). The N-methylated derivatives of nortopsentin B 21-22 showed 
in vitro a significant improvement in the citotoxycity against P-388 cells to that of the parent 
compound (0.9 and 0.34 g/ml) [22, 23, 24].  
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Due to the considerable biological activities shown and its low availability, nortopsentin has 
become an attractive field in medicinal chemistry.  
Between the several analogues reported in the literature, significant is the cytotoxic activity shown 
by 2,4-bis(3-indolyl)thiazoles 23-26, analogues of nortopsentins in which the imidazole central ring 
of the natural compound was replaced by a thiazole one. 
These compounds 23-26 showed cytotoxic activity against a wide number of human cancer cell 
lines, as shown in table 1 [23].  
 
S
N
N N
H H
R2 R1
23 R1= R2 = H
24 R1 = H, R2 = Br
25 R1 = Br, R2= H
26 R1 = R2 =Br  
Considering these interesting results, the authors have synthesized new derivatives with a bis-
indolyl-thiazole structure, modifying the substituents on the indole portion in order to increase the 
cytotoxic activity [24].  
S
N
N N
R2 R2
R R1
23     H       H       H
24     H     6-Br     H
25   6-Br    H        H
26   6-Br  6-Br     H
27      H     5-Br    H
28     5-Br       5-Br         H
29     6-Br      6-OMe      H
30     6-Br       5-Br         H
31     6-OMe   6-Br         H
32     5-Br       6-Br         H
33       H           H          Me
R      R1     R2 R           R1         R2
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Table 1. Cancer cell growth inhibitory activity of compounds 23-33 in vitro. 
Cell Line Cytotoxicity (GI50 in μM) 
 23 24 25 26 27 28 29 30 31 32 33 
Leukemia            
CCRF-CEM ND 14.6 10.9 10.1 2.11 2.40 27.7 2.58 2.66 2.99 >100 
HL-60(TB) ND ND ND 0.95 2.43 2.76 ND 3.76 4.13 3.86 >100 
K-562 3.27 18.8 5.61 4.69 1.96 1.94 15.2 2.13 1.74 2.25 11.2 
MOLT-4 5.31 19.9 31.2 5.80 1.41 1.75 23.0 1.55 2.95 2.26 14.1 
RPMI82226 ND 19.4 12.2 11.4 1.97 1.95 27.1 2.24 2.03 1.84 20.8 
Non-small cell 
lung cancer 
           
NCI-226 >100 14.4 24.4 3.3 2.10 3.14 45.4 2.48 2.24 7.23 32.2 
NCIH322M >100 16.7 18.9 18.4 2.01 1.99 70.8 2.51 3.09 2.99 24.5 
NCI-H460 >100 16.1 7.31 16.4 2.55 1.93 23.2 2.31 1.58 2.00 26.5 
EKVX >100 15.6 29.5 28.6 ND ND 32.1 0.48 0.29 0.55 ND 
Colon cancer            
HCT-15 >100 15.2 17.8 8.50 1.81 2.51 7.54 2.70 0.81 2.84 >100 
SW-620 >100 16.5 25.6 12.5 1.52 2.14 7.00 3.57 5.50 2.89 59.4 
CNS cancer            
SF-295 33.6 14.6 9.23 4.81 1.98 2.71 73.5 4.56 ND ND 23.5 
SF-268 ND 18.3 32.1 ND 1.52 2.44 26.0 2.69 13.8 1.80 58.2 
SNB-19 >100 17.8 41.8 17.2 2.11 3.75 >100 2.60 10.5 3.34 42.6 
U21 >100 17.9 28.1 15.3 2.10 2.30 25.0 3.34 5.07 3.00 32.4 
Ovarian cancer            
IGROV1 8.14 13.0 30.5 14.4 1.85 1.70 81.5 2.96 4.61 2.43 27.0 
OVCAR-5 >100 16.1 37.1 23.6 1.96 2.14 42.7 2.16 3.44 2.35 95.9 
Renal cancer            
786-0 >100 18.0 19.9 15.9 2.28 1.95 27.4 1.50 3.89 2.21 17.2 
A498 >100 17.0 25.7 23.2 1.92 2.48 89.4 2.19 7.43 2.40 12.6 
RXF 393 ND 22.4 7.62 18.4 1.81 1.69 11.9 2.42 2.03 1.66 14.1 
Prostate cancer            
PC-3 >100 15.6 16.9 15.3 2.02 2.57 10.4 4.16 3.49 2.81 21.9 
DU-145 >100 18.8 14.9 18.4 2.29 2.61 >100 3.74 5.46 2.03 42.9 
Breast cancer            
MCF7 >100 16.7 27.2 6.46 2.13 2.70 54.1 0.88 4.36 3.82 45.5 
MDAMB435 33.1 14.9 25.6 4.34 2.53 2.27 7.70 4.54 14.6 3.97 26.4 
MDA-N 83.0 19.2 31.5 2.94 1.88 2.09 8.27 2.86 6.84 3.77 24.9 
T-47D >100 24.8 23.9 16.2 3.27 2.90 59.3 3.33 4.12 1.76 28.1 
BT-549 >100 18.3 73.8 41.1 2.71 10.6 67.3 1.24 1.46 1.41 56.3 
Melanoma            
LOX IWVI 21.8 15.5 6.55 11.3 1.97 1.69 64.1 2.32 2.41 1.87 36.4 
MALME3M >100 16.9 >100 ND 1.28 1.72 1.72 1.45 1.50 2.83 19.0 
M14 >100 14.2 32.4 10.6 1.61 1.63 >100 2.86 5.49 2.77 26.7 
SKMEL2 >100 ND 37.5 68.8 1.81 1.98 19.1 3.25 7.30 2.91 38.8 
SKMEL28 >100 14.2 7.74 32.0 3.02 3.05 >100 9.84 1.36 4.96 61.5 
SKMEL5 ND 14.9 23.7 28.5 1.76 1.63 >100 2.82 5.13 3.36 26.9 
ND= not determined 
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The synthetized compounds were evalueted for citotoxicity in the National Cancer Institute (NCI, 
Bethesda MD) against approximately a panel of 60 human tumor cell lines (Tab. 2). All 
compounds, with the exception of compound 23, showed citotoxic activity in a wide range of 
human tumor cell lines. The position of bromine in the indole ring plays an important role for the 
cytotoxicity. Compounds 27, 28, with a bromine atom in position 5, exhibited an increased activity 
than derivatives 24, 25, with a bromine atom in position 6. Compounds dibrominated at 5’,6’ (30) 
and 5’,6’ (32) position showed a greater anti-proliferative activity than 6-6’dibrominated derivative 
26. The introduction of a methyl group in the indole moiety lead to 2,4-bis-(N-
methylindolyl)thiazole 33 in which we can observe a decrease of the activity against the most active 
cell lines.  
In the research lab where I carried out my PhD thesis, different analogues of nortopsentin has been 
synthesized, in which the imidazole ring of the natural compound was replaced by other five-
membered heterocycles, such as thiophene 34 [25], pyrazole 35 [26], furan 36 [27], isoxazole 37 
[27], and pyrrole 38 [28]. Some of them showed remarkable antiproliferative activity in cancer 
cells, often with IC50 values at submicromolar level.  
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Furthermore, considering the interesting antitumor activity of 2,4-bis(3’-indolil)thiazole reported in 
literature, different analogues of nortopsentin in which the heterocyclic core of the system is 
constituted by a thiazole ring have been synthesized.   
In particular 3-(2-phenyl-1,3-thiazol-4-yl)-1H-indoles 39, 3-(2-phenyl-1,3-thiazol-4-yl)-1H-7-
azaindoles 40 and 3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl)-1H-4-azaindoles 41  have been reported.   
Derivatives 39, in which one indole ring has been substituted by a phenol one, tested at a single 
concentration (10
-5
M), did not exhibited considerable anti-proliferative activity [29].  
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39
 
 
Instead 3-(2-phenyl-1,3-thiazol-4-yl)-1H-7-azaindoles 40, in which the indole ring of the 
derivatives 39 has been substituted with a 7-azaindole one, showed anti-proliferative activity 
against a wide range of human tumor cell lines with GI50 values from micromolar to nanomolar 
concentrations. They were also able to inhibit the activity of cyclin-dependent kinase I (CDK1) with 
GI50 values less than 1 M [29].  
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S
N
N
N
R3
  3-(2-phenyl-1,3-thiazol-4-yl)-1H-7-azaindoles
R
R1
R2
R = H, Cl, F
R1 = H, Me, F
R2 = H, Me, OMe, Cl, Br, F
R3 = H, Me
40
 
Further studies led to the synthesis of 3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl)-1H-4-azaindoles 41 in 
which the indole ring of the 2,4-bis(3-indolyl)thiazole derivatives, reported in literature, has been 
substituted with a 4-azaindole one. Some of them reduced the growth of four cell lines with 
different histologic origin (breast cancer MDA-MB-231, pancreatic carcinoma Mia PaCa-2, 
androgen-independent prostate cancer PC3, diffuse malignant peritoneal mesothelioma STO) with 
GI50 values of 4.1-49.1 M. Studies to understand the mechanism of action revealed that they acted 
as CDK1 inhibitor (GI50 value of 0.64-0.87 M) causing a cell cycle arrest at G2/M phase [30].  
 
S
N
N N
N
R R3
R1 R2
3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl)-1H-4-azaindoles
41
R = H, Me, OMe, Cl, Br, F
R1 = H, Me, Boc
R2 = H, Me
R3 = H, OMe  
 
Thereafter the attention was focused on the synthesis of indolyl-7-azaindolyl thiazoles 42a-n, 43a-j, 
44a-j in which 4-azaindole ring has been replaced by a 7-azaindole one (Tab.2) [31].  
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S
N
N
N
R2
N
R
R1
42a-n
43a-j
44a-j
3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl)-1H-7aza-indoles
 
 
Table 2. 3-[2-(1H-Indol-3-yl)-1,3-thiazol-4-yl)-1H-7-azaindoles 42a-n, 43a-j, 44a-j. 
Compd R R1 R2 Yield% Compd R R1 R2 Yield 
42a H Me H 85 43d Cl Boc H 90 
42b Me Me H 70 43e Br Boc H 80 
42c OMe Me H 90 43f H Boc Me 92 
42d Cl Me H 78 43g Me Boc Me 53 
42e Br Me H 60 43h OMe Boc Me 90 
42f F Me H 95 43i Cl Boc Me 90 
42g H Me Me 75 43j Br Boc Me 72 
42h Me Me Me 60 44a H H H 99 
42i OMe Me Me 85 44b Me H H 95 
42j Cl Me Me 57 44c OMe H H 99 
42k Br Me Me 55 44d Cl H H 99 
42l F Me Me 91 44e Br H H 54 
42m F H H 87 44f H H Me 71 
42n F H Me 60 44g Me H Me 99 
43a H Boc H 85 44h OMe H Me 90 
43b Me Boc H 60 44i Cl H Me 99 
43c OMe Boc H 90 44j Br H Me 90 
 
All the synthesized indolyl-azaindolyl thiazoles 42a-n, 43a-j and 44a-j were submitted to the 
National cancer Institute (NCI; Bethesda MD) in order to evaluate their biological activity as 
antitumor agents. Biological screening were performed according to the NCI protocol, at the 10
-5
 M 
dose for the in vitro disease-oriented antitumor screenings against a panel of about 60 human tumor 
cell lines derived from 9 human cancer cell types, that have been grouped in disease sub-panel 
including leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, 
melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer cell lines. Compounds 
42a, 42d, 42f, 42g, 42l-n, 43f, 44b-f selected by the NCI for full evaluation at five concentration 
levels (10
-4
-10
-8
 M), showed antiproliferative activity with GI50 at micro to sub-micromolar range 
(Tab.3). 
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Table 3.  In vitro inhibition of cancer cell lines growth by compounds 42a, 42d, 42f, 42g, 42l-n, 
43f, 44b-f. 
Compd N° of cell 
line tested 
N° of active 
cell lines 
GI50 (M) 
Range           MG_MID 
42a 59 56 0.84-0.60 0.70 
42d 59 59 0.85-0.66 0.73 
42f 60 60 0.87-0.72 0.75 
42g 59 59 0.83-0.72 0.76 
42l 55 55 0.82-0.72 0.77 
42m 23 14 0.80-0.69 0.69 
42n 58 58 0.82-0.63 0.75 
43f 59 59 0.78-0.68 0.72 
44b 48 3 0.82-0.74 0.61 
44c 58 58 0.79-0.62 0.73 
44d 59 59 0.77-0.71 0.74 
44e 59 59 0.77-0.70 0.74 
44f 60 60 0.86-0.70 0.79 
 
The five most active compounds 42f, 42g, 42l, 42n, 44f were further tested by Istituto Nazionale dei 
Tumori (Fondazione IRCCS, Milano) against in 2 additional cell lines: STO and Meso II, derived 
from human Diffuse Malignant Peritoneal Mesothelioma (DMPM), a tumor type not included in the 
NCI panel. After 72 hours of exposure to increasing concentrations of each compound, compounds 
42f, 44f and 42l showed a dose-dependent inhibition of cell proliferation in both cellular models 
and they did not interfere with the proliferation of normal cells (W138) (Tab.4).  
Table 4. Cytotoxic activity of compounds 42f, 42g, 42l, 42n, 44f in DMPM and normal cells. 
Compd  
STO 
GI50 (M)
(a)
 
MesoII            WI38 
42f 0.49±0.07 25.12±3.06 >100 
44f 0.33±0.07 4.11±0.22 >100 
42g 0.61±0.14 16.77±1.99 18.76±3.21 
42l 0.43±0.11 4.85±0.64 >100 
42n 0.54±0.09 13.27±0.74 15.44±3.87 
 
a 
Data are reported as GI
50
 values (concentration of drug required to inhibit growth by 50%) determined by MTS assay after 72 h of 
continuous exposure to each compound. The data represents mean values ± SD of at least three independent experiments. 
The antitumoral activity of compounds 42f, 44f and 42l was investigated on STO cells 
xenotransplanted in athymic nude mice and after the treatment with each compound it was possible 
to observe a marked tumor growth inhibition (Fig.5). 
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Figure 5. Activity of 42f, 44f, and 42l derivatives on STO cells xenotransplanted on athymic mice. 
Drugs were administered ip at 25 (42f and 42l) or 50 (44f) mg/kg qd×4−5/w×3w, starting from the 
day after the injection. **p < 0.01, *p < 0.05. 
In particular, a statistically significant tumor volume inhibition (TVI) compared with the control 
(73%, 75%, 58% for 42f, 42l, 44f compounds, respectively) it was observed (Tab. 5). Two complete 
responses were observed in each treatment group, with the disappearance of tumor induced by 
treatment. 
 
Table 5. Activity of derivatives 42f, 44f, 42l on STO cells xenotransplanted on athymic mice.  
 
Compd TVI (%)
a
 CR
b
 BWL (%)
c
 TOX
d
 
42f 73* 2/8 4 0/8 
42l 75** 2/8 1 0/8 
44f 58* 2/8 7 0/8 
 
aTumor volume inhibition (%) in treated vs control mice, determined 17 days after the end of drug treatment (day 35). bComplete 
response, disappearance of tumor induced by treatment. cBWL, body weight loss induced by treatment (%). dToxic death on treated 
animals. **p <0.01, *p < 0.05. 
 
As many nortopsentin analogues exhibited the cellular effects by inhibiting of kinase activity, in 
order to study the mechanism of action, compounds 42f, 42l and 44f were tested on several protein 
kinases (CDK1, CDK5, EGFR, FGFR1, RET, MET, KIT, JAK2, PKCA, PKCB, CHKI, MAPK12, 
GSK, PKA, GSK3, GSK3). Results showed that those compounds markedly repressed CDK1 
activity with GI50 values (0.89±0.07, 0.75±0.03, 0.86±0.04) comparable to those reported for CDK1 
20 
 
inhibitors roscovitine and purvalanol A (0.73±0.06, and 0.59±0.08, respectively) and they decreased 
CDK1 activity in a time-dependent way. These compounds were also active against GSK3 protein, 
but only at very high concentration (Tab.6). 
 
Table 6. In vitro Kinase inhibitory activity of derivatives 42f, 42l, 44f.  
GI50 (M)
(a)
 
Protein kinase 42f 42l 44f Roscovitine Purvalanol A 
CDK1 0.89±0.07 0.75±0.03 0.86±0.04 0.73±0.06 0.59±0.08 
GSK-3 42.18±3.28 40.18±2.94 35.68±1.69 >50 >50 
a 
Concentration of drug required to inhibit by 50% (GI
50
) the activity of CDK1 e GSK-3β. Values represent the mean values ± SD of 
three independent experiments. 
Moreover, it was study the phosphorylation status of histone H1, a specific substrate for CDK1, in 
STO cell lines, in order to confirm the ability of these 3 derivatives to inhibit CDK1 activity in 
living cells; the obtained results showed a substantial and time dependent reduction of kinase 
activity (Fig.6 A-B). 
 
 
Figure 6.  Effect of 42f, 44f, and 42l derivatives on CDK1 kinase activity in DMPM cells. (A) Representative kinase assay 
illustrating the CDK1 activity in STO cells at different intervals after exposure to 1% (v/v) DMSO (control cells; C) or to derivative 
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44f (GI50; T). (B) Densitometric quantification of CDK1 activity in STO cells exposed to derivatives 42f, 44f, and 42l for 24, 48, and 
72 h. CDK1 activity was achieved by immunoprecipitation. Data are reported as the percentage of CDK1 activity in cells exposed to 
derivatives 42f, 44f, and 42l (gray column) compared with DMSO-treated cells (black column) and represent the mean values ± SD 
of at least three independent experiments. ***p <0.001, **p < 0.01, *p < 0.05. 
These compounds were also tested in STO and Meso II cells to observe the importance of 
nortopsentin analogue treatment on cell cycle progression. Compound 42f, 44f, 42l induced a time-
dependent accumulation of cells in the G2/M phase, and a concomitant decrease of the percentage of 
cells in the G1 phase. It was also observe a marched growth in the number of cells with apoptotic 
morphology (as chromatin condensation and DNA morphology) and a significant increase in the 
activity of caspase 9 and 3 (Fig. 7). 
 
Figure 7. Effect of 42f, 44f, and 42l derivatives on cell-cycle progression and apoptosis induction. (A) STO and MesoII cells were 
exposed to 1% (v/v) DMSO (control cells; C) or to derivatives 42f, 44f, and 42l (GI50) for 48 and 72 h. Data are reported as the 
percentage of cells in sub-G1 (dark gray), G1 (light gray), S (black), and G2/M (white) phases and represent the mean values of three 
independent experiments; SDs were always within 5%. (B) The percentage of cells with apoptotic morphology was assessed by 
fluorescence microscopy after exposure of DMPM cells to 1% (v/v) DMSO (control cells; C) or to derivatives 42f, 44f, and 42l at 48 
h (black column) and 72 h (gray column) after treatment. Data are expressed as mean values ± SD of at least three independent 
experiments. **p < 0.001, *p < 0.01. (C) The catalytic activity of caspases was assessed after 72 h of exposure of the DMPM cells to 
1% (v/v) DMSO (control cells; C) or to derivatives 42f, 44f, and 42l. Caspase-9 (black column) and caspase-3 (gray column) 
catalytic activity was determined in vitro by hydrolysis of the fluorogenic substrates (LEHD-pNA and DEVD-pNA, respectively). 
Data are expressed as mean values ± SD of at least three independent experiments. ***p < 0.001, **p < 0.01, *p < 0.02. 
It was previously demonstrated that DMPM chemo-resistance was principally caused by the 
dysregulation of apoptotic pathway, thorough the over-expression of members of the inhibitors of 
apoptosis protein family (IAP), such as survivin [32], a multifunctional protein involved in cell 
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division and in the suppression of apoptosis and selectively overexpressed in most human cancers 
[33]. It has been demonstrated that to carry out its functions, survivin needs to be physically 
associated with CDK1 and phosphorylated on the Thr
34
 residue by CDK1/Cyclin B1 complex [33, 
34]. 
It was investigated the effect of these compounds on survivin activation. Immunoblotting 
experiments demonstrated that 1H-pyrrolo[2,3-b]pyridine derivatives induced apoptosis in DMPM 
cells through a relevant and time-dependent decrease of levels of the active form of survivin, 
phosphorylated in THr
34 
(Fig. 8). 
 
 
Figure 8. Effect of 42f, 44f, and 42l derivatives on survivin phosphorylation. (A) Representative Western blotting illustrating the 
survivin phosphorylation status in STO cells after exposure to 1% (v/v) DMSO (control cells; C) or to derivative 44f, (GI50; T). (B) 
Densitometric quantification of surviving phosphorylation levels in STO cells exposed to 42f, 44f, and 42l for 24, 48, and 72 h. The 
phosphorylation of survivin on the Thr34 residue was evaluated on STO cells treated with 1% (v/v) DMSO (control cells; black 
column) or to derivatives 42f, 44f, and 42l (IC50; gray column) by Western immunoblotting. Survivin was immunoprecipitated using 
the antihuman survivin antibody and analyzed with the antibody to phosphorylated Thr34. Data are expressed as mean values ± SD of 
at least three independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05. 
 
The cytotoxic effect of the most active compound 44f was also investigated in DMPM cells alone or 
in combination with the taxan paclitaxel. At the beginning STO and MesoII cells were treated only 
with the taxan for 24 h and then for 72 h they were exposure also to compound 44f. At all 
concentrations, it was observed a synergistic cytotoxic effect to inhibit DMPM cell survival.  After 
the combination of two drugs, an inhibition of cell proliferation bigger than that estimated by simple 
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addition/amount of the effects of the two agents it was detected (Fig. 9A). A higher catalytic 
activity of caspase-3 was identified in cells treated with the two compounds than in those exposed 
to each single agent (Fig. 9B).  
 
 
Figure 9. Cytotoxic effect of 44f derivative in combination with paclitaxel in DMPMcells. (A) The cytotoxic effect of paclitaxel and 
44f derivative, alone or in combination, was assessed by MTS assay. The dashed lines represent the expected additive effect of the 
combination, calculated as the product of the effects of the individual drugs. Data are expressed as mean values ± SD of at least three 
independent experiments. CI was calculated according to Chou and Talalay.47 (B) Caspase-3 catalytic activity was determined in 
vitro by the hydrolysis of the specific fluorogenic substrate (DEVD-pNA). Data are expressed as mean values ± SD of at least three 
independent experiments. *p < 0.001. 
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Considering the interesting results shown by indolyl-7-azaindolyl thiazoles of type 42-44, the aim 
of my PhD project was the synthesis of new biologically active their analogues. In particular, three 
new series have been synthesized:  
 [3,3'-(1,3-thiazole-2,4-diyl)bis(1H-pyrrolo[2,3-b]pyridines] 45 in which two 7-azaindole 
rings are linked to the thiazole central ring;  
 [3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines] 46, 47, 48 in which the 
indole and 7-azaindole moieties, respectively in position 2 and 5, have been switched;  
  [7-chloro-3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridines] 49, 50, 51 in 
which the 7-azaindole unit is replaced by a 6-azaindole moiety.  
 
 
3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridines
3,3'-(1,3-thiazole-2,4-diyl)bis1H-pyrrolo[2,3-b]pyridines
S
N
N
N
R1
N
N
R
R2
S
N
N
N
R2
N
R
R1
S
N
N
R1
N
N
R
R2
S
N
N
N
R2
N
R
R1
Cl
3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines
7-chloro-3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine
45 46, 47, 48
49, 50, 51
42a-n, 43a-j, 44a-j
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RESULTS AND DISCUSSIONS: CHEMISTRY 
The synthetic pathway involves the synthesis of thiazole derivatives 45-51 (Tab. 7-9), by a 
Hantzsch reaction between two key intermediates: thioamides of type 54, 78, 79, 80 and 3-
haloacetyl compounds of type 56, 67, 85, 86 at reflux in ethanol (Scheme 1, 9,18).  
For the preparation of 3,3'-(1,3-thiazole-2,4-diyl)bis(1H-pyrrolo[2,3-b]pyridines 45a-l we focused 
on the synthesis of carbothioamides 54a,b and 3-bromoacetyl compounds 56a-f (Scheme 1). 
Scheme 1. Synthesis of 3,3'-(1,3-thiazole-2,4-diyl)bis(1H-pyrrolo[2,3-b]pyridines 45a-l. 
N N
R
N N
R
O
NH2
N N
R
S
NH2
CN
52a R = H
52b R = Me
54a R=H
54b R=Me
53a R=H
53b R=Me
S
N
N N
N N
R R1
R2
45a-l
N N
R1
R2
O
Br
N N
R1
R2
55a R1 =R2 =  H
55b R1 = Me, R2 = H
55c R1 = H, R2 = Br
55d R1 = Me, R2 = Br
55e R1 = H, R2 = F
55f  R1 = Me, R2 = F
56a R1 =R2 =  H
56b R1 = Me, R2 = H
56c R1 = H, R2 = Br
56d R1 = Me, R2 = Br
56e R1 = H, R2 = F
56f  R1 = Me, R2 = F
 
Carbothioamides 54a,b were obtained starting from 3-cyano-7azaindoles 52a,b (Scheme 2). 
Derivative 52b, was obtained in good yields (85%) from the 7-azaindole 52a, using potassium t-
butoxide as base,  tris[2-(2-methoxyethoxy)ethyl]amine (TDA-1) (1 or 2 drops) as phase transfer 
catalyst and methyl iodide as methylating agent in toluene at room temperature.  
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Scheme 2.  
N N
H
N N
Me
1) t-BuOK, toluene, TDA-1, rt
2) MeI, rt
CN CN
52a 52b  
 
3-Cyano-7azaindoles 52a,b were reacted with concentrated sulfuric acid at room temperature for 15-60 
minutes and the subsequent alkalinization with concentrated sodium hydroxide afforded the 
corresponding carboxamides 53a,b in high yields (95-99%). 3-Carboxythioamides 54a,b were 
conveniently prepared in excellent yields (88-99%) from the corresponding carboxamides 53a,b using 
2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide (Lawesson’s Reagent) in 
tetrahydrofuran under reflux for 30 minutes  (Scheme 3) [35].  
 
Scheme 3. 
N N
R
N N
R
O
NH2
N N
R
S
NH2
CN
52a R = H
52b R = Me
54a R = H
54b R = Me
Lawesson's reagent, THF
reflux
53a R = H
53b R = Me
1) H2SO4, rt
2) NaOH
 
 
Lawesson’s reagent [2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide] 57 is 
constituted by a four membered central ring in which there are alternating sulfur and phosphorus 
atoms. It is a mild and convenient thionating agent for ketons, esters and amides that allows the 
preparation of thioketons, thioesters and thioamides in good yields.   
In solution Lawesson’s reagent is in equilibrium with two more reactive dithiophosphine ylides 58 
and 59. The reaction of the ylide 59 with a carbonyl group 60 gives a thiaoxaphosphetane 
intermediate 61.Than through Wittig rearrangement, the thiaoxaphosphetane intermediate 61 
decomposes and generates the stable phenyl (thioxo) phosphine oxide 62 and the corresponding 
thioamide 63 (Scheme 4). 
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Scheme 4.  
MeO
S
P
S
P OMe
S
S
MeO
S
P
S
MeO
S
P
S
2
Lawesson's Reagent dithiophosphine ylide
57 58 59  
 
 
MeO
S
P
S
O
H2N
+ MeO
S
P O
S
NH2
N
R
N
R
59 60 61
X X
 
 
 
MeO
S
P O
S
NH2
N
R
MeO P
O
S
+
N
R
S
H2N
61 62 63
X
X
 
 
The variously substituted 7-azaindoles 55a,c,e were converted into the corresponding N-methyl 
derivatives 55b,d,f (60-96%) using potassium tert-butoxide, TDA-1 and methyl iodide  (Scheme 5) 
[27, 29].  
 
Scheme 5. 
 
N N
H
N N
Me
55a, 55c,55e 55b, 55d, 55f
R2 R21) t-BuOK, toluene, TDA-1, rt
2) MeI, rt
R2 = H, Br, F  
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3-Bromoacetyl-7-azaindoles 56a-f were efficiently synthesized (70-92%) by acylation of 
derivatives 55a-f with bromoacetyl bromide in the presence of aluminium chloride in 
dichloromethane at reflux (Scheme 6) [29].  
Scheme 6. 
N N
R1
N N
R1
56a-f
R2 R2
O
Br
55a-f
AlCl3, DCM, BrCOCH2Br
reflux
R1 = H, Me
R2 = H, Br, F  
5-Fluoro-7-azaindole 55e was prepared starting from the commercial available 5-bromo-7-
azaindole 55c. 5-Bromo 7-azaindole 55c was reacted with triisopropylsilyl chloride in the presence 
of sodium hydride in tetrahydrofuran to afforde with a quantitative yield 5-bromo-1-[tri(propan-2-
yl)silyl]-1H-pyrrolo[2,3-b]pyridine 64. The subsequent introduction of a fluorine atom by addiction 
of n-butyl lithium (solution 2.5 M in tetrahydrofuran) and N-fluorobenzensulfonimide at -78°C 
under a nitrogen atmosphere gave 5-fluoro-1-[tri(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridine 65 
(yield 70%). After the deprotection of derivative 65 with tetrabutylammonium fluoride (TBAF) in 
tetrahydrofuran at room temperature, 5-fluoro 7-azaindole 55e was isolated (yield 80%) (Scheme 7) 
[36].  
Scheme 7.  
N N
H
N N
Si
Br Br
N N
Si
F
N N
H
F
55c 64 65
55e
1) NaH, THF, rt
2) TIPS-Cl, 80 °C
1) n-BuLi, THF, -78 °C
2) (PhSO2)2NF, -78 °C
TBAF, THF, rt
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Reaction of thioamides 54a,b and 3-bromoacetyl-7-azaindole compounds 56a-f in ethanol at reflux 
for 30 minutes gave, after crystallization, the desired bis-7-azaindolyl thiazoles 45a-l (Scheme 8) 
from good to excellent yields (60-94%) (Tab. 7).  
Scheme 8. 
S
N
N N
N N
R R1
N
N
R
S
NH2
N
N
R1
O
Br
R2 R2
45a-l54a,b 56a-f
EtOH 
reflux
45a R = H, R1 = R2 = H
45b R = R1 = H, R2 = Br
45c R = R1 = H, R2 = F
45d R = Me, R1 = R2 = H
45e R = Me, R1 = H, R2 = Br
45f R = Me, R1 = H, R2 = F
45g R = R1 = Me, R2 = H
45h R = R1 = Me, R2 = Br
45i  R = R1 = Me, R2 = F
45j R = R2 = H, R1 = Me
45k R = H, R1 = Me, R2 = Br
45l R = H, R1 = Me, R2 = F
54a R=H
54b R=Me
56a R1 =R2 =  H
56b R1 = Me, R2 = H
56c R1 = H, R2 = Br
56d R1 = Me, R2 = Br
56e R1 = H, R2 = F
56f  R1 = Me, R2 = F
 
Table 7. Substituted 3,3'-(1,3-thiazole-2,4-diyl)bis(1H-pyrrolo[2,3-b]pyridines 45a-l. 
 
Compd R R1 R2 Yield% Compd R R1 R2 Yield% 
45a H H H 63 45g Me Me H 60 
45b H H Br 60 45h Me Me Br 90 
45c H H F 75 45i Me Me F 60 
45d Me H H 90 45j H Me H 85 
45e Me H Br 94 45k H Me Br 80 
45f Me H F 90 45l H Me F 72 
 
Derivatives 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines 46a-d, 47a-d, 48a-d 
were conveniently prepared by the same cyclization between the key intermediates: 
carbothioamides  54a,b and  3-haloacetyl compounds 67b, c, e, f (Scheme 9).  
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Scheme 9. Synthesis of 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines 46a-d, 
47a-d, 48a-d. 
N N
R
N N
R
O
NH2
N N
R
S
NH2
CN
52a R = H
52b R = Me
54a R=H
54b R=Me
53a R=H
53b R=Me
S
N
N N
N
R R1
R2
46a-d
47a-d
48a-d
N
R1
R2
O
X
N
R1
R2
O
N
R1
R2
66d R1 = R2 =  H
66e R1 = Me, R2 =H
66f R1 =SO2PhMe, R2 = H
66a R1 = H, R2 =  F
66b R1 = Me, R2 = F
66c R1 =SO2PhMe, R2 = F
67b R1 = Me, R2 =  F, X = Cl
67c R1 = SO2PhMe, R2 =F, X = Cl
67e R1 = Me, R2 = H, X = Br
67f R1 = SO2PhMe, R2 =H, X = Br
 
Thioamides 54a,b were obtained from the corresponding 3-cyano-7azaindoles 52a,b, through the 
formation of carboxamides 53a,b (Scheme 10) [29, 35].  
Scheme 10. 
N N
R
N N
R
O
NH2
N N
R
S
NH2
CN
52a, b 54a, b53a, b
R = H,  Me
Lawesson's reagent, THF
reflux
1) H2SO4, rt
2) NaOH
 
For the synthesis of 5-fluoro-3-haloacetylindole intermediates it was initially synthesized derivative 
66b by methylation of 5-fluoro indole 66a using potassium t-butoxide, TDA-1 and methyl iodide 
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(yield 98%) [31]. The subsequent acylation of N-methyl derivative 66b with acetic anhydride in the 
presence of aluminium chloride at room temperature in dichloromethane under nitrogen atmosphere 
gave the intermediate 68 (yield 41%), which reacted with bromine in methanol at reflux to give 3-
bromoacetyl indole 69 but in very low yield (35%) (Scheme 11).  
Scheme 11. 
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Me
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O
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Me
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O
Br
35%
Low yield
41%
Low yield
68
69
Br2, MeOH
reflux
AlCl3, DCM
Ac2O, rt
1) t-BuOK, toluene, TDA-1, rt
2) MeI, rt
 
It was therefore decided to synthesize 3-chloro acetyl indole 67b starting from 5-fluoro-1-methyl-
indole indole 66b with chloroacetyl chloride in presence of aluminium chloride in dichloromethane 
at room temperature (yield 50%) (Scheme 12).  
Scheme 12. 
N
Me
F
66b
N
Me
F
O
Cl
67b
AlCl3, DCM,
ClCOCH2Cl, rt
 
In the meantime, 5-fluoro indole 66a was placed to react with acetic anhydride in the presence of 
aluminium chloride at reflux under nitrogen atmosphere to obtain 3-acetyl indole 70 (yield 55%). 
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However, the following bromination with bromine in methanol did not afford to the desired 3-
bromoacetyl indole 71 (Scheme 13). 
Scheme 13. 
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O
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70 71
Br2, MeOH 
reflux
AlCl3, DCM
Ac2O, rt
 
So it was necessary to change the reaction pathway and to protect the amino function of 5-fluoro 
indole with a p-toluensulfonil group. 
In fact, the reaction of 5-fluoroindole 66a using sodium hydride and p-toluenesulfonyl chloride in 
tetrahydrofuran at room temperature gave desired compound 66c with an excellent yield (96%). 
Derivative 67c was obtained in good yield (55%) from the corresponding protected indole 66c by 
reaction with chloroacetyl chloride and aluminium chloride in dichloromethane (Scheme 14). 
 
Scheme 14. 
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67c
1) NaH, THF, rt
2) p-TsCl, rt
AlCl3,DCM 
ClCOCH2Cl,rt
 
Acetyl indoles 66e,f were brominated using bromine in methanol at reflux to yield 3-bromoacetyl 
indoles 67e,f in good yields (70% and 40%, respectively) [29]. Derivatives 66e,f were obtained 
from the commercial available 3-acetyl indole 66d, which was subjected to a methylation reaction 
in the presence of t-butoxide, TDA-1 and methyl iodide  to give compound 66e (yield 80%) [31]; or 
protected using sodium hydride and p-toluenesulfonyl chloride in tetrahydrofuran at room 
temperature to give 66f (yield 90%) (Scheme 15). 
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Scheme 15.  
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67f
66e
66f
Br2, MeOH
reflux
Br2, MeOH
reflux1) NaH, THF, rt
2) CH3C6H4SO2Cl, rt
1) t-BuOK, toluene 
    TDA-1, rt
2) MeI, rt
 
Thioamides 54a,b and 3-bromo or 3-chloro acetylindole compounds 67b, c, e, f were reacted in 
ethanol at reflux for 30 minutes.  After crystallization with ethanol provided the desired 3-[4-(1H-
indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines 46a-d, 47a-d, in good yields (30-97%) 
(Scheme 16) (Tab. 8). 
 
Scheme 16. 
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67b R1 = Me, R2 =  F, X = Cl
67c R1 = SO2PhMe, R2 =F, X = Cl
67e R1 = Me, R2 = H, X = Br
67f  R1 = SO2PhMe, R2 =H, X = Br
46a R = H, R1 = Me, R2 =  F
46b R = R1 = Me, R2 =  F
46c R = R2 = H, R1 = Me
46d R = R1 = Me, R2 =  H
47a R = H, R1 = SO2PhMe, R2 =F
47b R = Me, R1 = SO2PhMe, R2 =F
47c R = R2 =H, R1 = SO2PhMe
47d R = Me, R1 = SO2PhMe, R2 =H
+
54a R=H
54b R=Me
EtOH 
reflux
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The alkaline hydrolysis of N-tosil compounds 47a-d with potassium hydroxide in ethanol at reflux 
afforded the corresponding NH compounds 48a-d from moderate to excellent yields (40-98%) 
(Scheme 17) (Tab. 8).  
Scheme 17. 
EtOH, KOH
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N N
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R2S
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R R1
R2
 47a-d
47a R = H,R1 = SO2PhMe, R2 =F
47b R = Me, R1 = SO2PhMe, R2 =F
47c R = H, R1 = SO2PhMe, R2 =H
47d R = Me, R1 = SO2PhMe, R2 =H
48a R = R1 = H, R2 =  F
48b R = Me, R1 = H, R2 =  F
48c R = R1 = R2 =  H
48d R = Me, R1 = R2 =  H
 48a-d
 
Table 8.  Substituted 3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines 46a-d, 47a-
d, 48a-d.  
 
Compd R R1 R2 Yield% Compd R R1 R2 Yield% 
46a H Me F 97 47c H SO2PhMe H 90 
46b Me Me F 30 47d Me SO2PhMe H 50 
46c H Me H 60 48a H H F 98 
46d Me Me H 60 48b Me H F 40 
47a H SO2PhMe F 97 48c H H H 98 
47b Me SO2PhMe F 40 48d Me H H 98 
 
The synthesis of  7-chloro-3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridines 49a-j, 
50a-f, 51a-f involve a Hantzsch reaction between thioamides 78d, 79a-d, 80a-c and 6-azaindoles 
85, 86 (Scheme 18).  
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Scheme 18. Synthesis of 7-chloro-3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine 
49a-j, 50a-f, 51a-f. 
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R R R
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N N
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N Cl
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+
Mg
Br
R
Cl
a R = H, b R = OMe, c R = Br, d R = F
78d R1=H
79a-d R1=Me
80a-c R1 = Boc
81
82
83 R2 = H
84 R2 = Me
85 R2 = H
86 R2 = Me
 
The first step for the synthesis of carbothioamides 78d, 79a-d and 80a-c was the functionalization 
of the indolyl moiety. In particular, the methylation of the variously substituted indoles 72b-d (73a 
is commercial available), gave methylated derivatives 73b-d in excellent yields (96-98%) (Scheme 
19) [27].  
Scheme 19.  
N
H
N
CH3
72b-d 73b-d
R R
b R = OMe, c R = Br, d R = F
1) t-BuOK, toluene, TDA-1, rt
2) MeI, rt
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Moreover, the indoles 72a-d were also protected as N-tert-butylcarboxylate using di-tert-butyl 
dicarbonate and triethylamine in tetrahydrofuran under reflux to obtain derivatives 74a-d in very 
good to quantitative yields (90-100%) (Scheme 20) [30, 31]. 
Scheme 20.  
N
H
N
C
72a-d 74a-d
R R
a R = H, b R = OMe, c R = Br, d R = F
O O
(BOC)2O, TEA, 
THF, reflux
 
All the indoles 73a-d, 74a-d were converted into the corresponding carboxamide derivatives by the 
reaction with chloroacetyl isocyanate (CSI) in acetonitrile, followed by alkaline hydrolysis of the 
chlorosulfonyl group. The reaction was carried out at room temperature and gave carboxamide 
derivatives 76a-d and 77a-c in good yields (40-60%) (Scheme 21) [30, 31].   
Scheme 21. 
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73a-d R1 = Me
74a-c R1 = Boc
76a-d R1=Me
77a-c R1 = Boc
R R
a R = H, b R = OMe, c R = Br, d R = F
1) CSI, MeCN, rt
2) 10% KOH, aq. acetone
 
For compound 74d the reaction with chloroacetyl isocyanate at room temperature did not work and 
it was necessary force the reaction conditions, increasing the temperature and only under reflux it 
was possible to isolate the unprotected carboxamide in moderate yield (40%) 75d (Scheme 22).  
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Scheme 22.  
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1) CSI, MeCN, rt
2) 10% KOH, aq. acetone
 
The subsequent treatment of carboxamides 75d, 76a-d, 77a-c with Lawesson’s reagent in 
tetrahydrofuran under reflux afforded the thioamides 78d, 79a-d and 80a-c (90-98%) (Scheme 23) 
[30,31]. 
Scheme 23. 
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Starting from the commercial 2-chloro-3-nitropyridine 81 and vinylmagnesium bromide 82 in 
tetrahydrofuran at -78 °C under nitrogen atmosphere it was possible to obtain, after acid workup, 
the 6-azaindole 83 (Scheme 24) [37].  
Scheme 24. 
N N
HCl
N Cl
NO2
+
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Br
81 82
83
1) THF, -78°C
2) 20% NH4Cl
 
This reaction is carried out through the Bartoli indole synthesis, an organic reaction where a 
substituted nitroarene is converted to an indole ring using an excess of a vinyl Grignard reagent, 
followed by an acid workup. The mechanism begins by the addition of the Grignard reagent 82 onto 
the nitroarene 81 to form intermediate 87. This intermediate spontaneously decomposes to form a 
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nitrosoarene 88 and a magnesium salt 89. Upon reaction workup, the magnesium salt 89 will 
liberate a carbonyl compound 90. Reaction of the compound 88 with a second equivalent of the 
Grignard reagent 82 forms intermediate 91. The steric bulk of the ortho group causes a [3,3]-
sigmatropic rearrangement (Claisen) forming the intermediate 92. Cyclization and tautomerization 
give intermediate 94, which will react with a third equivalent of the Grignard reagent 82 to give a 
dimagnesium indole salt 95, which upon elimination of water gives the indole 83 (Scheme 25) [38].  
Scheme 25. 
N
Cl
N
O
O-
N
Cl
N
O
MgBr
O N
Cl
N
O
BrMgO
O
H
N
Cl
N
MgBr
ON
Cl
N
MgBr
O
N
Cl
N
OMgBr
N
Cl
N
H
OMgBr
N
Cl
N
OMgBr
MgBr
N
Cl
N
H
H3O
+
81
83
87 88
8990
919293
94 95
82
82
82
 
The 6-azaindole 83 obtained was converted into the corresponding N-methyl derivative 84 (70%). 
Compound 83 and 84 were transformed into the corresponding 3-bromoacetyl-6aza-indoles 85, 86 
(88-98%) by reaction with bromoacetyl bromide in the presence of aluminium chloride in 
dichloromethane under reflux for 40 minutes (Scheme 26). 
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Scheme 26. 
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Reaction of all thioamides 78d, 79a-d, 80a-c and 3-bromoacetyl-6-azaindole compounds 85,86 in 
ethanol under reflux provided, after crystallization, the desired indolyl-6azaindolyl thiazoles 49a-j 
and 50a-f (65-98%) (Scheme 27) (Tab. 9).  
Scheme 27.  
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R1 R2
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R
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78d R1=H
79a-d R1=Me
80a-c R1 = Boc
85 R2 = H
86 R2 = Me
+
EtOH
reflux
49a R = R2 = H, R1 = Me
49b R = OMe, R1 = Me, R2 = H
49c R = Br, R1 = Me, R2 = H
49d R = F, R1 = Me, R2 = H
49e R = H, R1 = R2 = Me
49f R = OMe, R1 = R2 = Me
49g R = Br, R1 = R2 = Me
49h R = F, R1 = R2 = Me
49i R = F, R1 = H, R2 = Me
49j R = F, R1 = R2 = H
50a R = R2 = H, R1 = Boc
50b R = OMe, R1 = Boc, R2 = H
50c R = Br, R1 = Boc, R2 = H
50d R = H, R1 = Boc, R2 = Me
50e R = OMe, R1 = Boc, R2 = Me
50f R = Br, R1 = Boc, R2 = Me
 
The subsequent hydrolisis of N-Boc compounds 50a-f with trifluoroacetic acid in dichlorometane at 
reflux afforded, after neutralization, the corresponding N-unprotected thiazoles 51a-f (62-99%) 
(Scheme 28) (Tab. 9).  
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Scheme 28. 
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50b R = OMe, R2 = H
50c R = Br, R2 = H
50d R = H, R2 = Me
50e R = OMe, R2 = Me
50f R = Br, R2 = Me
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DCM, reflux
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51a R = H, R2 = H
51b R = OMe, R2 = H
51c R = Br, R2 = H
51d R = H, R2 = Me
51e R = OMe, R2 = Me
51f R = Br, R2 = Me
O O
51a-f
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Table 9. Substituted 7-chloro-3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine 
49a-j, 50a-f, 51a-f. 
Compd R R1 R2 Yield% Compd R R1 R2 Yield% 
49a H Me H 98 50b OMe Boc H 77 
49b OMe Me H 65 50c Br Boc H 77 
49c Br Me H 93 50d H Boc Me 91 
49d F Me H 97 50e OMe Boc Me 92 
49e H Me Me 96 50f Br Boc Me 91 
49f OMe Me Me 79 51a H H H 93 
49g Br Me Me 98 51b OMe H H 62 
49h F Me Me 95 51c Br H H 98 
49i F H Me 82 51d H H Me 75 
49j F H H 66 51e OMe H Me 73 
50a H Boc H 84 51f Br H Me 99 
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RESULTS AND DISCUSSIONS: BIOLOGY 
All the synthesized thiazoles 45a-l, 46a-d, 47a-d, 48a-d, 49a-j, 50a-f and 51a-f (Tab. 7-9) were 
submitted to the National Cancer Institute (NCI, Bethesda MD) in order to evaluate their antitumor 
activity. 
Biological screening were performed on derivatives 45a-l, 46c,d, 47c,d, 48c,d, 49a-j, 50a-f, 51a-f, 
according to the NCI protocol, at the 10
-5
 M dose for the in vitro disease-oriented antitumor 
screenings against a panel of about 60 human tumor cell lines derived from 9 human cancer cell 
types, that have been grouped in disease sub-panel including leukemia, non-small cell lung cancer, 
colon cancer, central nervous system cancer, melanoma, ovarian cancer, renal cancer, prostate 
cancer and breast cancer cell lines (Tab. 10). 
Table 10. Mean Growth Percent of compounds 45a-l, 46c-d, 47c-d, 48c-d, 49a-j, 50a-f, 51a-f. 
Mean Growth Percent 
Compd 45a 45b 45c 45d 45e 45f 45g 45h 45i 45j 
 96.25 73.88 81.60 60.08 68.77 98.94 93.30 87.69 75.71 86.53 
Compd 45k 45l 46c 46d 47c 47d 48c 48d 49a 49b 
 31.86 69.34 72.28 28.74 94.54 53.02 89.28 29.80 91.91 76.64 
Compd 49c 49d 49e 49f 49g 49h 49i 49j 50a 50b 
 84.71 96.96 87.56 92.20 91.54 77.46 65.01 36.21 90.88 68.50 
Compd 50c 50d 50e 50f 51a 51b 51c 51d 51e 51f 
 88.11 58.74 89.46 73.58 41.11 37.10 17.34 66.84 38.95 56.23 
 
Compounds 45k, 46d, 48d and 51c satisfied the criteria set by the NCI for activity in this assay and 
were selected for further screenings at 5 concentrations at 10-fold dilution (10
-4
-10
-8
 M) on the full 
panel (Tab. 11). The antitumor activity of compounds was given by three parameters for each cell 
line: GI50 (GI50 is the molar concentration of the compound that inhibits 50% net cell growth), TGI 
(TGI is the molar concentration of the compound leading to total inhibition of net cell growth), and 
LC50 (LC50 is the molar concentration of the compound that induces 50% net cell death). The 
average values of mean graph midpoint (MG_MID) were calculated for each of these parameters.  
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Table 11. In vitro inhibition of cancer cell line growth by compounds 45k, 46d, 48d, 51c (M)a.  
Cell lines GI50 (M) 
 45k 46d 48d 51c 
Leukemia     
CCRF-CEM 6.81 0.40 0.43 3.16 
HL-60(TB) >100 0.30 0.32 2.64 
K-562 8.76 0.07 0.12 2.73 
MOLT-4 >100 0.67 0.66 3.02 
RPMI-8226 >100 0.46 0.65 4.03 
SR ND
b
 0.06 0.14 1.27 
Non-Small Cell Lung Cancer     
A549/ATCC 2.59 0.56 0.71 3.83 
EKVK 1.27 0.91 0.91 3.11 
HOP-62 2.39 0.81 0.94 2.11 
HOP-92 5.03 0.35 0.31 2.43 
NCI-H226 1.97 0.74 0.65 2.40 
NCI-H23 2.80 0.72 0.67 2.42 
NCI-H322M >100 0.76 ND
b
 3.54 
NCI-H460 2.98 0.30 0.37 2.16 
NCI-H522 4.86 0.04 0.05 2.28 
Colon Cancer      
COLO-205 ND
b
 0.19 0.19 1.80 
HCC-2998 >100 1.13 1.18 2.22 
HCT-116 2.91 0.38 0.39 2.35 
HCT-15 13.7 0.17 0.29 1.40 
HT29 6.75 0.25 0.19 2.66 
KM12 5.70 0.21 0.40 2.15 
SW-620 4.46 0.22 0.30 1.92 
CNS Cancer     
SF-268 6.01 2.44 0.94 4.06 
SF-295 3.01 0.25 0.31 2.48 
SF-539 27.7 0.18 0.25 1.87 
SNB-19 6.74 0.63 0.64 3.25 
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SNB-75 2.18 0.16 0.14 2.37 
U251 2.70 0.41 0.43 2.05 
Melanoma     
LOX IMVI 4.26 0.54 0.51 1.63 
MALME-3M 3.01 1.04 0.75 ND
b
 
M14 4.06 0.27 0.29 2.22 
MDA-MB-435 3.17 0.04 0.03 3.43 
SK-MEL-2 19.8 0.58 0.41 4.09 
SK-MEL-28 ND
b
 1.20 0.77 1.85 
SK-MEL-5 2.05 0.24 0.27 2.61 
UACC-257 ND
b
 13.00 14.20 2.68 
UACC-62 3.47 0.30 0.42 2.19 
Ovarian Cancer      
IGROV1 2.21 1.33 1.18 2.51 
OVCAR-3 2.91 0.10 0.25 3.45 
OVCAR-4 2.03 7.22 0.52 3.25 
OVCAR-5 >100 1.41 2.39 3.14 
OVCAR-8 3.72 0.66 0.82 3.65 
NCI/ADR-RES  3.88 0.09 0.15 2.71 
SK-OV-3 3.25 0.57 0.52 2.78 
Renal Cancer     
786-0 9.65 0.97 0.72 1.37 
A498 10.9 0.50 0.37 1.56 
ACHN 2.35 0.72 0.51 2.02 
CAKI-1 1.56 0.38 0.44 1.96 
RXF393 2.05 0.33 0.52 1.48 
SN12C ND
b
 12.10 5.48 3.35 
TK-10 3.77 0.60 0.99 4.16 
UO-31 ND
b
 0.90 0.69 0.93 
Prostate Cancer     
PC-3 4.35 0.46 0.56 3.86 
DU-145 3.51 0.39 0.57 1.76 
Breast Cancer     
MCF7 6.77 0.33 0.37 2.20 
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MDA-MB-231/ATCC 3.02 2.82 1.29 1.68 
HS 578T 2.43 0.59 0.66 3.70 
BT-549 20.5 0.47 0.44 4.70 
T-47D 1.80 ND
b
 ND
b
 3.12 
MDA-MB-468 0.81 0.28 0.23 1.18 
a Data obtained from NCI’s in vitro disease-oriented tumor cells screen 
b ND = Not Determined  
An evaluation of the data reported in table 12 pointed out that all derivatives resulted active at 
micromolar to nanomolar concentration, against most of the tested cell lines, as it has been 
confirmed by the range of GI50 value of 0.81-27.7, 0.04-13.00, 0.03-14.20, 0.93-4.70 M, 
respectively for compounds 45k, 46d, 48d, 51c.  
The indolyl-thiazolyl-pyrrolo[2,3-b]pyridine 46d, 48d and indolyl-thiazolyl-pyrrolo[2,3-c]pyridine 
51c resulted more active than thiazolyl-bis-pyrrolo[2,3-b]pyridine derivative 45k in terms either of 
GI50 (mean value 1.09, 0.86, 2.59 and 5.26 µM, respectively) and percentage of sensitive cell lines 
out of the total number of cell lines investigated (100%, 100%, 100% and 89%, respectively). 
Derivative 45k showed selectivity with respect to MDA-MB-468 (GI50 0.81 µM) of breast cancer 
subpanel, EKVK (GI50 1.27 µM) of non small cell lung, and CAKI-1 (GI50 1.56 µM) of renal 
cancer subpanel.  
Derivative 46d was shown to be selective with respect to the leukemia subpanel having all the 
subpanel cell lines GI50 in the range 0.06-0.67 µM. The most sensitive cell lines are K-562 (GI50 
0.07 µM) and SR (GI50 0.06 µM) of leukemia, NCI-H522 (GI50 0.04 µM) of non-small cell lung 
cancer, MDA-MB-435 (GI50 0.04 µM) of melanoma, OVCAR-3 and NCI/ADR-RES (GI50 0.10, 
0.09 µM, respectively) of ovarian cancer.  
Derivative 48d was shown to be selective with respect to the non-small cell lung cancer subpanel 
having all the subpanel cell lines GI50 in the range 0.05-0.94 µM. The most sensitive cell lines are 
K-562 (GI50 0.12 µM) and SR (GI50 0.14 µM) of leukemia, NCI-H522 (GI50 0.05 µM) of non-small 
cell lung cancer, SNB-75 (GI50 0.14 µM) of CNS cancer, MDA-MB-435 (GI50 0.03 µM) of 
melanoma, NCI/ADR-RES (GI50 0.15 µM) of ovarian cancer. 
Derivative 51c was shown to be selective with respect to the renal cancer subpanel having all the 
subpanel cell lines GI50 in the range 0.93-4.16 µM. The most sensitive cell lines are UO-31 (GI50 
0.93 µM), 786-0 (GI50 1.37 µM), RXF393 (GI50 1.48 µM), and A498 (GI50 1.56 µM). Cell lines 
sensitive to derivative 51c were also SR (GI50 1.27 µM) of leukemia, HCT-15 (GI50 1.40 µM) of 
colon cancer, and MDA-MB-468 (GI50 1.18 µM) of breast cancer subpanel. 
45 
 
Table 12. Overview of compounds 45k, 46d, 48d and 51c. 
Compd N° of cell line 
tested 
N° of active cell 
lines 
GI50 (M) 
Range                                MD_MID 
45k 54 48 0.81-27.7 5.26 
46d 59 59 0.04-13.00 1.09 
48d 58 58 0.03-14.20 0.86 
51c 59 59 0.93-4.70 2.59 
 
Comparing the antiproliferative activity of the most active derivatives of 7-azaindolyl thiazole 46d, 
48d and 6-azaindolyl thiazole 51c with analogues of the previous series, already published [31] 
(40g, 42f, 42e) (Scheme 29), we can observe that all compounds were active against the total 
number of cell lines investigated (Tab. 13). As show in the table 13, it is possible to observe that the 
switching of the indole and 7-azaindole rings (46d, 48d) led to a comparable antiproliferative 
activity than compounds 40g and 42g. Conversely, the substitution of the 7-aza-indole moiety (42e) 
with a 6-aza-indole one (51c) cause a reduction of the antitumoral activity, as it is possible to 
observe by GI50 values reported.  
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Table 13. Overview of compounds 46d, 48d, 51c, 40g, 42f, 42e. 
Compd. N° of cell line 
tested 
N° of active cell 
lines 
GI50 (M) 
       Range                             MD_MID 
42f 58 58 0.72-0.84 0.79 
48d 58 58 0.03-14.20 0.86 
40g 58 58 0.72-0.83 0.76 
46d 59 59 0.04-13.00 1.09 
42e 59 59 0.69-0.77 0.74 
51c 59 59 0.93-4.16 2.59 
 
The antiproliferative activity of all the synthesized thiazoles 45a-l, 46a-d, 47a-d, 48a-d, 49a-j, 50a-
f and 51a-f was further examined by Istituto Nazionale dei Tumori (Fondazione IRCCS, Milano) in 
two additional cell lines, STO and MesoII, derived from human DMPM, a tumor type non included 
in the NCI panel.  
Cells were exposed to increasing concentrations (from 0.01 to 50 μM) of each compound for 72 
hours after which time the amount of proliferation was determined by the MTS assay. 
The MTS assay is a cell-based assay often used for screening collections of compounds to 
determine if the test molecules have effects on cell proliferation or show direct cytotoxic effects that 
can lead to cell death. It is a chromogenic assay that involves the biological reduction by viable 
cells of the tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)2H-tetrazolium (or MTS), which is  negatively charged and do not readily penetrate 
cells. NADH in metabolically active viable cells can reduce tetrazolium compounds into brightly 
colored formazan products (Fig. 10).  
Figure 10. Intermediate electron acceptor pheazine ethyl sylfate (PES) transfers electron from 
NADH in the cytoplasm to reduce MTS in the culture medium into an aqueous soluble formazan. 
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This reaction only takes place when mitochondrial reductase enzymes are active, so the conversion 
of the substrate to a colored product can be related to the viability of cells in the culture and can be 
detected with a plate reader (Fig.11). 
 
Figure 11. Metabolic indicator of cell viability. 
It is typically used with an intermediate electron acceptor as phenazine methyl sulfate (PMS) or 
phenazine ethyl sulfate (PES) which can transfer electrons from the cytoplasm or plasma membrane 
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to facilitate the reduction of the tetrazolium into the colored formazan product, that is directly 
soluble in cell culture medium. 
With the exception of derivative 45e and 45k (GI50 49.5±1.1, 34.5±5.3, respectively in MesoII 
cells), any thiazolyl-bis-pyrrolo[2,3-b]pyridine derivative showed antiproliferative activity against 
STO and MesoII cells (Tab. 14). 
 
Table 14. Cytotoxic activity of thiazole derivatives 45a-l in STO and MesoII cell lines. 
 
GI50 (M)
a
 
Compd STO MesoII Compd STO MesoII 
45a > 5.0 > 50.0 45g > 5.0 > 50.0 
45b N.A.
b
 N.A.
b
 45h > 5.0 > 50.0 
45c > 5.0 > 50.0 45i > 5.0 > 50.0 
45d > 5.0 > 50.0 45j > 5.0 > 50.0 
45e > 5.0 49.5±1.1 45k > 5.0 34.5±5.3 
45f > 5.0 > 50.0 45k > 5.0 > 50.0 
 
(a) Data are reported as IC50 values (concentration of drug required to inhibit growth by 50%) determined by the MTS 
assay after 72 hours of continuous exposure to each compound. Data represent mean values ± SD of at least three 
independent experiments.  
(b) N.A.: not assessed because the compound was insoluble. 
 
Respect to indolyl-thiazolyl-pyrrolo[2,3-c]pyridines, compounds 49j and 51f showed comparable 
antiproliferative activity against both cellular models with GI50 values of 4.5±0.2, 29.0±1.0 and 
4.9±0.1, 28.7±0.2 M, respectively. Compound 49a and 49c exhibited comparable inhibitory 
activity in STO cells (GI50 values of 3.7±0.1, 3.3±0.2 M, respectively); compounds 49i, 50a, 50b, 
50c, 51c and 51e were active against MesoII cells (GI50 values of 27.6±1.1, 33.2±1.2, 31.1±1.2, 
31.2±0.3, 16.7±0.1, 46.1±2.1, respectively) (Tab. 15). 
 
Table 15. Cytotoxic activity of thiazole derivatives 49a-j, 50a-f, 51a-f.  
GI50 (M)
a
 
Compd STO MesoII Compd STO MesoII 
49a 3.7±0.1 > 50.0 50b > 5.0 31.1±1.2 
 49b > 5.0 > 50.0 50c > 5.0 31.2±0.3 
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49c 3.3±0.2 > 50.0 50d > 5.0 > 50.0 
49d > 5.0 > 50.0 50e > 5.0 > 50.0 
49e > 5.0 > 50.0 50f N.A.
b
 N.A.
b
 
49f > 5.0 > 50.0 51a > 5.0 > 50.0 
49g > 5.0 > 50.0 51b N.A.
b
 N.A.
b
 
49h > 5.0 > 50.0 51c > 5.0 16.7±0.1 
49i > 5.0 27.6±1.1 51d > 5.0 > 50.0 
49j 4.5±0.2 29.0±1.0 51e > 5.0 46.1±2.1 
50a > 5.0 33.2±1.2 51f 4.9±0.1 28.7±0.2 
 
(a) Data are reported as IC50 values (concentration of drug required to inhibit growth by 50%) determined by the MTS 
assay after 72 hours of continuous exposure to each compound. Data represent mean values ± SD of at least three 
independent experiments.  
(b) N.A.: not assessed because the compound was insoluble. 
 
Indolyl-thiazolyl-pyrrolo[2,3-b]pyridines 46a-d, 47a-d and 48a-d, exhibited better antiproliferative 
activity. As indicated by the drug concentration required to inhibit growth by 50% (GI50 values 
which ranged from 0.08 to 3.9 M), compounds 46d, 48b and 48d presented good inhibitory affect 
in both cellular models. In particular, compounds 46d, 48b and 48d induced the best growth 
inhibitory effect against STO cells (GI50 values of 0.08±0.01, 0.4±0.02, 0.4±0.1 M, respectively). 
 
Table 16. Cytotoxic activity of thaizole derivatives 46a-d, 47a-d, 48a-d. 
GI50 (M)
a
 
Compd STO MesoII Compd STO MesoII 
46a 3.4±0.1 > 50.0 47c > 5.0 > 50.0 
46b N.A.
b
 N.A.
b
 47d 4.3±0.2 > 50.0 
46c > 5.0 > 50.0 48a > 5.0 > 50.0 
46d 0.08±0.01 3.2±0.1 48b 0.4±0.02 3.9±0.2 
47a 3.5±0.2 > 50.0 48c > 5.0 > 50.0 
47b N.A.
b
 N.A.
b
 48d 0.4±0.1 4.3±0.1 
 
(a) Data are reported as IC50 values (concentration of drug required to inhibit growth by 50%) determined by the MTS 
assay after 72 hours of continuous exposure to each compound. Data represent mean values ± SD of at least three 
independent experiments.  
(b) N.A.: not assessed because the compound was insoluble. 
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Compounds 45k, 46d, 48d and 51c, which were selected for screenings at 5 concentrations at 10-
fold dilution (10
-4
-10
-8
 M) on the full panel by the NCI, were further tested in order to elucidate the 
mechanism of action. About compounds 46d and 48d, biological assays are currently under 
investigation. 
Instead, selective toxicity of compounds 45k and 51c towards tumor cells was investigated. To this 
aim human HTC-116 colorectal carcinoma cells, against which both compounds exhibited a 
comparable antiproliferative effects (GI50 2.91 and 2.35 M, Table 11), and intestinal normal-like 
differentiated Caco-2 cells were exposed to the compounds for 24 h and viability compared using 
by colorimetric MTT assay.   
NADH-dependent cellular oxidoreductase enzymes, present in the cytosolic compartment of the 
cells, may, under defined conditions, reflect the number of viable cells present. These enzymes are 
capable of reducing the water soluble tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide to its insoluble formazan crystals, which has a purple color (Fig. 
12). A solubilization solution (usually dimethyl sulfoxide, an acidified ethanol solution, a solution 
of the detergent sodium dodecyl sulfate in diluted hydrochloric acid, acidified isopropanol, 
dimethylformamide, or combinations of detergent and organic solvent) is added to dissolve the 
insoluble purple formazan product into a colored solution. The absorbance of this colored solution 
can be quantified by measuring at a certain wave length (usually 570 nm) using a plate reading 
spectrophotometer. Viable cells with active metabolism convert MTT into a purple colored 
formazan product. When cells die, they lose the ability to convert MTT into formazan [39, 40].  
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Figure 12. Structures of MTT and colored formazan product. 
While both derivatives 45k and 51c, in the range 5 to 100 M, dose-dependently inhibited the 
intestinal HCT-116 cell proliferation, they did not affect the differentiated Caco-2 cell viability, 
suggesting tumor cells as the main target of their cytocidal action (Fig. 13). GI50 values of 45k and 
51c calculated after 24 h treatment of HCT-116 cells, were 33.552.31 M and 13.150.95 M, 
respectively.  
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Figure 13. Effect of 45k (triangle) and 51c (circle) on the viability of human intestinal cell lines 
either tumoral (HCT-116; full line) or normal-like (differentiated Caco-2; dashed line). Cells were 
treated with the compounds 45k and 51c and cell survival was measured after 24 h by MTT assay in 
comparison to cells treated with vehicle alone (control). Values are the mean of three separate 
experiments in triplicate. 
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It was next determinated alterations in the cell cycle caused by derivatives 45k and 51c in colorectal 
cancer cells. Flow cytometry analysis of nuclear DNA content after 24 h treatment of HCT-116 
cells was determined using propidium iodide (PI) 96, in order to distinguish cells in different phases 
of the cell cycle. Drug concentrations were chosen on the basis that they represent values above and 
below the respective GI50 values.  
Propidium iodide (PI) 96 is a fluorescent molecule that binds nucleic acid with little or no sequence 
preference. Because PI binds RNA as well as DNA, RNaseA (ribonuclease A) is also used to digest 
cellular RNA and thus decrease background RNA staining from the experiment. Since PI is 
membrane impermeant, a detergent is used to both fix and permeabilize cells.  
Propidium Iodide
96
N
H2N NH2
I-
N I
-
 
This dye binds in a stoichiometric way the amount of DNA present in the cell. In this way, as the 
DNA content of cells duplicates during the S phase of the cell cycle, the relative amount of cells in 
the G0 phase and G1 phase (before S phase), in the S phase, and in the G2 phase and M phase (after 
S phase) can be determined. In eukaryotic cells, the cell cycle, the complex sequence of events by 
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which cells grow and divide, includes a series of four distinct phases. The G1, S, and G2 phases of 
the cell cycle are collectively referred to as interphase; the mitosis phase involves the separation of 
nuclear chromosomes, followed by cytokinesis (division of the cytoplasm forming two distinct 
cells). At the end of the mitotic cell cycle, two distinct cells are produced, which contains identical 
genetic material (Fig. 14). 
During the G1 phase, the period prior to the synthesis of DNA, the cell increases in mass and 
organelle number in preparation for cell division. During the S phase, the cell synthesizes DNA and 
the chromosome content is doubled. The G2 phase is the period after DNA synthesis but before the 
start of mitosis and the cell synthesizes additional proteins. Once a cell has completed the cell cycle, 
it goes back into the G1 phase and repeats the cycle again. Cells in the body can also be placed in a 
non-dividing state called the Gap phase (G0) at any point in their life. 
Figure 14. Cell cycle. 
 
So cells that are in S phase will have more DNA than cells in G1. They will take up proportionally 
more dye and will fluoresce more brightly because they have doubled their DNA content. The cells 
in G2/M will be approximately twice as bright as cells in G1. 
Compared to control cells, 45k caused a dose-dependent accumulation of cells in G2/M phase, 
paralleled by a reduction in the percentage of cells in the G1 phase and by a significant increase of 
cells in the sub-G1 phase, which is representative of cells with fragmented DNA. On the other hand, 
51c induced a dose-dependent accumulation of cells in G1 phase accompanied by a decrement in 
the percentage of cells in G2/M phases. Moreover, accumulation of sub-G1 population was 
significantly higher than control (p<0.05) only at high concentration of the drug (Fig. 15). These 
results indicated that the two compounds caused arrest of the HCT-116 cancer cell growth involving 
different check points of the cell cycle.  
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Figure 15. Effect of 45k and 51c on the cell cycle distribution of HCT-116 cells. Flow cytometric 
analysis of propidium iodide-stained cells after 24 h treatment with the compounds or vehicle alone 
(control). The percentage of cells in the different phases of the cycle was calculated by Expo32 
software. Values are the meanSD of three separate experiments in triplicate. 
 
To determine whether HCT-116 cells undergo apoptosis upon treatment with the nortopsentin 
analogues, cells were treated with 45k or 51c for 24 h, stained with both propidium iodide (PI) 96 
and Annexin V-fluorescein isothiocyanate (FITC), and analyzed by flow cytometry.   
The apoptotic program is characterized by certain morphologic features, including loss of plasma 
membrane, condensation of the cytoplasm and nucleus, and inter-nucleosomal cleavage of DNA.  
In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is translocated from the 
inside to the outside of the plasma membrane, and PS is exposed to the external cellular 
environment.  Annexin V is a 35-36 kDa Ca
2+
 dependent phospholipid-binding protein that has high 
affinity for PS, and binds to cells with exposed PS. Annexin V can be conjugated with 
fluorochromes including FITC (Fluorescein isothiocyanate). Since this complex binds with high 
affinity PS, it can be used as a sensitive probe for flow cytometric analysis of cells that are 
undergoing apoptosis. In particular, the externalization of PS happens in the earlier stages of 
apoptosis, so Annexin V-FITC staining can be used to identify apoptosis at an earlier stage.  
Staining with FITC Annexin V is typically used in combination with a vital dye such as propidium 
iodide (PI) 96, in order to distinguish early, late apoptosis or necrosis. Indeed PI 96 does not enter 
viable cells, but in dead and damaged cells the membrane become permeable to PI. We can 
distinguish: 
 viable cells in which PI and annexin V-FITC are negative; 
 early apoptosis cells in which PI is negative and annexin V-FITC is positive; 
 late apoptosis cells in which PI and annexin V-FITC are positive; 
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 necrotic cells in which PI is positive and annexin V-FITC is negative. 
In figure 16 we can observe that neither compound caused cell necrosis. Rather, while the 
percentage of cells in late apoptosis increased at the increase of the 45k doses, apoptotic effects of 
51c were evident only at high concentrations (GI70), when cells in early apoptosis appeared 
significantly increased with respect to control (p<0.05). 
Figure 16. Effect of 45k and 51c on apoptosis of HCT-116 cells. Percentage of Annexin 
V/propidium iodide (PI) double-stained cells, as determined by flow cytometry after 24 h treatment 
with the compounds or vehicle alone (control). The percentage of cells in the different phases of 
apoptosis was calculated by Expo32 software. Values are the meanSD of three separate 
experiments in triplicate. 
 
Mitochondria play a critical role in regulating the apoptotic machinery. Mitochondrial membrane 
potential (Δψm) is an important parameter of mitochondrial function and an indicator of cell health. 
Loss of Δψm suggests the leak of mitochondrial membrane integrity, signal of the beginning of the 
proapoptotic pathway. It was then examinated mitochondrial membrane potential (m) loss using 
DiOC6 (3,3'-dihexyloxacarbocyanine iodide) 97, a cationic lipophilic fluorescent mitochondria-
specific and voltage-dependent dye, after treatment with compounds 45k and 51c.  
O
N
O
N
I-
DiOC6
97  
DiOC6 97 accumulates in mitochondria matrix to its large negative membrane potential, and it can 
be useful to monitor the mitochondrial membrane potential using flow cytometric detection. 
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Changes on mitochondrial membrane potential are indicated by a reduction in the DiOC6-induced 
fluorescence intensity. 
As indicated by the decrement in DiOC6 green-associated fluorescence, treatment of HCT-116 cells 
with 45k, for 24 h, induced a remarkable dose-dependent dissipation of m (Fig.17).  
 
Figure 17. Effects of compounds 45k and 51c on mitochondrial transmembrane potential in HCT-
116 cells. The m was detected by fluorescence intensity of 3,3’-dihexyloxacarbocyanine iodide-
treated cells, as determined by flow cytometry. Control, cells treated with vehicle. Representative 
images of three experiments with comparable results. 
 
 
On the other hand, incubation with 51c did not cause mitochondrial dysfunction at GI30, whereas 
induced a significant increase in m loss at higher concentrations. Overall our findings indicated 
that, although the thiazole derivatives inhibited the HCT-116 tumor cell growth, they may elicit 
different molecular pathways of programmed cell death. 
Morphology of HCT-116 cells treated for 24 h with compounds 45k and 51c was assessed by 
microscopy analysis after Giemsa staining. Both compounds caused an evident dose-dependent 
reduction of the cell population with respect to control (Fig. 18). However, whereas 45k caused 
highly condensate cells, as a sign of their apoptotic fate, more complex alterations were observed 
after treatment with 51c. Low concentration of drug (GI30) caused evident expansion of whole 
cytoplasm, with a massive accumulation of multiple-membrane bounded vacuoles without apparent 
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loss of nuclear material, a morphology characteristic of autophagic cell death. On the other hand, 
when HCT-116 cells were treated with higher concentration of 51c (GI70), vacuolization was less 
evident and cells with condensed morphology prevailed, indicating evolution of the cell fate 
towards apoptosis. 
Figure 18. Compound 51c induces accumulation of acid vacuoles in HCT-116 cells.  (A) 
Micrographs of Giemsa-stained cells in 40x magnification. Control, cells treated with vehicle. 
Representative images of three experiments with comparable results.  
 
Then, it was performed FACS analysis of acridine-orange stained acid vacuoles (AVO) using the 
red to green ratio as an indicator of acid vacuolar organelle accumulation [41]. 
Several studies proposed two types of programmed cell death [42]. Type I or apoptosis, is mediated 
by a cascade of caspases and factors released by the mitochondria. It is characterized by typical 
morphological and biochemical features such as chromatin margination and condensation, early 
nuclear collapse. Type II programmed cell death is characterized by increased autophagy and early 
destruction of the cytoplasm [43]. In particular this response is dominated by the appearance and 
accumulation of acidic vesicular organelles [44]. 
 Acridine-orange (AO) 98 is a fluorescent molecule used to identify apoptotic cell death or 
autophagy. Being cell-permeable, it can interact with DNA emitting green fluorescence or 
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accumulate in acidic organelles in which it becomes protonated forming aggregates that emit bright 
red fluorescence. In acridine-orange stained cells, the cytoplasm and nucleolus fluoresce bright 
green, whereas acidic compartements fluorescence bright red. The intensity of the red fluorescence 
is proportional to the amount of acidity and/or volume of the cellular acidic compartment. By 
comparing the red/green fluorescence ratio it is possible to quantity change in the degree of acidity 
or the fractional volume of their cellular acidic compartment.  
Acridine-orange
98
NN N
 
As shown in Figure 19, treatment of the cells with 51c (GI30), for 24 h, led to a 10-fold increase of 
the bright red to green fluorescence intensity ratio of acrydine orange, indicating an elevated 
induction of cell vacuolization associated to autophagy. Instead, the treatment of cells with the 
highest drug concentration did not significantly modify the percent of cells with AVO with respect 
to control, supporting the concept of a different cell death.  
 
Figure 19. Compond 51c induces accumulation of acid vacuoles in HCT-116 cells.  The percentage 
of bright red (FL3) fluorescence-positive cells after AO staining and FACS analysis. Results are the 
meanSD of two triplicate experiments. Mean values with unlike superscript letters were 
significantly different (P<0.05; Bonferroni’s test). 
 
 
Newly synthesized nortopsentin analogues showed cytotoxicity towards a broad spectrum of human 
cancer cell lines included in the NCI panel. In particular, compounds 45k, 46d, 48d and 51c 
exhibited the best results and were selected for further screenings at 5 concentrations at 10-fold 
dilution (10
-4
-10
-8
 M) on the full panel. 
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These derivatives resulted active at micromolar to nanomolar concentration, against most of the 
tested cell lines, as it has been confirmed by the range of GI50 value of 0.81-27.7, 0.04-13.00, 0.03-
14.20, 0.93-4.70 M, respectively for compounds 45k, 46d, 48d, 51c.  
The antiproliferative activity of all compouds 45a-l, 46a-d, 47a-d, 48a-d, 49a-j, 50a-f and 51a-f, 
was further examined by Istituto Nazionale dei Tumori (Fondazione IRCCS, Milano) in two 
additional cell lines, STO and MesoII, derived from human DMPM, a tumor type not included in 
the NCI panel. Results showed that only some of them impaired the growth of both experimental 
models of DMPM.  
Compounds 45k, 46d, 48d and 51c, which showed the best results on the full panel by the NCI, 
were tested in order to explain the mechanism of action. About compounds 46d and 48d, biological 
assaies are currently in progress.  
Importantly, compounds 45k and 51c did not appreciably impair vitality of intestinal normal like 
cells. Investigating mechanisms underlying the antiproliferative effect in HCT-116 colon cancer 
cells, it was showed that 45k caused a dose-dependent increase of the apoptotic cell population, 
activating the mitochondria-mediated pathway and inducing cell cycle arrest at the G2/M phase.  
On the other hand 51c elicited distinct responses in accordance with the dose. Concentrations lower 
than its GI50, induced antiproliferative effects and morphological changes with massive 
accumulation of autophagic vacuoles without apparent signs of apoptosis. The observed arrest of 
cell cycle at G1 phase supports the autophagic fate of the cells [45].  
Evolution of the cells toward apoptotic death following treatment with higher drug concentrations, 
suggests that 51c may orchestrate a potential axis of autophagy and apoptosis in HCT-116 cells 
which can facilitate cellular destruction. The autophagy-signaling cascade induced by 51c in HCT-
116 cells is currently under investigation. Modulating authophagy appears of great interest in 
cancer. Indeed, current evidence suggests that authophagic cell death can be induced as an 
alternative to apoptosis with therapeutic purpose in cancer cells that are resistant to apoptosis. 
Compound 51c may candidate as a lead compound for nortopsentin derivatives with autophagic 
activity. 
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EXPERIMENTALE SECTION 
CHEMISTRY 
General methods 
All melting points were taken on a Buchi-Tottoly capillary apparatus and are uncorrected. IR 
spectra were determined in bromoform with a Shimadzu FT / IR 8400S spectrophotometer. 
1
H and 
13
C NMR spectra were measured at 200 and 50.0 MHz, respectively, on DMSO-d6 or CDCl3 
solution, using a Bruker Avance II series 200 MHz spectrometer. Compounds 46a, 46b, 49d-f, h, j, 
50e,f were characterized only by 
1
H NMR spectra, for their poor solubility, the 
13
C spectra were not 
performed. Chromatography column was performed with MERK silica gel 230-400 mesh ASTM or 
FLASH40i Biotage chromatography or with Buchi Sepacore chromatography module (prepacked 
cartridge reference). 
Synthesis of 1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (52b)  
To a cold solution of 52a (1.0 g, 7.0 mmol) in anhydrous toluene (20 mL), potassium t-butoxide 
(1.1 g, 9.5 mmol) and TDA-1 (1 or 2 drops) were added at 0 °C. The reaction mixture was stirred at 
room temperature for 6 h and then methyl iodide (7.0 mmol, 0.44 mL) was added at 0 °C. TLC 
analysis (DCM/ethyl acetate 9/1) revealed that methylation was complete after 1 h. The solvent was 
evaporated under reduced pressure. The residue was treated with water, extracted with DCM, dried 
(Na2SO4), evaporated and purified by column chromatography using DCM/ethyl acetate (9/1) as 
eluent. White solid; yield: 85%; mp: 106.1-106.6 °C; IR 2224 (CN) cm-1; 1H NMR (200 MHz, 
DMSO-d6) δ: 3.90 (s, 3H, CH3), 7.35 (dd, 1H, J = 4.7, 8.0 Hz, H-5), 8.15 (dd, 1H, J = 1.5, 8.0 Hz, 
H-4), 8.47 (dd, 1H, J = 1.5, 4.7 Hz, H-6), 8.48 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) δ: 31.6 
(q), 81.9 (s), 115.3 (s), 118.1 (d), 119.2 (s), 127.6 (d), 138.4 (d), 144.8 (d), 146.4 (s). Anal. Calcd for 
C9H7N3: C, 68.78; H, 4.49; N, 26.74. Found: C, 68.61; H, 4.21; N, 26.92. 
Synthesis of carboxamides (53a,b) [35] 
A solution of appropriate carbonitrile derivatives 52a,b (6.3 mmol) in concentrated sulphuric 
acid (3.3 mL) was stirred at room temperature for 15-60 min. The solution was slowly poured into 
ice and basified with concentrated NaOH. The residue was extracted with ethyl acetate dried 
(Na2SO4) and concentrated under reduced pressure to afford desired carboxamides 53a,b.  
 
1H-Pyrrolo[2,3-b]pyridine-3-carboxamide (53a)  
Conditions: room temperature for 60 min. Brown solid; yield: 95%; mp: 273-274 °C; IR 3389, 
3335 (NH2), 3021 (NH), 1636 (CO) cm
-1; 1H NMR (200 MHz, DMSO-d6) δ: 7.16 (dd,1H, J = 4.7, 
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7.9 Hz, H-5), 7.52 (bs, 2H, NH2), 8.16 (d, 1H, J = 2.5 Hz, H-2), 8.27 (dd, 1H, J = 1.7, 4.7 Hz, H-6), 
8.46 (dd, 1H, J = 1.7, 7.9 Hz, H-4), 12.10 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 109.3 
(s), 116.8 (d), 118.5 (s), 128.6 (d), 129.2 (d), 143.3 (d), 148.4 (s), 165.8 (s). Anal. Calcd for 
C8H7N3O: C, 59.62; H, 4.38; N, 26.07. Found: C, 59.46; H, 4.59; N, 26.25. 
1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (53b)  
Conditions: room temperature for 15 min. White solid; yield: 99%; mp: 218-219 °C; IR 3347, 
3326 (NH2), 1614 (CO) cm
-1; 1H NMR (200 MHz, DMSO-d6) δ: 3.85 (s, 3H, CH3), 7.20 (dd, 1H, J 
= 4.7, 7.9 Hz, H-5), 7.48 (bs, 2H, NH2), 8.17 (s, 1H, H-2), 8.33 (dd, 1H, J = 1.7, 4.7 Hz, H-6), 8.45 
(dd, 1H, J = 1.7, 7.9 Hz, H-4); 13C NMR (50 MHz, DMSO-d6) δ:  31.2 (q), 108.2 (s), 117.0 (d), 
118.7 (s), 129.4 (d), 132.3 (d), 143.2 (d), 147.4 (s), 165.5 (s). Anal. Calcd for C9H9N3O: C, 61.70; 
H, 5.18; N, 23.99. Found: C, 61.55; H, 5.44; N, 24.19. 
Synthesis of 1H-pyrrolo[2,3-b]pyridine-3-carbothioamides (54a,b) [35] 
A mixture of Lawesson’s reagent (0.33 g, 0.8 mmol) and appropriate carboxamides 53a,b (1.3 
mmol) in THF (10 mL) was heated under reflux for 30 min. The solution was cooled to room 
temperature and the solvent was removed under reduced pressure. The residue was purified by 
column chromatography using ethyl acetate as eluent to give desired carbothioamides 54a,b. 
 
1H-Pyrrolo[2,3-b]pyridine-3-carbothioamide (54a)  
Yellow solid; yield: 88%; mp: 220-222 °C; IR 3306, 3180 (NH2), 3020 (NH), 1590 (CS); 
1
H 
NMR (200 MHz, DMSO-d6) : 7.22 (dd, 1H, J = 4.7, 8.0 Hz, H-5), 8.23 (d, 1H, J = 2.7 Hz,  H-2), 
8.29 (dd, 1H, J = 1.5, 4.7 Hz, H-6), 8.99 (dd, 1H, J = 1.5, 8.0 Hz, H-4), 9.00 (s, 1H, SH), 9.10 (s, 
1H, NH), 12.30 (bs, 1H, NH); 
13
C NMR (50 MHz, DMSO-d6) : 114.7 (s), 117.1 (d), 118.8 (s), 
127.6 (d), 130.3 (d), 143.5 (d), 148.9 (s), 193.0 (s). Anal. Calcd for C8H7N3S: C, 54.22; H, 3.98; N, 
23.71. Found: C, 54.02; H, 4.08; N, 23.91. 
1-Methyl-1H-pyrrolo[2,3-b]pyridine-3-carbothioamide (54b)  
Yellow solid; yield: 99%; mp: 232-233 °C; IR 3336, 3182 (NH2), 1540 (CS) cm
-1
; 1H NMR (200 
MHz, DMSO-d6) δ: 3.86 (s, 3H, CH3), 7.26 (dd, 1H, J = 4.7, 8.0 Hz, H-5), 8.28 (s, 1H, H-2), 8.33 
(dd, 1H, J = 1.6, 4.7 Hz, H-6), 8.93 (dd, 1H, J = 1.6, 8.0 Hz, H-4), 8.97 (s, 1H, SH), 9.16 (bs, 1H, 
NH); 13C NMR (50 MzHDMSO-d6) δ:  31.3 (q), 113.7 (s), 117.4 (d), 118.7 (s), 130.3 (d), 131.8 (d), 
143.3 (d), 147.8 (s), 192.6 (s). Anal. Calcd for C9H9N3S: C, 56.52; H, 4.74; N, 21.97. Found: C, 
56.32; H, 4.59; N, 22.27. 
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Synthesis of 1-methyl-1H-pyrrolo[2,3-b]pyridines (55b, d, f)   
To a cold solution of appropriate pyrrolo-pyridines 55a,c,e (2.5 mmol) in anhydrous toluene (25 
mL), potassium t-butoxide (0.38 g, 3.4 mmol) and TDA-1 (1 or 2 drops) were added at 0 °C. The 
reaction mixture was stirred at room temperature for 3 h and then methyl iodide (2.5 mmol, 0.2 mL) 
was added at 0 °C. TLC analysis (ethyl acetate) revealed that methylation was complete after 1 h. 
The solvent was evaporated under reduced pressure. The residue was treated with water, extracted 
with DCM, dried (Na2SO4), evaporated and purified by column chromatography using DCM/ethyl 
acetate (9/1) as eluent to give derivatives 55b, d, f. 
 
1-Methyl-1H-pyrrolo[2,3-b]pyridine (55b) [29] 
Oil; yield: 96%;  1H NMR (200 MHz, CDCl3) δ: 3.87 (s, 3H, CH3), 6.43 (d, 1H, J = 3.4 Hz, H-
3), 7.03 (dd, 1H, J = 4.8, 7.8 Hz, H-5), 7.15 (d, 1H, J = 3.4 Hz, H-2), 7.88 (1H, dd, J = 1.5, 7.8 Hz, 
H-4), 8.33 (1H, d, J = 4.8 Hz, H-6); 13C NMR (50 MHz, CDCl3) δ: 31.1 (q), 99.1 (d), 115.3 (d), 
120.4 (s), 128.6 (d), 128.9 (d+s), 142.6 (d). Anal. Calcd for C8H8N2: C, 72.70; H, 6.10; N, 21.20. 
Found:  C, 72.55; H, 6.03; N, 21.38. 
 
5-Bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine (55d) [27]  
Brown solid; yield: 85%; mp: 62-63 °C ; 1H NMR (200 MHz, DMSO-d6) δ: 3.83 (s, 3H, CH3), 
6.44 (d, 1H, J = 3.4 Hz, H-3), 7.60 (d, 1H, J = 3.4 Hz, H-2), 8.21 (d, 1H, J = 2.1, H-4), 8.33 (d, 1H, 
J = 2.1 Hz, H-6); 13C NMR (50 MHz, DMSO-d6) δ: 31.0 (q), 98.5 (d), 110.7 (s), 121.7 (s), 130.3 
(d), 131.8 (d), 142.2 (d), 145.7 (s). Anal. Calcd for C8H7BrN2: C, 45.53; H, 3.34; N, 13.27. Found: 
C, 45.38; H, 3.24; N, 13.45. 
5-Fluoro-1-methyl-1H-pyrrolo[2,3-b]pyridine (55f)  
Brown solid; yield: 60%; mp: 72-74 °C; 1H NMR (200 MHz, DMSO-d6) δ: 3.83 (s, 3H, CH3), 
6.47 (d, 1H, J = 3.4 Hz, H-3) 7.63 (d, 1H, J = 3.4 Hz, H-2), 7.87 (dd, 1H, J = 2.7, 9.5 Hz, H-4), 
8.24-8.27 (m, 1H, H-6); 13C NMR (50 MHz, DMSO-d6) δ: 31.1 (q), 98.8 (d, JC3-F = 4.5 Hz), 113.9 
(d, JC4-F = 20.5 Hz), 119.9 (s, JC3a-F = 7.5 Hz), 130.4 (d, JC6-F = 29.2 Hz), 132.3 (d), 144.3 (s), 155.0 
(s, JC5-F = 238.0 Hz). Anal. Calcd for C8H7FN2: C, 63.99; H, 4.70; N, 18.66. Found: C, 63.69; H, 
4.91; N, 18.48. 
Synthesis of 2-bromo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanones (56a-f)  
To a solution of appropriate 7-azaindoles 55a-f (2.5 mmol) in 10 mL of anhydrous DCM, 
anhydrous aluminium chloride (1.2 g, 8.8 mmol) was slowly added. The reaction mixture was 
heated under reflux and bromoacetyl bromide (2.5 mmol, 0.2 mL) in 2 mL of anhydrous DCM was 
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added dropwise. The resulting solution was allowed to stir under reflux for 40 min. After cooling, 
water and ice were slowly added and the obtained precipitate (for derivative 56a) was filtered off or 
the oil residue (for derivatives 56b-f) was extracted with DCM and purified by column 
chromatography using DCM/ethyl acetate (9/1) as eluent.  
 
2-Bromo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone (56a) [29] 
White solid; yield: 92%; mp: 280-282°C; IR 3556 (NH), 1678 (CO) cm-1; 1H NMR (200 MHz, 
DMSO-d6) δ: 4.71 (s, 2H, CH2), 7.30 (dd, 1H, J = 4.7, 7.8 Hz, H-5), 8.37 (d, 1H, J = 4.7 Hz, H-6), 
8.47 (d, 1H, J = 7.8 Hz, H-4), 8.65 (s, 1H, H-2), 12.70 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6) 
δ: 46.3 (t), 112.3 (s), 117.7 (s), 118.4 (d), 129.5 (d), 135.1 (d), 144.6 (d), 149.0 (s), 186.4 (s). Anal. 
Calcd for C9H7BrN2O: C, 45.22; H, 2.95; N, 11.72. Found: C, 45.40; H, 2.82; N, 11.54. 
 
2-Bromo-1-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone (56b) [29] 
White solid; yield: 80%; mp: 116-117°C; IR 1650 (CO) cm-1; 1H NMR (200 MHz, DMSO-d6) δ: 
3.91 (s, 3H, CH3), 4.65 (s, 2H, CH2), 7.34 (dd, 1H, J = 7.6, 4.7 Hz, H-5), 8.40-8.48 (m, 2H, H-4, H-
6), 8.70 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) δ: 31.7 (q), 32.9 (t), 110.8 (s), 118.1 (d), 118.7 
(s), 129.8 (d), 138.7 (d), 144.4 (d), 148.1 (s), 186.1 (s). Anal. Calcd for C10H9BrN2O: C, 47.46; H, 
3.58; N, 11.07. Found: C, 47.22; H, 3.63; N, 11.25. 
 
2-Bromo-1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone (56c)  
Brown solid; yield: 75%; mp: 244-245 °C; IR 3019 (NH), 1655 (CO) cm-1; 1H NMR (200 MHz, 
DMSO-d6) δ: 4.72 (s, 2H, CH2), 8.46 (d, 1H, J = 2.2 Hz, H-4), 8.57 (d, 1H, J = 2.2 Hz, H-6), 8.71 
(d, 1H, J = 3.2 Hz, H-2), 13.0 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 33.1 (t), 111.7 (s), 
113.8 (s), 119.4 (s), 131.2 (d), 136.9 (d), 144.8 (d), 147.4 (s), 186.6 (s). Anal. Calcd for 
C9H6Br2N2O: C, 34.00; H, 1.90; N, 8.81. Found: C, 33.87; H, 2.11; N, 8.99. 
2-Bromo-1-(5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone (56d)  
Brown solid; yield: 70%; mp: 166-167 °C; IR 1653 (CO) cm-1; 1H NMR (200 MHz, DMSO-d6) 
δ: 3.89 (s, 3H, CH3), 4.66 (s, 2H, CH2), 8.49 (d, 1H, J = 2.2 Hz, H-4), 8.54 (d, 1H, J = 2.2 Hz, H-6), 
8.74 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) δ: 31.9 (q), 32.9 (t), 110.2 (s), 114.2 (s), 119.6 
(s), 131.4 (d), 139.9 (d), 144.6 (d), 146.5 (s), 186.1 (s). Anal. Calcd for C10H8Br2N2O: C, 36.18; H, 
2.43; N, 8.44. Found: C, 36.02; H, 2.67; N, 8.64. 
2-Bromo-1-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone (56e)  
Brown solid; yield: 74%; mp: 206-207 °C; IR 3555 (NH), 1654 (CO) cm-1; 1H NMR (200 MHz, 
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DMSO-d6) δ: 4.71 (s, 2H, CH2), 8.20 (dd, 1H, J = 2.8, 9.1 Hz, H-4), 8.37-8.39 (m, 1H, H-6), 8.73 
(d, 1H, J = 3.3 Hz, H-2), 12.88 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 33.7 (t), 112.2 (s, 
JC7a-F = 3.9 Hz), 115.0 (d, JC4-F = 21.5 Hz), 118.1 (s, JC3a-F = 7.9 Hz), 133.0 (d, JC6-F = 26.5 Hz), 
137.4 (d), 145.7 (s), 156.4 (s, JC5-F = 243.0 Hz), 186.5 (s). Anal. Calcd for C9H6BrFN2O: C, 42.05; 
H, 2.35; N, 10.90. Found: C, 41.85; H, 2.56; N, 10.76. 
2-Bromo-1-(5-fluoro-1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone (56f)  
Brown solid; yield: 74%; mp: 149-150 °C; IR 1668 (CO) cm-1; 1H NMR (200 MHz, DMSO-d6) 
δ: 3.90 (s, 3H, CH3), 4.65 (s, 2H, CH2), 8.20 (dd, 1H, J = 2.8, 9.0 Hz, H-4), 8.42-8.44 (m, 1H, H-6), 
8.78 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) δ: 32.0 (q), 32.8 (t), 110.6 (s, JC7a-F = 3.9 Hz), 
115.3 (d, JC4-F = 21.9 Hz), 118.3 (s, JC3a-F = 7.9 Hz), 132.8 (d, JC6-F = 29.3 Hz), 140.4 (d), 144.8 (s), 
156.7 (s, JC5-F = 243.5 Hz), 186.0 (s). Anal. Calcd for C10H8BrFN2O: C, 44.31; H, 2.97; N, 10.33. 
Found: C, 44.14; H, 2.73; N, 10.53. 
Synthesis of 5-bromo-1-[tri(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridine (64) [36]  
Sodium hydride (0,12 g, 5 mmol) was added in small portion to a stirred solution of 5-bromo-7-
azaindole 55c (0.4g, 2.03 mmol) in tetrahydrofuran (6 mL) at room temperature. The resulting 
suspension was stirred at room temperature for 30 min. Triisopropylsilyl chloride (0.6 mL, 3.05 
mmol) was added and the reaction mixture was heated at 80 °C for 3h. The solvent was evaporated 
under reduced pressure and the residue was dissolved in water, extracted with DCM, dried 
(Na2SO4) and purified by column chromatography using DCM as eluent. White solid, yield: 99%, 
mp: 55 -56 °C, 
1H NMR (200 MHz, DMSO-d6) δ: 1.03 (s, 9H, 3xCH3), 1.07 (s, 9H, 3xCH3), 1.78-
1.93 (m, 3H, 3xCH), 6.62 (d, 1H, J = 3.5 Hz, H-3), 7.55 (d, 1H, J = 3.5 Hz, H-2), 8.20 (d, 1H, J = 
2.3 Hz, H-4), 8.27 (d, 1H, J = 2.3 Hz, H-6); 13C NMR (50 MHz, DMSO-d6) δ: 11.4 (d), 17.8 (q), 
102.9 (d), 111.49 (s), 123.9 (s), 130.1 (d), 133.6 (d), 142.1 (d), 151.7 (s). Anal. Calcd for 
C16H25BrN2Si: C, 54.38; H, 7.13; N, 7.93. Found: C, 54.18; H, 7.38; N, 7.74. 
Synthesis of 5-fluoro-1-[tri(propan-2-yl)silyl]-1H-pyrrolo[2,3-b]pyridine (65) [36]                
 To a stirred solution of compound 64 (0.74 g, 2.1 mmol) in tetrahydrofuran (18 mL) over a 
period of 10 minutes at -78 °C under nitrogen atmosphere, a solution of butyl lithium (2.5 M, 1.3 
mL, 3.1 mmol) was added dropwise. The resulting solution was stirred at -78 °C for 1 h and solid 
N-fluorobenzenesulfonimide (0.82 g, 2.6 mmol), was added in one portion and stirred at -78 °C for 
2h. The solvent was removed under reduced pressure. The crude was extracted with ethyl acetate. 
The organic extract was dried with Na2SO4, concentrated and purified by column chromatography 
using ciclohexane/ethyl acetate (9/1) as eluent. Yellow oil; yield: 70%, 
1H NMR (200 MHz, 
64 
 
DMSO-d6) δ: 1.04 (s, 9H, 3xCH3), 1.08 (s, 9H, 3xCH3), 1.78-1.93 (m, 3H, 3xCH), 6.63 (d, 1H, J = 
3.5 Hz, H-3), 7.58 (d, 1H, J = 3.5 Hz, H-2), 7.84 (dd, 1H, J = 2.8, 9.4 Hz, H-4), 8.21 (dd, 1H, J = 
1.6, 2.8 Hz, H-6); 13C NMR (50 MHz, DMSO-d6) δ: 11.4 (d), 17.8 (q), 103.4 (d, JC3-F = 4 Hz),113.6 
(d, JC4-F = 20.12 Hz ), 122.3 (s, JC3a-F = 7 Hz ), 130.1 (d, JC6-F = 28.7 Hz), 134.2 (d), 150.0 (s), 
155.1 (s, JC5-F = 245 Hz). Anal. Calcd for C16H25FN2Si: C, 65.71; H, 8.62; N, 9.58. Found: C, 
65.46; H, 8.81; N, 9.34. 
Synthesis of 5-fluoro-1H-pyrrolo[2,3-b]pyridine (55e)  [36]  
Tetrabutylamonium fluoride (TBAF), 1M in tetrahydrofuran (0.6 mL) was added to a stirred 
solution of compound 65 (0.320 g, 1.09 mmol) in tetrahydrofuran (2.5 mL) at room temperature and 
stirred for 15 min. The solvent was evaporated and the crude was purified by column 
chromatography using ciclohexane/ethyl acectate (8/2) as eluent. White solid; yield: 80%, mp: 180-
181 °C; IR 3453 (NH) cm-1; 1H NMR (200 MHz, DMSO-d6) δ: 6.46 (d, 1H, J = 3.4 Hz, H-3), 7.58 
(d, 1H, J = 3.4 Hz, H-2), 7.84 (dd, 1H, J = 2.4, 9.6 Hz, H-6), 8.20 (dd, 1H, J = 2.1, 2.5 Hz, H-4), 
11.81 (bs, 1H, NH);  13C NMR (50 MHz, DMSO-d6) δ: 99.9 (d, JC3-F = 4.5 Hz), 113.5 (d, JC4-F = 
20.1), 119.7 (s, JC3a-F = 7 Hz), 128.6 (d), 130.5 (d, JC6-F = 30 Hz), 145.3 (s), 155.0 (s, JC5-F = 238 
Hz). Anal. Calcd for C7H5FN2: C, 61.76; H, 3.70; N, 20.58. Found: C, 61.51; H, 3.99; N, 20.35. 
Synthesis of substituted -(1,3-thiazole-2,4-diyl) bis(1H-pyrrolo[2,3-b]pyridines (45a-l)  
A suspension of the appropriate pyrrolo[2,3-b]pyridine-carbothioamides 54a,b (5 mmol) and 
proper 3-bromoacetyl-pyrrolo[2,3-b]pyridine compound 56a-f (5 mmol) in anhydrous ethanol (20 
mL) was heated under reflux for 30 min. The precipitate, obtained after cooling, was filtered off, 
dried and crystallized with ethanol to afford derivatives 45a-l. 
 
3,3'-(1,3-Thiazole-2,4-diyl)bis(1H-pyrrolo[2,3-b]pyridine (45a)  
Yellow solid; yield: 63%; mp: 346-347 °C; IR 3410, 3166 (NH) cm-1; 1H NMR (200 MHz, 
DMSO-d6) δ: 7.48 (dd, 1H, J = 5.0, 7.9 Hz, ArH), 7.60 (dd, 1H, J = 5.5, 7.9 Hz, ArH), 8.00 (s, 1H, 
ArH), 8.39 (s, 1H, ArH), 8.46 (s, 1H, ArH), 8.48 (d, 1H, J = 5.5 Hz, ArH), 8.55 (d, 1H, J = 5.0 Hz, 
ArH), 8.87 (d, 1H, J = 7.9 Hz, ArH),  9.11 (d, 1H, J = 7.9 Hz, ArH), 12.75 (bs, 1H, NH), 12.90 (bs, 
1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 109.6 (d), 110.5 (s), 116.3 (d), 117.3 (d), 118.7 (s), 
125.8 (s), 126.9 (d), 127.9 (d), 129.6 (s), 131.4 (d), 134.8 (d), 137.2 (d), 141.5 (d), 143.2 (s), 145.9 
(s), 147.9 (s), 149.2 (s). Anal. Calcd for C17H11N5S: C, 64.34; H, 3.49; N, 22.07. Found: C, 64.54; 
H, 3.70; N, 22.23. 
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5-Bromo-3-[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
(45b)  
Yellow solid; yield: 60%; mp: 390-311 °C; IR 3334, 3350 (NH) cm
-1
; 
1
H NMR (200 MHz, 
DMSO-d6) : 7.35 (dd, 1H, J = 4.8, 8.0 Hz, H-5’), 7.87 (s, 1H, H-5), 8.24 (d, 1H, J = 2.6 Hz, H-
2’’), 8.35 (d, 1H, J = 2.1 Hz, H-6’’), 8.38-8.42 (2H, m, H-2’, H-6’), 8.80 (dd, 1H, J = 1.2, 8.0 Hz, 
H-4’), 8.81 (d, 1H, J = 2.1 Hz, H-4’’), 12.26 (bs, 1H, NH), 12.46 (bs, 1H, NH); 13C NMR (50 MHz, 
DMSO-d6) : 108.2 (d), 109.5 (s), 109.8 (s), 111.5 (s), 117.1 (d), 118.3 (s), 118.7 (s), 126.8 (d), 
127.5 (d), 130.3 (d), 130.9 (d), 131.6 (s), 142.0 (d), 143.0 (d), 147.0 (s), 149.0 (s), 161.0 (s). Anal. 
Calcd for C17H10BrN5S: C, 51.53; H, 2.54; N, 17.67. Found: C, 51.30; H, 2.26; N, 17.86. 
5-Fluoro-3-[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-b]pyridine 
(45c)  
Yellow solid; yield: 75%; mp: 373-374 °C; IR 3247, 3156 (NH) cm
-1
; 
1
H NMR (200 MHz, 
DMSO-d6) δ: 7.37 (dd, 1H, J = 4.8, 7.9 Hz, H-5’), 7.83 (s, 1H, H-5), 8.27 (d, 1H, J = 2.6 Hz, H-
2’’), 8.31 (t, 1H, J = 1.7 Hz, H-6’’), 8.36 (d, 1H, J = 2.2 Hz, H-2’), 8.41 (dd, 1H, J = 1.3, 4.8 Hz, H-
6’), 8.48 (d, 1H, J = 1.7 Hz, H-4’’), 8.80 (dd, 1H, J = 1.3, 7.9 Hz, H-4’), 12.19 (bs, 1H, NH), 12.49 
(bs, 1H, NH); 
13
C NMR (50 MHz, DMSO-d6) δ: 108.1 (d), 110.0 (s), 114.0 (d, JC-4’’ = 21.2 Hz), 
116.9 (s), 117.1 (s), 117.2 (d), 127.7 (d), 128.1 (d), 131.2 (d, JC-6’’ = 28.6 Hz), 132.7 (d), 140.4 (d), 
144.8 (s), 145.5 (s), 147.4 (s), 149.2 (s), 153.0 (s), 159.2 (s, JC-5’’ = 149 Hz). Anal. Calcd for 
C17H10FN5S: C, 60.88; H, 3.01; N, 20.88. Found: C, 60.58; H, 2.80; N, 21.04. 
1-Methyl-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine 
(45d)  
Yellow solid; yield: 90%; mp: 278-279 °C; IR 3450 (NH) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) 
: 3.95 (s, 3H, CH3), 7.39 (dd, 1H, J = 4.8, 7.9 Hz, ArH), 7.55 (dd, 1H, J = 5.4, 7.8 Hz, ArH), 7.93 
(s, 1H, ArH), 8.33 (s, 1H, ArH), 8.44-8.53 (m, 3H, 3xArH), 8.69 (d, 1H, J = 7.9 Hz, ArH), 9.05 (d, 
1H, J = 7.8 Hz, ArH), 12.80 (bs, 1H, NH); 
13
C NMR (50 MHZ, DMSO-d6) : 31.4 (q), 107.7 (s), 
109.0 (d), 110.7 (s), 115.8 (s), 116.2 (d), 117.3 (d), 120.0 (s), 126.6 (d), 129.4 (d), 130.7 (d), 134.18 
(d), 137.7 (d), 142.4 (s), 143.2 (d), 146.7 (s), 148.1 (s), 151.0 (s). Anal. Calcd for C18H13N5S: C, 
65.24; H, 3.95; N, 21.13. Found: C, 65.06; H, 4.19; N, 21.43. 
3-[4-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1-methyl-1H-pyrrolo[2,3-
b]pyridine (45e)  
Yellow solid; yield: 94%; mp: 311 °C; IR 3347 (NH) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) : 
3.94 (s, 3H, CH3), 7.36 (dd, 1H, J = 4.7, 7.9 Hz, H-5’), 7.86 (s, 1H, H-5), 8.23 (d, 1H, J = 2.6 Hz, 
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H-2’’), 8.39 (d, 1H, J = 2.2 Hz, H-6’’), 8.41 (s, 1H, H-2’), 8.44 (dd, 1H, J = 1.6, 4.7 Hz, H-6’), 8.72 
(dd, 1H, J = 1.6, 7.9 Hz, H-4’), 8.81 (d, 1H, J = 2.2 Hz, H-4’’), 12.27 (bs, 1H, NH); 13C NMR (50 
MHz, DMSO-d6) : 31.6 (q), 108.1 (d), 108.3 (s), 109.4 (s), 111.5 (s), 117.2 (d), 117.6 (s), 118.8 
(s), 126.8 (d), 130.2 (d), 130.4 (d), 130.8 (d), 142.6 (d), 142.9 (d), 146.5 (s), 147.0 (s), 149.0 (s), 
161.0 (s). Anal. Calcd for C18H12BrN5S: C, 52.69; H, 2.95; N, 17.07. Found: C, 52.84; H, 3.19; N, 
16.93. 
3-[4-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1-methyl-1H-pyrrolo[2,3-
b]pyridine (45f)  
Yellow solid; yield: 90%; mp: 316 °C; IR 3377 (NH) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) : 
3.94 (s, 3H, CH3), 7.38 (dd, 1H, J = 4.8, 7.9 Hz, H-5’), 7.83 (s, 1H, H-5), 8.27 (d, 1H, J = 2.7 Hz, 
H-2’’), 8.32 (t, 1H, J = 1.7 Hz, H-6’’), 8.43-8.48 (m, 3H, H-2’, H-4’’, H-6’), 8.71 (dd, 1H, J = 1.5, 
7.9 Hz, H-4’), 12.18 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) :  31.5 (q), 107.6 (d), 108.2 (s), 
109.9 (s, JC7”a-F = 4.2 Hz), 114.1 (d, JC4”-F = 21.3 Hz), 117.0 (s, JC3”a-F = 7.3 Hz), 117.3 (d), 117.6 
(s), 127.5 (d), 127.6 (d), 130.4 (d, JC6”-F = 27.2 Hz), 130.9 (d), 131.5 (d),  142.7 (d), 145.5 (s), 146.6 
(s), 149.2 (s), 155.3 (s, JC5”-F = 239 Hz), 160.9 (s). Anal. Calcd for C18H12FN5S: C, 61.88; H, 3.46; 
N, 20.04. Found: C, 61.68; H, 3.72; N, 20.23. 
3,3'-(1,3-Thiazole-2,4-diyl)bis(1-methyl-1H-pyrrolo[2,3-b]pyridine) (45g)  
Yellow solid; yield: 60%; mp: 310-311°C; 
1
H NMR (200 MHz, DMSO-d6) : 3.94 (s, 3H, CH3), 
3.98 (s, 3H, CH3), 7.36-7.45 (m, 2H, 2xArH), 7.82 (s, 1H, ArH), 8.32 (s, 1H, ArH), 8.42 (s, 1H, 
ArH), 8.45-8.52 (m, 2H, 2xArH), 7.75 (dd, 1H, J = 1.0, 7.9 Hz, ArH), 8.81 (d, 1H, J = 7.8 Hz, 
ArH); 
13
C NMR (50 MHz, DMSO-d6) : 31.4 (q), 31.7 (q), 108.2 (d), 109.5 (s), 116.1 (d), 117.3 
(d), 117.4 (s), 129.9 (d), 130.8 (d), 131.5 (d), 140.0 (d), 140.1 (d), 143.0 (d), 144.9 (s), 145.1 (s), 
145.2 (s), 146.9 (s), 148.7 (s), 161.2 (s). Anal. Calcd for C19H15N5S: C, 66.07; H, 4.38; N, 20.27. 
Found: C, 65.92; H, 4.20; N, 20.40. 
5-Bromo-1-methyl-3-[2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-4-yl]-1H 
pyrrolo[2,3-b]pyridine (45h)  
Yellow solid; yield: 90%; mp: 308 °C; 
1
H NMR (200 MHz, DMSO-d6) : 3.92 (s, 3H, CH3), 
3.93 (s, 3H, CH3), 7.36 (dd, 1H, J = 4.7, 7.9 Hz, H-5’), 7.85 (s, 1H, H-5), 8.31 (s, 1H, H-2’’), 8.40 
(s, 1H, H-2’), 8.42 (dd, 1H, J = 1.6, 4.7 Hz, H-6’), 8.45 (d, 1H, J = 2.2 Hz, H-6’’),  8.73 (dd, 1H, J 
= 1.6, 7.9 Hz, H-4’), 8.79 (d, 1H, J = 2.2 Hz, H-4’’); 13C NMR (50 MHz, DMSO-d6) : 31.2 (q), 
31.5 (q), 107.9 (d), 108.2 (s), 108.3 (s), 111.7 (s), 117.2 (d), 117.5 (s), 118.7 (s), 130.0 (d), 130.4 
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(d), 130.5 (d), 130.6 (d), 130.7 (d), 142.9 (d), 146.0 (s), 146.7 (s), 148.6 (s), 161.0 (s). Anal Calcd 
for C19H14BrN5S: C, 53.78; H, 3.33; N, 16.50. Found: C, 53.65; H, 3.08; N, 16.73. 
5-Fluoro-1-methyl-3-[2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-4-yl]-1H-
pyrrolo[2,3-b]pyridine (45i)  
Yellow solid; yield: 60%; mp: 301-302°C; 
1
H NMR (200 MHz, DMSO-d6) : 3.92 (s, 3H, CH3), 
3.93 (s, 3H, CH3), 7.37 (dd, 1H, J = 4.7, 7.9 Hz, H-5’), 7.81 (s, 1H, H-5), 8.35-8.49 (m, 5H, H-2’, 
H-2’’, H4’’, H-6’, H-6’’), 8.72 (dd, 1H, J = 1.5, 7.9 Hz, H-4’); 13C NMR (50 MHz, DMSO-d6) : 
31.3 (q), 31.4 (q), 107.4 (d), 108.2 (s), 108.7 (s, JC7’’a-F = 4.2 Hz), 114.2 (d, JC4’’-F = 21.7 Hz), 117.0 
(s, JC3’’a-F = 7.3 Hz), 117.2 (d), 117.4 (s), 130.0 (d), 130.8 (d), 131.0 (d, JC6’’-F = 27.1 Hz), 131.4 (d), 
143.0 (d), 144.5 (s), 146.9 (s), 148.9 (s), 153.2 (s), 159.5 (s, JC5’’-F = 155.0 Hz). Anal. Calcd for 
C19H14FN5S: C, 62.79; H, 3.88; N, 19.27. Found: C, 62.94; H, 4.15; N, 19.38. 
1-Methyl-3-[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine 
(45j)  
Yellow solid; yield: 85%; mp: 303-304 °C; IR 3410 (NH) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) 
: 3.96 (s, 3H, CH3), 7.36 (dd, 1H, J = 4.8, 7.9 Hz, ArH), 7.42 (dd, 1H, J = 4.9, 7.9 Hz, ArH), 7.82 
(s, 1H, ArH), 8.31 (s, 1H, ArH), 8.39 (s, 1H, ArH), 8.42-8.46 (m, 2H, 2xArH), 8.73 (dd, 1H, J = 
1.4, 7.9 Hz, ArH), 8.87 (dd, 1H, J = 1.5, 7.9 Hz, ArH), 12.60 (bs, 1H, NH); 
13
C NMR (50 MHz, 
DMSO-d6) : 31.44 (q), 108.0 (d), 109.3 (s), 109.8 (s), 116.2 (d), 117.2 (d), 118.2 (s), 118.5 (s), 
127.5 (d), 129.6 (d), 130.2 (d), 130.8 (d), 131.5 (s), 140.7 (s), 141.4 (d), 141.6 (s), 142.3 (d), 148.9 
(s). Anal. Calcd for C18H13N5S: C, 65.24; H, 3.95; N, 21.13. Found: C, 65.09; H, 3.69; N, 21.36.  
5-Bromo-1-methyl-3-[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-
b]pyridine (45k)  
Yellow solid; yield: 80%; mp: 301 °C; IR 3174 (NH) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) : 
3.92 (s, 3H, CH3), 7.35 (dd, 1H, J = 4.8, 7.9 Hz, H-5’), 7.86 (s, 1H, H-5), 8.32 (s, 1H, H-2’’), 8.33 
(d, 1H, J = 3.1 Hz, H-2’), 8.41 (dd, 1H, J = 1.4, 4.8 Hz, H-6’), 8.43 (d, 1H, J = 2.2 Hz, H-6’’), 8.79 
(dd, 1H, J = 1.4, 7.9 Hz, H-4’), 8.80 (d, 1H, J = 2.2 Hz, H-4’’), 12.44 (bs, 1H, NH); 13C NMR (50 
MHz, DMSO-d6) : 31.2 (q), 108.4 (d), 109.9 (s), 111.7 (s), 117.1 (d), 118.6 (s), 118.7 (s), 127.9 
(d), 130.4 (d), 130.7 (d), 132.1 (d), 141.0 (d), 141.1 (s), 142.9 (d), 145.4 (s), 146.0 (s), 148.6 (s), 
160.9 (s). Anal. Calcd for C18H12BrN5S: C, 52.69; H, 2.95; N, 17.07. Found: C, 52.93; H, 3.09; N, 
17.23. 
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5-Fluoro-1-methyl-3-[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-
b]pyridine (45l)  
Yellow solid; yield: 72%; mp: 295-296 °C; IR 3434 (NH) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) 
: 3.93 (s, 3H, CH3), 7.38 (dd, 1H, J = 4.8, 7.9 Hz, H-5’), 7.83 (s, 1H, H-5), 8.36-8.50 (m, 5H, H-2’, 
H-2’’, H4’’, H-6’, H-6’’), 8.81 (dd, 1H, J = 1.4, 7.9 Hz, H-4’), 12.50 (bs, 1H, NH); 13C NMR (50 
MHz, DMSO-d6) : 31.3 (q), 107.8 (d), 108.7 (s, JC3a’’-F = 4.1 Hz), 109.8 (s), 114.2 (d, JC6’’-F = 21.8 
Hz), 116.9 (s), 117.1 (d), 117.2 (d), 118.3 (s), 127.7 (d), 130.8 (d), 131.5 (d,  JC4-F’’ = 14.1 Hz), 
141.5 (d), 144.5 (s), 145.9 (s), 148.9 (s), 153.2 (s), 159.4 (s, JC5’-F’ = 152.0 Hz). Anal. Calcd for 
C18H12FN5S: C, 61.88; H, 3.46; N, 20.04. Found: C, 62.04; H, 3.70; N, 20.19. 
Synthesis of 5-fluoro-1-methyl-1H-indole (66b) [31]  
To a cold solution of 5-fluoro-indole 66a (5 mmol) in anhydrous toluene (50 mL), potassium t-
butoxide (0.76 g, 6.8 mmol) and TDA-1 (1 or 2 drops) were added. The reaction mixture was stirred 
at room temperature for 5h, and then methyl iodide (0.31 mL, 5 mmol) was added. The reaction 
mixture was stirred at room temperature for 1h. The solvent was evaporated under reduced pressure. 
The residue, treated with water, was filtered off and extracted with DCM, dried (Na2SO4), and 
evaporated to afford the pure methyl derivative. Yellow solid; yield: 98%; mp: 55-56 °C; 1H NMR 
(200 MHz, CDCl3) δ: 3.72 (s, 3H, CH3), 6.41 (d, 1H, J = 3.2 Hz, H-3), 6.89-7.05 (m, 2H, H-4, H-6), 
7.15-7.28 (m, 2H, H-2, H-7). 13C NMR (50 MHz, CDCl3) δ: 33.0 (q), 100.7 (d, JC3-F = 4.9 Hz), 
105.4 (d, JC7-F = 5.6 Hz), 109.6 (d, JC4-F = 23.3 Hz), 109.9 (d, JC6-F = 10.8 Hz), 130.3 (d), 130.4 
(sx2), 157.8 (s, JC5-F = 233.0 Hz). Anal. Calcd for C9H8FN: C, 72.47; H, 5.41; N, 9.39. Found: C, 
72.82; H, 5.21; N, 9.12. 
 
Synthesis of 5-fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indole (66c)  
To a stirred ice-cooled solution of 5-fluoro-indole 66a (1.0 g, 7.4 mmol) in tetrahydrofuran (5 
mL) sodium hydride (60% dispersion in mineral oil, 0.39 g, 9.6 mmol) was added and the mixture 
was stirred at room temperature for 24 h. To the mixture was added p-toluenesulfonyl chloride (2.12 
g, 11.1 mmol) and the mixture was stirred at room temperature for 4 h. The residue was evaporated 
under reduced pressure, treated with water, extracted with ethyl acetate. The organic phase was 
dried (Na2SO4), evaporated under reduced pressure and purified by column chromatography using 
petroleum ether/DCM (9/1) as eluent. White solid; yield: 96%; mp: 111 -112 °C; IR 1373, 1172 
(SO2) cm
-1; 1H NMR (200 MHz, DMSO-d6) δ: 2.32 (s, 3H, CH3), 6.82-6.84 (m, 1H, H-7), 7.19 (td, 
1H, J = 2.6, 9.2, 11.0 Hz, H-6), 7.39 (d, 2H, J = 8.7 Hz, H-3’, H-5’), 7.45 (d, 1H, J = 2.6 Hz, H-3), 
7.87 (d, 2H, J = 8.7 Hz, H-2’, H-6’), 7.88-7.97 (m, 2H, H-2, H-4); 13C NMR (50 MHz, DMSO-d6) 
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: 21.0 (q), 107.0 (d, JC4-F = 24.1 Hz), 109.3 (d, JC3-F = 4.2 Hz), 112.5 (d, JC6-F = 25.8 Hz), 114.4 (d, 
JC7-F = 9.6 Hz), 126.7 (dx2), 128.9 (d), 130.2 (dx2), 130.6 (s), 131.6 (s, JC3a-F = 10.4 Hz), 133.9 (s), 
145.6 (s), 158.9 (s, JC5 = 237.7 Hz). Anal. Calcd for: C15H12FNO2S: C, 62.27; H, 4.18; N,4.84. 
Found: C, 62.57; H, 4.38; N, 4.69. 
Synthesis of 1-(1-methyl-1H-indol-3-yl)ethanone (66e)  [29]  
Potassium t-butoxide (1.0 g, 8.6 mmol) and TDA-1 (1– 2 drops) were added to a cold solution of 
3-acetylindole 66d (1.0 g, 6.3 mmol) in anhydrous toluene (50 mL). The reaction mixture was 
stirred at room temperature for 8h and then methyl iodide (0.4 mL, 6.3 mmol) was added. 
Methylation was complete after 2h. The solvent was evaporated under reduced pressure. The 
residue was treated with water, extracted with DCM, dried, evaporated, and purified by column 
chromatography using DCM/ethyl acetate (9/1) as eluent. White solid; yield: 80%, mp: 108-109 °C; 
IR 1643 (CO) cm-1; 1H NMR (200 MHz, DMSO-d6) 2.44 (s, 3H, CH3), 3.85 (s, 3H, CH3), 7.19-
7.32 (m, 2H, H-5, H-6), 7.52 (dd, 1H, J  = 6.4, 1.8 Hz, H-7), 8.23 (dd, 1H, J=6.4, 1.8 Hz, H-4), 8.29 
(s,1 H, H-2); 13C NMR (50 MHz, DMSO-d6) : 27.2 (q), 33.0 (q), 110.5 (d), 115.6 (s), 121.4 (d), 
121.9 (d), 122.7 (d), 125.7 (s), 137.2 (s), 137.9 (d), 192.0 (s). Anal. Calcd for: C11H11NO: C, 76.28; 
H, 6.40; N, 8.09. Found: C, 76.41; H, 6.29; N. 7.87. 
 
Synthesis of 1-{1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}ethanone (66f)  
To a cooled solution of 3-acetylindole 66d (1.0 g, 6.3 mmol) in tetrahydrofuran (5 mL) sodium 
hydride (60% dispersion in mineral oil, 0.25 g, 6.3 mmol) was added and the mixture was stirred at 
room temperature for 1 h. p-Toluenesulfonyl chloride (1.2 g, 6.3 mmol) was added and the mixture 
was stirred at room temperature for 24 h. The reaction mixture was purified by column 
chromatography using DCM as eluent. White solid; yield: 90%; mp: 148-149 °C; IR 1382, 1299 
(SO2), 1662 (CO) cm
-1; 1H NMR (200 MHz, DMSO-d6) δ: 2.33 (s, 3H, CH3), 2.60 (s, 3H, CH3), 
7.32-7.39 (m, 2H, H-5, H-6), 7.43 (d, 2H, J = 7.8 Hz, H-3’, H-5’), 7.95 (d, 1H, J = 7.5 Hz, H-7), 
8.04 (d, 2H, J = 7.8 Hz, H-2’, H-6’), 8.19 (d, 1H, J = 7.5 Hz, H-4), 8.81 (s, 1H, H-2); 13C NMR (50 
MHz, DMSO-d6) δ: 21.0 (q), 27.8 (q), 113.0 (d), 120.7 (s), 122.3 (d), 124.8 (d), 125.6 (d), 127.0 (s), 
127.2 (dx2), 130.5 (dx2), 133.5 (s), 134.0 (s), 134.2 (d), 146.2 (s), 193.9 (s). Anal. Calcd for: 
C17H15NO3S: C, 65.16; H, 4.82; N, 4.47. Found: C, 65.28, H, 5.06, N, 4.37. 
Synthesis of 2-chloro-1-(5-fluoro-1H-indol-3-yl)ethanones (67b, 67c)  
To a stirred ice-cooled suspension of anhydrous aluminium chloride (1.14 g, 8.5 mmol), in DCM 
(18 mL), was added dropwise at 0 °C a solution of suitable indole 66b,c (1.21 mmol) in DCM (5 
mL) under nitrogen atmosphere. Then chloroacetyl chloride (0.3 mL, 3.63 mmol) was slowy added 
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to the reaction mixture. The resulting mixture was stirred at room temperature for 1 h and poured in 
stirred ice and water and extracted with DCM.  The organic phase was dried (Na2SO4), evaporated 
under reduced pressure and purified by column chromatography using DCM as eluent. 
 
2-Chloro-1-(5-fluoro-1-methyl-1H-indol-3-yl)ethanone (67b)                                       
White solid; yield: 50 %; mp: 185-186 °C; IR 1653.07 (CO) cm-1; 1H NMR (200 MHz, DMSO-
d6) δ: 3.89 (s, 3H, CH3), 4.84 (s, 2H, CH2), 7.20 (td, 1H, J = 2.6, 9.2, 11.0 Hz, H-6), 7.62 (dd, 1H, J 
= 4.5, 9.2 Hz, H-7), 7.84 (dd, 1H, J = 2.6, 11 Hz, H-4), 8.51 (bs, 1H, H-2); 13C NMR (50 MHz, 
DMSO-d6) : 33.7 (q), 46.2 (t), 106.1 (d, JC4-F = 24.8 Hz), 111.3 (d, JC6-F = 26. 1), 112.3 (s), 112.4 
(d, JC7-F = 9.8), 126.4 (s, JC3a-F = 11.0 Hz), 133.9 (s), 139.5 (d), 159.0 (s, JC5-F = 236 Hz), 185.6 (s). 
Anal. Calcd for C11H9ClFNO: C, 58.55; H, 4.02; N, 6.21. Found: C, 58.85; H, 4.14; N, 6.01. 
2-Chloro-1-{5-fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}ethanone (67c)  
White solid; yield: 55%; mp: 155-156 °C; IR 1375, 1171 (SO2), 1683 (CO) cm
-1; 1H NMR (200 
MHz, CDCl3) δ: 2.39 (s, 3H, CH3), 4.54 (s, 2H, CH2), 7.13 (td, 1H, J = 2.6, 8.9, 11.0 Hz, H-6), 7.31 
(d, 2H, J = 8.0 Hz, H-3’, H-5’), 7.82 (d, 2H, J = 8.0 Hz, H-2’, H-6’), 7.90 (dd, 1H, J = 4.9, 8.9 Hz, 
H-7), 7.98 (dd, 2H, J = 2.6, 11.0 Hz, H-4), 8.34 (s, 1H, H-2); 13C NMR (50 MHz, CDCl3) δ: 21.7 
(q), 45.8 (t), 108.9 (d, JC6-F = 25.5 Hz), 114.1 (s), 114.2 (d), 114.5 (d, JC4-F = 14.0 Hz), 117.9 (s, JC7a-
F = 4.5 Hz), 127.2 (dx2), 130.2 (s), 130.4 (dx2), 133.5 (d), 134.1 (s), 146.5 (s), 160.1 (s, JC5-F = 241 
Hz), 186.7 (s). Anal. Calcd for C17H13ClFNO3S: C, 55.82; H, 3.58; N, 3.83. Found: C, 55.99; H, 
3.36; N, 4.10. 
Synthesis of 2-bromo-(1H-indol-3-yl)ethanones (67e, 67f)  
To a cold suspension of the appropriate 3-acetylindoles 66e,f (1.9 mmol) in anhydrous methanol 
(3 mL), bromine (0.1 mL, 1.9 mmol) was added dropwise. The mixture was heated at reflux for 2 h. 
After cooling the solvent was evaporated under reduced pressure. The residue was treated with 
water, made alkaline by adding NaHCO3 and extracted with ethyl acetate. The organic phase was 
dried, evaporated under reduced pressure and purified by column chromatography using DCM as 
eluent.  
 
2-Bromo-1-(1-methyl-1H-indol-3-yl)ethanone  (67e) [29]  
Brown solid; yield: 70%; mp: 205-206 °C; IR 1643 (CO) cm-1; 1H NMR (200 MHz, DMSO-d6) 
: 3.37 (s, 3H, CH3), 4.60 (s, 2H, CH2), 7.27–7.33 (m, 2H, H-5, H-6), 7.59 (dd, 1H, J = 6.0, 1.9 Hz, 
H-7), 8.18 (dd, 1H, J = 6.0, 1.9 Hz, H-4), 8.50 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) : 33.3 
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(q), 33.4 (t), 110.9 (d), 112.3 (s), 121.3 (d), 122.5 (d), 123.3 (d), 125.9 (s), 137.4 (s), 138.7 (d), 
185.8 (s). Anal. Calcd for C11H10BrNO: C, 52.41; H, 4.00; N, 5.56. Found: C, 52.57; H, 4.11; N, 
5.39. 
 
2-Bromo-1-{1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}ethanone (67f)  
Solid; yield: 40%; mp: 134-135 °C; IR 1379, 1177 (SO2), 1668 (CO) cm
-1; 1H NMR (200 MHz, 
CDCl3) δ: 2.38 (s, 3H, CH3), 4.36 (s, 2H, CH2), 7.29 (d, 2H, J = 8.2 Hz, H-3’, H-5’), 7.36-7.40 (m, 
2H, H-5, H-6), 7.83-7.87 (m, 2H, H-2’, H-6’), 7.91-7.96 (1H, m, H-7), 8.28-8.34 (2H, m, H-2, H-4); 
13C NMR (50 MHz, CDCl3) δ: 21.7 (q), 31.4 (t), 113.1 (d), 123.1 (d), 124.3 (s), 125.1 (d), 126.1 (d), 
127.2 (dx2), 127.5 (s), 130.4 (dx2), 132.8 (d), 134.2 (s), 134.8 (s), 146.2 (s), 187.0 (s). Anal. Calcd 
for C17H14BrNO3S: C, 52.05; H, 3.60; N, 3.57. Found: C, 52.25; H, 3.70; N, 3.35. 
Synthesis of 1-(5-fluoro-1-methyl-1H-indol-3-yl)ethanone (68)  
To a cooled suspension of anhydrous aluminium chloride (1.58 g, 11.76 mmol) in DCM (25 mL) 
was added drop-wise a solution of 66b (0.250 g, 1.68 mmol) in dichloromethane (5 mL), under a 
nitrogen atmosphere. To the reaction mixture was slowly added acetic anhydride (0.48 mL, 5.04 
mmol). The resulting mixture was stirred at room temperature for 4 h and it was poured into ice 
water and extracted with DCM. The organic phase was dried over Na2SO4, evaporated under 
reduced pressure and purified by column chromatography using DCM as eluent. White solid; yield: 
41%, mp: 110-111 °C, IR 1683 (CO) cm-1; 1H NMR (200 MHz, CDCl3) δ: 2.50 (s, 3H, CH3), 3.84 
(s, 3H, CH3), 7.05 (td, 1H, J = 2.5, 8.9, 11.5 Hz, H-6), 7.22-7.28 (m, 1H, H-7), 7.71 (s, 1H, H-2),  
8.05 (dd, 1H, J = 2.6, 9.7 Hz, H-4). Anal. Calcd for C11H10FNO: C, 69.10; H, 5.27; N, 7.33. Found: 
C, 68.87; H, 5.53; N, 6.98. 
 
Synthesis of 2-bromo-1-(5-fluoro-1-methyl-1H-indol-3-yl)ethanone (69)  
To a cold suspension of the appropriate 3-acetylindole 68 (2.45 mmol) in anhydrous methanol (3 
mL), bromine (0.1 mL, 2.45 mmol) was added dropwise. The mixture was heated at reflux for 2 h. 
After cooling the solvent was evaporated under reduced pressure. The residue was treated with 
water, made alkaline by adding NaHCO3 and extracted with ethyl acetate. The organic phase was 
dried, evaporated under reduced pressure and purified by column chromatography using 
ciclohexane/ethyl acetate (8/2) as eluent. White solid; yield: 35%, mp: 200-201 °C; IR 1680 (CO) 
cm-1; 1H NMR (200 MHz, DMSO-d6) : 3.89 (s, 3H, CH3), 4.83 (s, 2H, CH2), 7.19 (td, 1H, J = 2.6, 
9.2, 11.8 Hz, H-6), 7.63 (dd, 1H, J = 4.4, 8.9 Hz, H-7), 7.84 (dd, 1H, J = 2.5, 9.7 Hz, H-4), 8.52 (s, 
1H, H-2); 13C NMR (50 MHz, DMSO-d6) : 33.7 (q), 46.2 (t), 106.1 (d, JC4-F = 24.8 Hz), 111.3 (d, 
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JC6-F = 26.0 Hz), 112.4 (d, JC7-F = 9.4 Hz), 126.3 (s), 126.5 (s), 133.9 (s), 139.5 (d), 159.0 (s, JC5-F = 
235 Hz), 185.6 (s). Anal. Calcd for C11H9BrFNO: C, 48.91; H, 3.36; N, 5.19. Found: C, 48.64; H, 
3.57; N, 5.43. 
 
Synthesis of 1-(5-fluoro-1H-indol-3-yl)ethanone  (70)  [46]  
To a solution of ammonium chloride (8.8 mmol, 0.47 g) suspended in DCM (4 mL) was added 
dropwise acetic anhydride (4.4 mmol, 0.42 ml) at room temperature, and the mixture was stirred at 
room temperature for 15 min. Then, 5-fluoro indole 66a (2.22 mmol, 0.300 g) in DCM (4 mL) was 
added dropwise and the mixture was stirred at room temperature for 2 h. AlCl3 (4.4 mmol, 0.60 g) 
was added. Acetic anhydride (2.22 mmol, 0.21 ml) was added, and the mixture was stirred for 30 
min. The mixtures was poured into crushed ice and subjected to extractive workups with EtOAc. 
The organic phase was dried, evaporated under reduced pressure and purified by column 
chromatography using dichlorometane/ethyl acetate (93/7) as eluent. White solid; yield: 55%; mp: 
200-201 °C; IR 1670 (CO) cm-1; 1H NMR (200 MHz, DMSO-d6) δ: 2.50 (s, 3H, CH3), 7.07 (td, 1H, 
J = 2.7, 9.1, 11.7 Hz, H-6), 7.48 (dd, 1H, J = 4.5, 8.8 Hz, H-4), 7.85 (dd, 1H, J = 2.6, 9.9 Hz, H-7), 
8.38 (s, 1H, H-2), 12.06 (bs, 1H, NH). Anal. Calcd for C10H8FNO: C, 67.79; H, 4.55; N, 7.91. 
Found: C, 67.53; H, 4.74; N, 7.71.  
 
Synthesis of substituted indolyl-thiazolyl-1H-pyrrolo[2,3-b]pyridines (46a-d), (47a-d)  
A suspension of the appropriate pyrrolo[2,3-b]pyridine-carbothioamide 54a,b (5 mmol) and 
halo-acetyl compounds 67b,c,e,f (5 mmol) in 3 mL of anhydrous ethanol was heated under reflux 
for 30 minutes. The precipitate, obtained after cooling, was filtered off, dried and crystallized with 
ethanol to afford derivatives 46a-d and 47a-d. 
3-[4-(5-Fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (46a)  
Yellow solid; yield: 97%; mp: 237-238 °C; IR 3550 (NH) cm-1; 1H NMR (200 MHz, DMSO-d6) 
δ: 3.90 (s, 3H, CH3), 7.12 (t, 1H, J = 8.2 Hz, H-6’’), 7.44 (dd, 1H, J = 5.2, 7.4 Hz, H-5’), 7.54 (dd, 
1H, J = 4.6, 8.2 Hz, H-7’’), 7.73 (s, 1H, H-2’’), 7.94 (dd, 1H, J = 9.7, 2.5 Hz, H-4’’), 8.16 (s, 1H, H-
2’), 8.38 (s, 1H, H-5), 8.45 (d, 1H, J = 3.7 Hz, H-6’), 8.89 (d, 1H, J = 7.4 Hz, H-4’), 12.74 (s, 1H, 
NH). Anal. Calcd for C19H13FN4S: C, 65.50; H, 3.76; N, 16.08. Found: C, 65.76; H, 3.55; N, 16.22. 
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3-[4-(5-fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine 
(46b)   
Yellow solid; yield: 30%; mp: 286-287 °C; 1H NMR (200 MHz, DMSO-d6) δ: 2.56 (s, 3H, CH3), 
4.03 (s, 3H, CH3), 6.02 (dd, 1H, J = 4.3, 10.7 Hz, H-7’’), 6.76 (td, 1H, J = 2.3, 9.5, 10.7 Hz, H-6’’), 
6.98 (dd, 1H, J = 5.0, 8.4 Hz, H-5’), 7.25 (dd, 1H, J = 2.3, 9.5 Hz, H-4’’), 7.72 (d, 1H, J = 7.8 Hz, 
H-4’), 8.19-8.81 (m, 4H, H-2’, H-2’’, H-5, H-6’). Anal. Calcd for C20H15FN4S: C, 66.28; H, 4.17; 
N, 15.46. Found: C, 66.53; H, 3.90; N, 15.23. 
3-[4-(1-Methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine  (46c)  
Yellow solid; yield: 60%; mp: 274-275 °C, IR 3427 (NH) cm-1; 1H NMR (200 MHz, DMSO-d6) 
δ: 3.90 (s, 3H, CH3), 7.21-7.30 (m, 2H, H-5’’, H-6’’), 7.36 (dd, 1H, J = 4.9, 7.7 Hz, H-5’), 7.53 (d, 
1H, J = 7.1 Hz, H-7’’), 7.66 (s, 1H, H-2’’), 8.05 (s, 1H, H-5), 8.19 (d, 1H, J = 7.1 Hz, H-4’’), 8.30 
(d, 1H, J = 2.0 Hz, H-2’), 8.40 (d, 1H, J = 4.9 Hz, H-6’), 8.79 (d, 1H, J = 7.7 Hz, H-4’), 12.40 (bs, 
1H, NH); 13C NMR (50 MHz, DMSO-d6) : 32.6 (q), 106.5 (d), 109.6 (s), 110.2 (d), 117.1 (d), 
117.3 (s), 119.9 (d), 120.1 (d), 121.6 (d), 124.9 (s), 126.9 (d), 129.2 (d), 129.7 (d), 137.1 (s), 143.2 
(d), 143.3 (s), 147.9 (s), 150.1 (s), 161.0 (s). Anal. Calcd for C19H14N4S: C, 69.07; H, 4.27; N, 
16.96. Found: C, 68.90; H, 4.46; N, 16.75. 
1-Methyl-3-[4-(1-methyl-1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (46d) 
Yellow solid; yield: 60%; mp: 290-291 °C; 1H NMR (200 MHz, DMSO-d6) δ: 3.90 (s, 3H, CH3), 
3.94 (s, 3H, CH3), 7.17-7.30 (m, 2H, H-5’’, H-6’’), 7.39 (dd, 1H, J = 4.7, 7.9 Hz, H-5’), 7.53 (dd, 
1H, J = 1.4, 6.9 Hz, H-7’’), 7.66 (s, 1H, H-2’’), 8.05 (s, 1H, H-2’), 8.19 (dd, 1H, J = 1.4, 6.9 Hz, H-
4’’), 8.41 (s, 1H, H-5), 8.45 (dd, 1H, J = 1.3, 4.7 Hz, H-6’), 8.78 (dd, 1H, J = 1.3, 7.9 Hz, H-4’); 13C 
NMR (50 MHz, DMSO-d6) : 31.4 (q), 32.6 (q), 106.5 (d), 108.3 (s), 110.0 (s), 110.2 (d), 117.2 (d), 
117.5 (s), 119.9 (d), 120.1 (d), 121.6 (d), 124.9 (s), 129.3 (d), 129.8 (d), 130.5 (d), 137.0 (s), 143.1 
(d), 147.0 (s), 150.1 (s), 160.7 (s). Anal. Calcd for C20H16N4S: C, 69.74; H, 4.68; N, 16.27. Found: 
C, 69.50; H, 4.84; N, 16.06. 
3-(4-{5-Fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}-1,3-thiazol-2-yl)-1H-pyrrolo[2,3-
b]pyridine (47a)   
Yellow solid; yield: 97%; mp: 257-258 °C; IR 1337 (NH), 1171, 1370 (SO2); 
1H NMR (200 
MHz, DMSO-d6) δ: 2.31 (s, 3H, CH3), 7.28-7.32 (m, 2H, ArH), 7.39-7.42 (m, 2H, H-3’’’, H-5’’’), 
7.94-7.98 (m, 2H, H-2’’’, H-6’’’), 8.03-8.15 (m, 3H, ArH), 8.42-8.49 (m, 3H, ArH), 8.74 (d, 1H, J = 
7.4 Hz, H-4’), 12.67 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 21.1 (q), 107.3 (d, JC4’’-F = 24.1 
Hz), 109.3 (s), 112.6 (d, JC6’’-F = 26.8 Hz), 113.4 (d), 114.9 (d, JC7’’-F = 9.9 Hz), 117.2 (d), 117.4 (s), 
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117.5 (s), 117.6 (s),  126.3 (d), 126.9 (2xd), 127.8 (d), 128.8 (s), 129.0 (s), 130.2 (d), 130.4 (2xd), 
131.1 (s), 133.6 (s), 142.3 (d), 145.9 (s), 146.9 (s), 159.4 (s, JC5’’-F = 245.5 Hz).  Anal. Calcd for 
C25H17FN4O2S2: C, 61.46; H, 3.51; N, 11.47. Found: C, 61.73; H, 3.25; N, 11.31. 
3-(4-{5-Fluoro-1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}-1,3-thiazol-2-yl)-1-methyl-1H-
pyrrolo[2,3-b]pyridine (47b)   
White solid; yield: 40%; mp: 230-231; IR 1299, 1380 (SO2) cm
-1; 1H NMR (200 MHz, DMSO-
d6) δ: 2.32 (s, 3H, CH3), 3.94 (s, 3H, CH3), 7.28-7.43 (m, 2H, ArH), 7.41 (d, 2H, J = 7.8 Hz, H-3’’’-
H5’’’), 7.87-7.94 (m, 2H, H2’’’, H6’’’), 7.99-8.13 (m, 3H, ArH), 8.42-8.48 (m, 3H, ArH), 8.60 (d, 
1H, J = 7.3 Hz, H-4’); 13C NMR (50 MHz, DMSO-d6) : 21.0 (q), 31.2 (q), 107.4 (d, JC4’’-F = 25.2 
Hz), 107.8 (s), 112.0 (d), 113.1 (d, JC6’’-F = 27.5 Hz), 114.8 (d, JC7’’-F = 9.1 Hz), 116.9 (s), 117.4 (d), 
117.5 (s, JC7’’a = 4.0 Hz), 126.3 (d), 126.9 (2xd), 128.6 (d), 128.8 (s), 129.0 (s), 130.4 (d), 130.8 
(2xd), 131.1 (s), 133.6 (s), 143.8 (d), 145.9 (s), 146.9 (s), 147.6 (s), 159.3 (s, JC5’’-F = 246.5 Hz). 
Anal. Calcd for C26H19FN4O2S2: C, 62.13; H, 3.81; N, 11.15. Found: C, 61.98; H, 3.99; N, 10.90. 
3-(4-{1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}-1,3-thiazol-2-yl)-1H-pyrrolo[2,3-b]pyridine 
(47c) 
Yellow solid; yield: 90%; mp: 260-261 °C; IR 1374, 1174 (SO2), 3498 (NH) cm
-1; 1H NMR (200 
MHz, DMSO-d6) δ: 2.30 (s, 3H, CH3), 7.31-7.41 (m, 5H, ArH), 7.94-7.98 (m, 2H, ArH), 8.01-8.07 
(m, 2H, ArH), 8.36-8.39 (m, 4H, ArH), 8.64 (d, 1H, J = 7.7 Hz, H-4’), 12.39 (s, 1H, NH); 13C NMR 
(50 MHz, DMSO-d6) : 21. 0 (q), 109.1 (s), 11.8 (d), 113.4 (d), 116.7 (s), 117.2 (d), 117.7 (s), 121.7 
(d), 124.0 (d), 124.5 (d), 125.2 (d), 126.8 (dx2), 127.2 (d), 127.9 (s), 128.6 (d), 130.3 (dx2), 133.8 
(s),  134.6 (s), 144.0 (d), 145.7 (s), 147.3 (s), 148.7 (s), 162.1 (s). Anal. Calcd for C25H18N4O2S2: C, 
63.81; H, 3.86; N, 11.91. Found: C, 63.55; H, 4.02; N, 11.76.  
1-Methyl-3-(4-{1-[(4-methylphenyl)sulfonyl]-1H-indol-3-yl}-1,3-thiazol-2-yl)-1H-pyrrolo[2,3-
b]pyridine (47d)  
Yellow solid; yield: 50%; mp: 250-251 °C; IR 1374, 1174 (SO2) cm
-1; 1H NMR (200 MHz, 
DMSO-d6) δ: 2.30 (s, 3H, CH3), 3.94 (s, 3H, CH3), 7.37-7.45 (m, 5H, ArH), 7.93-7.97 (m, 2H, 
ArH), 8.01-8.09 (m, 2H, ArH), 8.31-8.47 (m, 4H, ArH), 8.66 (d, 1H, J = 7.5 Hz, H-4’); 13C NMR 
(50 MHz, DMSO-d6) : 21.0 (q), 31.4 (q), 108.0 (s), 112.0 (d), 113.4 (d), 117.2 (s), 117.4 (d), 117.6 
(s), 121.7 (d), 124.0 (d), 124.6 (d), 125.2 (d), 126.8 (2xd), 127.8 (s), 129.3 (d), 130.3 (2xd), 130.9 
(d), 133.8 (s), 134.6 (s), 145.7 (s), 147.1 (s), 147.4 (s), 148.2 (d), 161.6 (s). Anal. Calcd for: 
C26H20N4O2S2: C, 64.44; H, 4.16, N, 11.56. Found: C, 64.19; H, 4.33; N, 11.25. 
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Synthesis of indolyl-thiazolyl-1H-pyrrolo[2,3-b]pyridines (48a-d) 
To a suspension of the appropriate derivatives 47a-d (0.60 mmol) in 2 mL of anhydrous ethanol, 
potassium hydroxide (0.1 g, 1.8 mmol) was added and the mixture was heated at reflux for 1-2 h. 
The precipitate, obtained after cooling, was filtered off, dried and crystallized with ethanol to afford 
derivatives 48a-d. 
3-[4-(5-Fluoro-1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (48a)  
Conditions: reflux for 1.5 h. Yellow solid; yield: 98 %; mp: 248-249 °C; IR 3550, 3600 (NH) cm-
1; 1H NMR (200 MHz, DMSO-d6) δ: 7.05 (t, 1H, J = 7.8 Hz, H-6’’), 7.47-7.53 (m, 2H, H-5’, H-7’’), 
7.78 (bs, 1H, H-2’’), 7.92 (d, 1H, J = 8.9 Hz, H-4’’), 8.19 (bs, 1H, H-2’), 8.47 (m, 2H, H-5, H-6’), 
8.95 (d, 1H, J = 7.4 Hz, H-4’), 11.70 (s, 1H, NH), 12.93 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-
d6) : 104.7 (d, JC4’’-F = 21.6 Hz), 107.3 (d), 109.7 (d, JC6’’-F = 26.1 Hz), 109.8 (s), 110.7 (s), 113.0 
(d, JC7’’-F = 10.0 Hz), 117.2 (d), 119.0 (s), 124.6 (s, J3’’a-F = 10.5 Hz), 127.2 (d), 128.2 (d), 132.3 (d), 
133.3 (s), 140.6 (d), 144.7 (s), 149.6 (s), 157.5 (s, JC5’’-F = 232 Hz), 160.5 (s). Anal. Calcd for 
C18H11FN4S: C, 64.66; H, 3.32; N, 16.76. Found: C, 64.37; H, 3.04; N, 16.57. 
3-[4-(5-Fluoro-1H-indol-3-yl)-1,3-thiazol-2-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine  (48b)  
Conditions: reflux for 1 h. Yellow solid; yield: 40%; mp: 243-244 °C; IR 3557 (NH) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 3.93 (s, 3H, CH3), 7.04 (td, 1H, J = 2.1, 9.1, 10.9 Hz, H-6’’), 7.35 
(dd, 1H, J = 4.6, 7.8 Hz, H-5’), 7.49 (dd, 1H, J = 4.6, 9.1 Hz, H-7’’), 7.70 (s, 1H, H-2’’), 7.96 (dd, 
1H, J = 2.1, 10.9 Hz, H-4’’), 8.11 (bs, 1H, H-2’), 8.38 (s, 1H, H-5), 8.42 (d, 1H, J = 4.6 Hz, H-6’), 
8.69 (d, 1H, J = 7.8 Hz, H-4’), 11.64 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 31.2 (q), 
104.9 (d, JC4’’-F = 24 Hz), 106.5 (d), 108.3 (s), 109.7 (d, JC6’’-F = 26 Hz), 111.3 (s, JC7’’a = 4.5 Hz), 
112.9 (d, JC7’’-F = 9.5 Hz), 117.0 (s), 117.2 (d), 124.8 (s, JC4’’a-F = 10.1 Hz), 126.8 (d), 129.0 (d), 
130.2 (d), 133.3 (s), 143.7 (d), 147.6 (s), 150.2 (s), 157.4 (s, JC5’’-F = 231.9 Hz), 160.8 (s). Anal. 
Calcd for C19H13FN4S: C, 65.50; H, 3.76; N, 16.08. Found: C, 65.36; H, 3.47; N, 15.82. 
3-[4-(1H-Indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridine (48c)  
Conditions: reflux for 2 h. Yellow solid; yield: 98 %; mp: 297-298 °C; IR 3557, 3676 (NH) cm-1; 
1H NMR (200 MHz, DMSO-d6) δ: 7.13-7.23 (m, 2H, H-5’’, H-6’’), 7.39 (dd, 1H, J = 4.9, 7.9 Hz, 
H-5’), 7.47-7.51 (m, 1H, H-7’’), 7.68 (s, 1H, H-2’’), 8.05 (d, 1H, J = 2.6 Hz, H-2’), 8.18 (dd, 1H, J 
= 2.7, 7.1 Hz, H-4’’),  8.34 (s, 1H, H-5), 8.42 (dd, 1H, J = 1.5, 4.9 Hz, H-6’), 8.82 (dd, 1H, J = 1.5, 
7.9 Hz, H-4’), 11.46 (bs, 1H, NH), 12.50 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 106.6 (d), 
109.7 (s), 110.9 (s), 111.9 (d), 117.1 (d), 117.6 (s), 119.8 (d), 120.0 (d), 121.5 (d), 124.6 (s), 125.1 
(d), 127.1 (d), 130.3 (d), 136.6 (s), 142.7 (d), 147.3 (s), 150.5 (s), 160.8 (s). Anal. Calcd for 
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C18H12N4S: C, 68.33; H, 3.82; N, 17.71. Found: C, 68.06; H, 4.07; N, 17.45. 
3-[4-(1H-Indol-3-yl)-1,3-thiazol-2-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine  (48d)  
Conditions: reflux for 1.5 h. Yellow solid; yield: 98%; mp: 276-277 °C; IR 3500 (NH) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 3.95 (s, 3H, CH3), 7.14-7.25 (m, 2H, H-5’’, H-6’’), 7.41 (dd, 1H, J 
= 5.0, 7.7 Hz, H-5’), 7.50 (dd, 1H, J = 2.1, 7.4 Hz, H-7’’), 7.69 (s, 1H, H-2’’), 8.05 (d, 1H, J = 5.0 
Hz, H-6’), 8.16-8.21 (m, 1H, H-4’’), 8.45-8.48 (m, 2H, H-5, H-2’), 8.78 (dd, 1H, J = 2.0, 7.7 Hz, H-
4’), 11.49 (s, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 31.6 (q), 106.8 (d), 108.4 (s), 110.7 (s), 
111.9 (d), 117.3 (d), 119.8 (d), 119.9 (d), 121.6 (d), 124.6 (s), 125.1 (d), 125.9 (s), 130.3 (d), 130.8 
(d), 135.7 (s), 136.6 (s), 142.6 (d), 150.3 (s), 160.6 (s). Anal. Calcd for C19H14N4S: C, 69.07; H, 
4.27; N, 16.96. Found: C, 69.31; H, 4.50; N, 16.70. 
Synthesis of 5-substituted 1- methyl-1H-indoles (73b−d)  
To a cold solution of indoles 72b−d (5 mmol) in anhydrous toluene (50 mL), potassium t-
butoxide (0.76 g, 6.8 mmol) and TDA-1 (1 or 2 drops) were added. The reaction mixture was stirred 
at room temperature for 1−24 h, and then methyl iodide (0.31 mL, 5 mmol) was added. Methylation 
was complete after 0.5−1 h. The solvent was evaporated under reduced pressure. The residue, 
treated with water, was filtered off and air dried or extracted with DCM, dried (Na2SO4), and 
evaporated to afford the pure methyl derivatives 73b-d.  
 
5-Methoxy-1-methyl-1H-indole (73b) [27] 
Conditions: room temperature for 1 h, then room temperature for 0.5 h. Workup: filtration. 
White solid; yield: 97%; mp: 84 °C; 
1
H NMR (200 MHz, CDCl3) : 3.67 (3H, s, CH3), 3.81 (3H, s, 
CH3), 6.38 (1H, d, J = 2.9 Hz, H-3), 6.87 (1H, dd, J = 2.9, 8.8 Hz, H-6), 6.96 (1H, d, J = 2.9 Hz, H-
4), 7.07 (1H, d, J = 2.9 Hz, H-2), 7.17 (1H, d, J = 8.8 Hz, H-7); 
13
C NMR (50 MHz, CDCl3) : 32.8 
(q), 55.8 (q), 100.3 (d), 102.4 (d), 109.8 (d), 111.8 (d), 128.7 (s), 129.2 (d), 132.1 (s), 153.9 (s). 
Anal. Calcd for C10H11NO: C, 74.51; H, 6.88; N, 8.69. Found: C, 74.76; H, 6.84; N, 8.43. 
 
5-Bromo-1-methyl-1H-indole (73c) [27]  
Conditions: room temperature for 24 h, then room temperature for 1 h. Workup: extraction. Oil; 
yield: 96%; 
1
H NMR (200 MHz, CDCl3) : 3.47 (3H s, CH3), 6.29 (1H, d, J = 3.1 Hz, H-3), 6.84 
(1H, d, J = 3.1 Hz, H-2), 6.94 (1H, d, J = 8.5 Hz, H-7), 7.17 (1H, dd, J = 1.7, 8.5 Hz, H-6), 7.65 
(1H, d, J = 1.7 Hz, H-4); 
13
C NMR (50 MHz, CDCl3) : 32.6 (q), 100.2 (d), 110.5 (d), 121.2 (s), 
122.9 (d), 123.9 (d), 127.6 (s), 129.8 (d), 135.1 (s). Anal. Calcd for C9H8BrN: C, 51.46; H, 3.84; N, 
6.67. Found: C, 51.62; H, 3.78; N, 6.89. 
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5-Fluoro-1-methyl-1H-indole (73d) [31]  
Conditions: room temperature for 5 h and then room temperature for 1 h. Workup: extraction. 
Yellow solid; yield 98%; mp: 55-56 °C. 
1
H NMR (200 MHz, CDCl3) δ: 3.72 (s, 3H, CH3), 6.41 (d, 
1H, J = 3.2 Hz, H-3), 6.89-7.05 (m, 2H, H-4 and H-6), 7.15-7.28 (m, 2H, H-2 and H-7); 
13
C NMR 
(50 MHz, CDCl3) δ: 33.0 (q), 100.7 (d, JC3-F = 4.9 Hz), 105.4 (d, JC7-F = 5.6 Hz), 109.6 (d, JC4-F = 
23.3 Hz), 109.9 (d, JC6-F = 10.8 Hz), 130.3 (d), 130.4 (2xs), 157.8 (d, JC5-F = 233.0 Hz). Anal. Calcd 
for C9H8FN: C, 72.47; H, 5.41; N, 9.39. Found: C, 72.82; H, 5.21; N, 9.12. 
 
Synthesis of 5-substituted tert-butyl 1H-indole-1-carboxylates (74a−d) [31] 
Di-tert-butyl dicarbonate (8.73 g, 40 mmol) and triethylamine (3.3 mL, 23.7 mmol) were added 
to a solution of appropriate indoles 72a−d (20 mmol) in tetrahydrofuran (10 mL). The reaction 
mixture was heated under reflux for 24−48 h. After cooling, the solvent was evaporated under 
reduced pressure, and the residue (derivatives 74a, 74b, 74d) was purified by column 
chromatography using DCM or DCM/petroleum ether (9/1) as eluent or recrystallized from ethanol 
(derivative 74c).  
 
tert-Butyl 1H-indole-1-carboxylate (74a)  
Conditions: 24 h at reflux. Column chromatography: DCM. Oil; yield: 93%; IR 1732 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 1.66 (s, 9H, 3xCH3), 6.55 (d, 1H, J = 3.7 Hz, H-3), 7.17-7.34 (m, 
2H, H-5 and H-6), 7.53-7.59 (m, 2H, H-2 and H-7), 8.15 (d, 1H, J = 7.8 Hz, H-4); 
13
C NMR (50 
MHz, CDCl3) δ: 28.1 (3xq), 83.5 (s), 107.2 (d), 115.1 (d), 120.9 (d), 122.6 (d), 124.1 (d), 125.8 (d), 
130.5 (s), 135.1 (s), 149.7 (s). Anal. Calcd for C13H15NO2: C, 71.87; H, 6.96; N, 6.45. Found: C, 
71.61; H, 7.32; N, 6.07. 
 
tert-Butyl 5-methoxy-1H-indole-1-carboxylate (74b) 
Conditions: 48 h at reflux. Column chromatography: DCM/petroleum ether (9/1). Brown solid; 
yield: 90%; mp: 76 °C; IR 1730 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 1.66 (s, 9H, 
3xCH3), 3.79 (s, 3H, CH3), 6.64 (d, 1H, J = 3.6 Hz, H-3), 6.93 (d, 1H, J = 9.0 Hz, H-6), 7.14 (s, 1H, 
H-4), 7.63 (d, 1H, J = 3.6 Hz, H-2) 7.93 (d, 1H, J = 9.0 Hz, H-7); 
13
C NMR (50 MHz, DMSO-d6) 
δ: 27.6 (3xq), 55.2 (q), 83.5 (s), 103.5 (d), 107.4 (d), 112.9 (d), 115.3 (d), 126.5 (d), 129.1 (s), 131.0 
(s), 149.0 (s), 155.4 (s). Anal. Calcd for C14H17NO3: C, 68.00; H, 6.93; N, 5.66. Found: C, 67.64; H, 
6.66; N, 5.87. 
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tert-Butyl 5-bromo-1H-indole-1-carboxylate (74c)  
Conditions: 24 h at reflux. Oil; yield: 100%; IR 1732 (CO) cm
-1
; 
1
H NMR (200 MHz, DMSO-
d6) δ: 1.63 (s, 9H, 3xCH3), 6.70 (d, 1H, J = 3.7 Hz, H-3), 7.47 (dd, 1H, J = 2.0, 8.8 Hz, H-6), 7.72 
(d, 1H, J = 3.7 Hz, H-2), 7.85 (d, 1H, J = 2.0 Hz, H-4), 8.00 (d, 1H, J = 8.8 Hz, H-7); 
13
C NMR (50 
MHz, DMSO-d6) δ: 27.6 (3xq), 84.2 (s), 106.7 (d), 115.2 (s), 116.4 (d), 123.5 (d), 126.7 (d), 127.5 
(d), 132.1 (s), 133.3 (s), 148.7 (s). Anal.Calcd for C13H14BrNO2: C, 52.72; H, 4.76; N, 4.73. Found: 
C, 53.03; H, 5.03; N, 5.08. 
 
tert-Butyl 5-fluoro-1H-indole-1-carboxylate (74d) 
Conditions: 48 h at reflux. Oil; yield: 100%; IR 1738 (CO) cm
-1
; 
1
H NMR (200 MHz, CDCl3) δ: 
1.65 (s, 9H, 3xCH3), 6.49 (d, 1H, J = 3.5 Hz, H-3), 7.01 (td, 1H, J = 2.7, 9.0, 11.5 Hz, H-6), 7.18 
(dd, 1H, J = 2.4, 8.8 Hz, H-4), 7.60 (d, 1H, J = 3.5 Hz, H-2), 8.08 (dd, 1H, J = 4.5, 8.6 Hz, H-7); 
13
C NMR (50 MHz, CDCl3) δ: 28.1 (qx3), 83.8 (s), 106.2 (d, JC4-F= 23.6 Hz), 106.9 (d, JC3-F = 4.2 
Hz), 111.8 (d, JC6-F = 25.0 Hz), 116.0 (d, JC7-F = 9.2 Hz), 127.3 (d+s), 131.0 (s), 149.4 (s), 159.1 (s, 
JC5-F = 238.6 Hz). Anal.Calcd for C13H14FNO2: C, 66.37; H, 6.00; N, 5.95. Found: C, 66.14; H, 
6.19; N, 5.71. 
 
Synthesis of 5-substituted 5-fluoro-1H-indole-3-carboxamide, 1-methyl-1H-indole-3-
carboxamides, 5-substituted-tert-butyl 3-carbamoyl-1H-indole-1-carboxylates (75d, 76a−d and 
77a−c) [30, 31] 
To a solution of the appropriate indoles 72d (0.80 g, 5.9 mmol), 73a-d or 74a-c (16 mmol) in 
anhydrous acetonitrile (20 mL) were added dropwise at 0 °C CSI (0.8 mL, 9.1 mmol for compound 
72d or 1.4 mL, 16 mmol for compounds 73a-d and 74a-c). The reaction mixture was warmed to 
room temperature and stirred for 0.5-2 h (for compounds 73a-d and 74a-c) or at reflux for 15 min. 
(for compound 75d). A solution of acetone (16 mL) and water (2 mL) was added and the solution 
was basified using 10% aqueous solution of KOH. The mixture was extracted with ethyl acetate, 
dried (Na2SO4) and the solvent evaporated under reduced pressure. The residue was purified by 
column chromatography using ethyl acetate (for compounds 75d and 76a-d) or DCM/ethyl acetate 
(1/1) (for compounds 77a-c) as eluent.  
 
5-Fluoro-1H-indole-3-carboxamide (75d)  
Conditions: 15 min after CSI addition. at reflux. White solid; yield: 91%; mp: 93 °C. Analytical 
and spectroscopic data are previously reported [47].  
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1-Methyl-1H-indole-3-carboxamide (76a) 
Conditions: 1 h at room temperature after CSI addition. White solid; yield: 50%; mp: 185-186 
°C; IR 1603 (CO), 3178, 3392 (NH2) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 3.81 (s, 3H, CH3), 
6.92 (bs, 2H, NH2), 7.10-7.25 (m, 2H, H-5, H-6), 7.47 (d, 1H, J = 7.9 Hz, H-7), 7.99 (s, 1H, H-2), 
8.17 (d, 1H, J = 7.9 Hz, H-4); 
13
C NMR (50 MHz, DMSO-d6) δ: 32.9 (q), 109.5 (s), 110.1 (d), 
120.6 (d), 121.2 (d), 121.8 (d), 126.6 (s), 132.3 (d), 136.8 (s), 166.2 (s). Anal. Calcd for C10H10N2O: 
C, 68.95; H, 5.79; N, 16.08. Found: C, 68.74; H, 6.05; N, 15.99. 
 
5-Methoxy-1-methyl-1H-indole-3-carboxamide (76b) 
Conditions: 1 h rt after CSI addition. White solid; yield: 55%; mp: 169-170°C; IR 1605 (CO), 
3182, 3373 (NH2) cm
-1
; 1H NMR (200 MHz, DMSO-d6) δ: 3.77 (s, 3H, CH3), 3.78 (s, 3H, CH3), 
6.84 (d, 1H, J = 8.9 Hz, H-6), 7.10 (bs, 2H, NH2), 7.37 (d, 1H, J = 8.9 Hz, H-7), 7.67 (s, 1H, H-4), 
7.94 (s, 1H, H-2); 
13
C NMR (50 MHz, DMSO-d6) δ: 33.0 (q), 55.2 (q), 102.7 (d), 109.0 (s), 110.9 
(d), 112.0 (d), 127.2 (s), 131.9 (s), 132.5 (d), 154.6 (s), 166.3 (s). Anal. Calcd for C11H12N2O2: C, 
64.69; H, 5.92; N, 13.72. Found: C, 64.39; H, 5.72; N, 13.45. 
 
5-Bromo-1-methyl-1H-indole-3-carboxamide (76c) 
Conditions: 0.5 h at room temperature after CSI addition. White solid; yield: 60%; mp: 235°C; 
IR 1608 (CO), 3172, 3373 (NH2); 
1
H NMR (200 MHz, DMSO-d6) δ: 3.83 (s, 3H, CH3), 7.00 (bs, 
2H, NH2), 7.34 (d, 1H, J = 8.4 Hz, H-6), 7.49 (d, 1H, J = 8.4 Hz, H-7), 8.06 (s, 1H, H-4), 8.35 (s, 
1H, H-2); 
13
C NMR (50 MHz, DMSO-d6) δ: 33.2 (q), 109.1 (s), 112.4 (d), 113.6 (s), 123.4 (d), 
124.4 (d), 128.3 (s), 133.5 (d), 135.5 (s), 165.7 (s). Anal. Calcd for C10H9BrN2O: C, 47.46; H, 3.58; 
N, 11.07. Found: C, 47.17; H, 3.52; N, 11.34. 
 
5-Fluoro-1-methyl-1H-indole-3-carboxamide (76d) 
Conditions: 1 h rt after CSI addition. White solid; yield: 40%; mp: 174-175 °C; IR 1626 (CO), 
3178, 3369 (NH2); 
1
H NMR (200 MHz, DMSO-d6) δ: 3.82 (s, 3H, CH3), 6.88 (bs, 2H, NH2), 7.06 
(td, 1H, J = 10.3, 8.9, 2.5 Hz, H-6), 7.51 (dd, 1H, J = 8.9, 4.6 Hz, H-7), 7.84 (dd, 1H, J = 10.3, 2.5 
Hz, H-4) 8.05 (s, 1H, H-2); 
13
C NMR (50 MHz, DMSO-d6) δ: 33.3 (q), 105.8 (d, JC4-F = 24.5 Hz), 
110.0 (d, JC6-F = 26.5 Hz), 111.5 (d, JC7-F = 10.0 Hz), 109.4 (s), 127.2 (s), 133.5 (s), 133.9 (d), 158.0 
(d, JC5-F = 234 Hz), 165.8 (s). Anal. Calcd for C10H9FN2O: C, 62.49; H, 4.72; N, 14.58. Found: C, 
62.20; H, 4.48; N, 14.32. 
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tert-Butyl 3-carbamoyl-1H-indole-1-carboxylate (77a) 
Conditions: 1 h at reflux after CSI addition. White solid; yield: 40%; mp: 163-164 °C. Analytical 
and spectroscopic data are previously reported [48].  
 
tert-Butyl 3-carbamoyl-5-methoxy-1H-indole-1-carboxylate (77b) 
Conditions: 1 h after CSI addition. White solid; yield: 48%; mp: 168-169°C; IR 1660, 1728 
(CO), 3215, 3343 (NH2); 
1
H NMR (200 MHz, DMSO-d6) δ: 1.65 (s, 9H, 3xCH3), 3.81 (s, 3H, CH3), 
6.98 (dd, 1H, J = 8.9, 2.0 Hz, H-6), 7.20 (s, 1H, NH), 7.77 (d, 1H, J = 2.0 Hz, H-4), 7.89 (s, 1H, 
NH), 7.96 (d, 1H, J = 8.9 Hz, H-7), 8.44 (s, 1H, H-2); 
13
C NMR (50 MHz, DMSO-d6) δ: 27.6 (3xq), 
55.2 (q), 84.5 (s), 104.1 (d), 113.7 (d), 114.7 (s), 115.3 (d), 128.8 (d), 128.9 (s), 129.3 (s), 148.8 (s), 
155.9 (s), 165.2 (s). Anal. Calcd for C15H18N2O4: C, 62.06; H, 6.25; N, 9.65. Found: C, 62.35; H, 
6.19; N, 9.99. 
 
tert-Butyl 5-bromo-3-carbamoyl-1H-indole-1-carboxylate (77c) 
Conditions: 2 h after CSI addition. White solid; yield: 45%; mp: 170-171°C; IR 1662, 1720 
(CO), 3233, 3352 (NH2) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 1.65 (s, 9H, 3xCH3), 7.29 (s, 1H, 
NH), 7.52 (dd, 1H, J = 8.8, 1.9 Hz, H-6), 7.96 (s, 1H, NH), 8.02 (d, 1H, J = 8.8 Hz, H-7), 8.41 (d, 
1H, J = 1.9 Hz, H-4), 8.53 (s, 1H, H-2); 
13
C NMR (50 MHz, DMSO-d6) δ: 27.6 (3xq), 85.2 (s), 
114.0 (s), 116.1 (s), 116.6 (d), 124.2 (d), 127.3 (d), 129.6 (d), 130.2 (s), 133.6 (s), 146.6 (s), 148.4 
(s). Anal. Calcd for C14H15BrN2O3: C, 49.57; H, 4.46; N, 8.26. Found: C, 49.34; H, 4.41; N, 7.99. 
 
Synthesis of 5-substituted-5-fluoro-1H-indole-3-carbothioamide, 1-methyl-1H-indole-3-
carbothioamides and 5-substituted-tertbutyl 3-carbamothioyl−1H-indole-1-carboxylates (78d, 
79a−d and 80a−c). [31] 
To a solution of appropriate derivatives 75d (0.17 g, 0.95 mmol) or 76a-d and 77a-c (4 mmol) in 
anhydrous toluene (20 mL) Lawesson’s reagent (0.38 g, 0.96 mmol for compound 75d or 0.8 g, 2 
mmol for compounds 76a-d and 77a-c) was added. The mixture was heated at reflux under nitrogen 
atmosphere for 0.5-24 h. After cooling the solvent was evaporated under reduced pressure and the 
residue was purified by column chromatography using ethyl acetate (for compound 78d), 
DCM/ethyl acetate (98/2) (for compounds 79a-d) or DCM (for compounds 80a-c) as eluent.  
 
5-Fluoro-1H-indole-3-carbothioamide (78d) 
Conditions: 24 h at reflux. Orange solid; yield: 90%; mp: 175-176°C; IR 1626 (CS) cm
-1
; 
1
H 
NMR (200 MHz, DMSO-d6) δ: 7.03 (td, 1H, J = 9.0, 8.7, 2.4 Hz, H-6), 7.60 (dd, 1H, J = 8.7, 4.9 
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Hz, H-7), 8.19 (d, 1H, J = 2.8 Hz, H-2), 8.47 (dd, 1H, J = 9.0, 2.4 Hz, H-4), 8.89 (s,1H, SH), 9.00 
(s,1H, NH); 
13
C NMR (50 MHz, DMSO-d6) δ: 106.8 (d, JC4-F = 25.7 Hz), 110.3 (d, JC6-F = 26.5 Hz), 
113.1 (d, JC7-F = 9.6 Hz, H-7), 116.0 (d, JC7a-F = 4.6 Hz), 126.8 (d, JC3a-F = 11.1 Hz), 129.4 (d), 
133.4 (s), 157.9 (d, JC5-F = 232.6 Hz), 193.2 (s). Anal. Calcd for C9H7FN2S: C, 55.65; H, 3.63; N, 
14.42. Found: C, 55.90; H, 3.40; N, 14.13. 
 
1-Methyl-1H-indole-3-carbothioamide (79a) 
Conditions: 1 h at reflux. Orange solide; yield: 79%; mp: 126-127 °C. Analytical and 
spectroscopic data are previously reported [49].  
 
5-Methoxy-1-methyl-1H-indole-3-carbothioamide (79b) 
Conditions: 1 h at reflux. Orange solid; yield: 95%; mp: 176-177°C; IR 1626 (CO), 3354, 3273 
(NH2) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 3.79 (s, 6H, CH3), 6.87 (dd, 1H, J = 8.9, 1.8 Hz, H-
6), 7.39 (d, 1H, J = 8.9 Hz, H-7), 8.05 (s, 1H, H-2), 8.17 (d, 1H, J = 1.8 Hz, H-4), 8.72 (s, 1H, SH), 
8.90 (s, 1H, NH); 
13
C NMR (50 MHz, DMSO-d6) δ: 33.2 (q), 55.3 (q), 103.9 (d), 111.2 (d), 111.8 
(d), 114.9 (s), 126.7 (s), 132.4 (s), 132.8 (d), 155.0 (s), 192.9 (s).  Anal. Calcd for C11H12N2OS: C, 
59.97; H, 5.49; N, 12.72. Found: 59.69; H, 5.28; N, 13.10. 
 
5-Bromo-1-methyl-1H-indole-3-carbothioamide (79c) 
Conditions: 1 h at reflux. Orange solid; yield: 93%; mp: 206-207 °C; IR 1628 (CO), 3276, 3157 
(NH2) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 3.83 (s, 3H, CH3), 7.37 (dd, 1H, J = 8.7, 1.8 Hz, H-
6), 7.50 (d, 1H, J = 8.7 Hz, H-7), 8.12 (s, 1H, H-2), 8.86 (d, 1H, J = 1.8 Hz, H-4), 8.90 (s, 1H, SH), 
9.06 (s, 1H, NH); 
13
C NMR (50 MHz, DMSO-d6) δ: 33.3 (q), 112.6 (d), 114.2 (s), 114.6 (s), 124.1 
(d), 124.7 (d), 128.0 (s), 133.0 (d), 136.1 (s), 192.5 (s). Anal. Calcd for C10H9BrN2S: C, 44.62; H, 
3.37; N, 10.41. Found: C, 44.87; H, 3.30; N, 10.34. 
 
5-Fluoro-1-methyl-1H-indole-3-carbothioamide (79d) 
Conditions: 0.5 h at reflux. Orange solid; yield: 93%; mp: 159-160°C; IR 1626 (CS), 3375, 3489 
(NH2) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 3.84 (s, 3H, CH3), 7.11 (td, 1H, J = 11.0, 9.0, 2.6 
Hz, H-6), 7.60 (dd, 1H, J = 9.0, 4.6 Hz, H-7), 8.16 (s, 1H, H-2), 8.43 (dd, 1H, J = 11.0, 2.6 Hz, H-
4), 8.86 (s, 1H, SH), 9.04 (s, 1H, NH); 
13
C NMR (50 MHz, DMSO-d6) δ: 33.3 (q), 106.8 (d, JC4-F = 
26.0 Hz), 110.3 (d, JC6-F = 26.0 Hz), 111.8 (d, JC7-F = 10.0 Hz, H-7), 115.0 (d, JC7a-F = 4.8 Hz), 
126.8 (d, JC3a-F = 11.0 Hz), 133.6 (d), 134.0 (s), 158.21 (d, JC5-F = 233.1 Hz), 192.6 (s).  
Anal. Calcd for C10H9FN2S: C, 57.67; H, 4.36; N, 13.45. Found: C, 57.29; H, 4.28; N, 13.22. 
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tert-Butyl 3-carbamothioyl-1H-indole-1-carboxylate (80a) 
Conditions: 1h at reflux. Orange solid; yield: 40%; mp: 98-99 °C. Analytical and spectroscopic 
data are reported elsewhere. [48]  
 
tert-Butyl 3-carbamothioyl-5-methoxy-1H-indole-1-carboxylate (80b) 
Conditions: 1 h at reflux. Orange solid; yield: 98%; mp: 153-154°C; IR 1597 (CO), 1738 (CS), 
3415, 3365 (NH2); 
1
H NMR (200 MHz, DMSO-d6) δ: 1.65 (s, 9H, 3xCH3), 3.80 (s, 3H, CH3), 7.00 
(dd, 1H, J = 9.1, 2.6, Hz, H-6), 7.99 (d, 1H, J = 9.1 Hz, H-7), 8.21 (d, 1H, J = 2.6 Hz, H-4), 8.32 (s, 
1H, H-2), 9.34 (s, 1H, SH), 9.52 (s, 1H, NH); 
13
C NMR (50 MHz, DMSO-d6) δ: 27.6 (3xq), 55.3 
(q), 84.8 (s), 105.1 (d), 113.5 (d), 115.3 (d), 119.8 (s), 126.8 (d), 128.8 (s), 129.6 (s), 148.7 (s), 
155.7 (s), 192.8 (s). Anal. Calcd for C15H18N2O3S: C, 58.80; H, 5.92; N, 9.14. Found: C, 58.51; H, 
5.86; N, 9.44. 
 
tert-Butyl 5-bromo-3-carbamothioyl-1H-indole-1-carboxylate (80c) 
Conditions:  1 h at reflux. Orange solid; yield: 96%; mp: 150-151°C; IR 1633 (CO), 1720 (CS), 
3380, 3284 (NH2) cm
-1
; 
1
H NMR (200 MHz, DMSO-d6) δ: 1.66 (s, 9H, 3xCH3), 7.54 (dd, 1H, J = 
8.8, 2.0 Hz, H-6), 8.05 (d, 1H, J = 8.8 Hz, H-7), 8.42 (s, 1H, H-2), 8.90 (d, 1H, J = 2.0 Hz, H-4), 
9.44 (s, 1H, SH), 9.60 (s, 1H, NH); 
13
C NMR (50 MHz, DMSO-d6) δ: 27.5 (3xq), 85.4 (s), 116.1 
(s), 116.5 (d), 118.9 (s), 124.9 (d), 127.3 (d), 127.4 (d), 129.8 (s), 134.0 (s), 148.4 (s), 192.1 (s). 
Anal. Calcd for C14H15BrN2O2S: C, 47.33; H, 4.26; N, 7.89. Found: C, 47.12; H, 4.24; N, 8.27. 
 
Synthesis of 7-chloro-1H-pyrrolo[2,3-c]pyridine (83)  
Chloro-3-nitropyridine 4 (0.3 g, 1.89 mmol) was dissolved in 13 mL of dry THF under nitrogen 
atmosphere and cooled to −78 °C. After dropwise addition of vinylmagnesium bromide solution (1 
M, 6.1 mL) the mixture was stirred for 7 h, quenched with 20% NH4Cl solution, extracted with 
ethyl acetate, dried over Na2SO4 and concentrated in vacuo. Crude product was purified by column 
chromatography using DCM/ethyl acetate (98/2) as eluent. Brown solid; yield: 33%; mp: 188-190 
°C. Analytical and spectroscopic data are reported elsewhere [37]. 
 
Syntjesis of 7-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridine (84)  
To a cold solution of 6-azaindole 83 (0.12 g, 0.8 mmol) in anhydrous toluene (4 mL), potassium 
t-butoxide (0.12 g, 1.1 mmol) and TDA-1 (1 or 2 drops) were added at 0 °C. The reaction mixture 
was stirred at room temperature for 5 h and then methyl iodide (0.8 mmol, 0.05 mL) was added at 0 
°C. TLC analysis (DCM/ethyl acetate 9/1) revealed that methylation was complete after 2 h. The 
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solvent was evaporated under reduced pressure. The residue was treated with water, extracted with 
DCM, dried (Na2SO4), evaporated and purified by column chromatography using DCM/ethyl 
acetate (95/5) as eluent. White solid; yield: 70%; mp: 60-61 °C; 
1H NMR (200 MHz, CDCl3) δ: 
4.16 (s, 3H, CH3), 6.49 (d, 1H, J = 3.1 Hz, H-3), 7.16 (d, 1H, J = 3.1 Hz, H-2), 7.41 (d, 1H, J = 5.4 
Hz, H-4), 7.95 (d, 1H, J = 5.4 Hz, H-5); 13C NMR (50 MHz, CDCl3) δ: 36.7 (q), 101.0 (d), 115.2 
(d), 129.2 (s), 134.1 (s), 134.7 (d), 136.5 (s), 137.5 (d). Anal. Calcd for: C8H7ClN2: C, 57.67; H, 
4.23; N, 16.81. Found: C, 57.90; H, 3.97; N, 16.63.  
 
Synthesis of 1-(7-chloro-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanones (85,86)  
To a solution of appropriate 6-azaindoles 83, 84 (2.5 mmol) in 10 mL of anhydrous DCM, 
anhydrous aluminium chloride (1.2 g, 8.8 mmol) was slowly added. The reaction mixture was 
heated under reflux and bromoacetyl bromide (2.5 mmol, 0.2 mL) in 2 mL of anhydrous DCM was 
added drop wise. The resulting solution was allowed to stir under reflux for 40 min. After cooling, 
water and ice were slowly added and the obtained precipitate (for derivative 85) was filtered off or 
the oil residue (for derivative 86) was extracted with DCM and purified by column chromatography 
using DCM/ethyl acetate (9/1) as eluent. 
.  
2-Bromo-1-(7-chloro-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone (85)  
White solid; yield: 88%; mp: 324-325 °C; 1676 (CO), 3557 (NH) cm
-1
; 
1H NMR (200 MHz, 
DMSO-d6) δ: 4.76 (s, 2H, CH2), 8.05 (d, 1H, J = 5.2 Hz, H-4), 8.15 (d, 1H, J = 5.2 Hz, H-5), 8.74 
(d, 1H, J = 3.0 Hz, H-2), 13.03 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 33.8 (t), 114.2 (s), 
115.6 (d), 130.2 (s), 132.7 (s), 134.3 (s), 138.5 (d), 140.6 (d), 186.6 (s). Anal. Calcd for: 
C9H6BrClN2O: C, 39.52; H, 2.21; N, 10.24. Found: C, 39.28; H, 2.36; N, 10.13. 
2-Bromo-1-(7-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone (86)  
White solid; yield: 98%; mp: 249-250 °C; IR 1647 (CO) cm-1; 1H NMR (200 MHz, DMSO-d6) 
δ: 4.18 (s, 3H, CH3), 4.90 (s, 2H, CH2), 8.07 (d, 1H, J = 5.3 Hz, H-4), 8.12 (d, 1H, J = 5.3 Hz, H-5), 
8.72 (s, 1H, H-2); 13C NMR (50 MHz, DMSO-d6) : 33.3 (t), 37.4 (q), 111.8 (s), 115.7 (d), 129.6 
(s), 133.9 (s), 134.3 (s), 140.7 (d), 143.2 (d), 185.9 (s). Anal. Calcd for: C10H8BrClN2O: C, 41.77; 
H, 2.80; N, 9.74. Found: C, 41.51; H, 3.07; N, 9.56. 
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Synthesis of indolyl-thiazolyl-pyrrolo[2,3-c]pyridines (49a-j), (50a-f)  
A suspension of the appropriate indole-3-carbothioamides 78d, 79a-d, 80a-c (5 mmol) and 
proper 3-bromoacetyl-pyrrolo[2,3-c] pyridines 85,86 (5 mmol) in anhydrous ethanol (20 mL) was 
heated under reflux for 1-3 h. The precipitate, obtained after cooling, was filtered off, dried and 
crystallized with ethanol to afford derivatives 49a-j and 50a-f. 
. 
7-Chloro-3-[2-(1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine  (49a)  
Conditions: reflux for 1 h. Yellow solid; yield: 98%; mp: 326-327 °C; IR 3393 (NH) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 3.93 (s, 3H, CH3), 7.29-7.35 (m, 2H, H-5’, H-6’), 7.56-7.61 (m, 1H, 
H-7’), 7.85 (s, 1H, H-2’), 8.12 (d, 1H, J = 5.6 Hz, H-4’’), 8.26 (s, 1H, H-5), 8.28-8.31 (m, 1H, H-
4’), 8.33 (d, 1H, J = 5.6 Hz, H-5’’), 8.40 (d, 1H, J = 2.7 Hz, H-2’’), 12.62 (bs, 1H, NH); 13C NMR 
(50 MHz, DMSO-d6) : 32.9 (q), 108.3 (d), 109.2 (s), 110.7 (d), 112.4 (s), 115.3 (d), 120.2 (d), 
121.1 (d), 122.5 (d), 124.5 (s), 129.8 (s), 130.5 (d), 130.8 (d), 131.8 (s), 133.4 (s), 136.7 (d), 137.0 
(s), 148.1 (s), 162.2 (s). Anal. Calcd for: C19H13ClN4S: C, 62.55; H, 3.59; N, 15.36. Found: C, 
62.28; H, 3.34; N, 15.53.  
7-Chloro-3-[2-(5-methoxy-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine 
(49b)   
Conditions: reflux for 1 h. Yellow solid; yield: 65%; mp: 216-217 °C; IR 3396 (NH) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 3.87 (s, 3H, CH3), 3.91 (s, 3H, OCH3), 6.95 (dd, 1H, J = 2.4, 8.9 
Hz, H-6’), 7.49 (d, 1H, J = 8.9 Hz, H-7’), 7.79 (s, 1H, H-2’), 7.90 (d, 1H, J = 2.4 Hz, H-4’), 8.05 (d, 
1H, J = 5.5 Hz, H-4’’), 8.17 (s, 1H, H-5), 8.32 (d, 1H, J = 2.7 Hz, H-2’’), 8.37 (d, 1H, J = 5.5 Hz, 
H-5’’), 12.46 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 33.0 (q), 55.1 (q), 96.3 (s), 101.8 (d), 
107.7 (d), 108.6 (s), 110.1 (s), 111.6 (d), 112.6 (d), 115.4 (d), 124.8 (s), 129.9 (d), 131.0 (d), 132.1 
(s), 132.8 (s), 134.2 (s), 136.8 (d), 146.6 (s), 155.1 (s), 162.8 (s). Anal. Calcd for: C20H15ClN4OS: C, 
60.83; H, 3.83; N, 14.19. Found: C, 60.62; H, 3.99; N, 13.99. 
3-[2-(5-Bromo-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-7-chloro-1H-pyrrolo[2,3-c]pyridine 
(49c)   
Conditions: reflux for 1 h. Yellow solid; yield: 93%; mp: 374-375 °C; IR 3410 (NH) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 3.89 (s, 3H, CH3), 7.42 (dd, 1H, J = 1.8, 8.7 Hz, H-6’), 7.57 (d, 1H, 
J = 8.7 Hz, H-7’), 7.84 (s, 1H, H-2’), 8.09 (d, 1H, J = 5.6 Hz, H-4’’), 8.28 (s, 1H, H-5), 8.30 (d, 1H, 
J = 5.6 Hz, H-5’’), 8.34 (d, 1H, J = 2.8 Hz, H-2’’), 8.49 (d, 1H, J = 1.8 Hz, H-4’), 12.56 (bs, 1H, 
NH); 13C NMR (50 MHz, DMSO-d6) : 33.1 (q), 108.4 (d), 108.9 (s), 112.5 (s), 112.8 (d), 113.8 (s), 
115.2 (d), 122.7 (d), 124.9 (d), 126.1 (s), 129.8 (s), 130.1 (d), 131.7 (s), 131.9 (d), 133.5 (s), 135.8 
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(s), 136.7 (d),  148.5 (s), 161.5 (s). Anal. Calcd for: C19H12BrClN4S: C, 51.43; H, 2.73; N, 12.63. 
Found: C, 51.17; H, 2.62; N, 12.88. 
7-Chloro-3-[2-(5-fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine 
(49d)  
Conditions: reflux for 1 h. Yellow solid; yield: 97%; mp: 337-338 °C; IR 3509 (NH) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 3.91 (s, 3H, CH3), 7.18 (td, 1H, J = 2.5, 9.2, 11.7 Hz, H-6’), 7.61 
(dd, 1H, J = 4.5, 9.2 Hz, H-7’), 7.82 (s, 1H, H-2’), 8.02 (dd, 1H, J = 2.5, 11.7 Hz, H-4’), 8.09 (d, 
1H, J = 5.6 Hz, H-4’’), 8.25 (d, 1H, J = 5.6 Hz, H-5’’), 8.30 (s, 1H, H-5), 8.34 (d, 1H, J = 2.8 Hz, 
H-2’’), 12.50 (bs, 1H, NH). Anal. Calcd for: C19H12ClFN4S: C, 59.61; H, 3.16; N, 14.63. Found: C, 
59.34; H, 3.21; N, 14.47. 
7-Chloro-1-methyl-3-[2-(1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine 
(49e)  
Conditions: reflux for 1 h. Yellow solid; yield: 96%; mp: 265-266 °C; 1H NMR (200 MHz, 
DMSO-d6) δ: 3.91 (s, 3H, CH3), 4.24 (s, 3H, CH3), 7.27 (m, 2H, H-5’, H-6’), 7.57-7.61 (m, 1H, H-
7’), 7.75 (s, 1H, H-2’), 8.06 (d, 1H, J = 5.5 Hz, H-4’’), 8.22 (s, 1H, H-2’’), 8.25 (d, 1H, J = 5.5 Hz, 
H-5’’), 8.33 (s, 1H, H-5), 8.35-8.38 (m, 1H, H-4’). Anal. Calcd for: C20H15ClN4S: C, 63.40; H, 3.99; 
N, 14.79. Found: C, 63.14; H, 3.75; N, 14.59. 
7-Chloro-3-[2-(5-methoxy-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-
c]pyridine  (49f)  
Conditions: reflux for 1 h. Yellow solid; yield: 79%; mp: 232-233 °C; 1H NMR (200 MHz, 
DMSO-d6) δ: 3.87 (s, 3H, CH3), 3.90 (s, 3H, OCH3), 4.22 (s, 3H, CH3), 6.94 (d, 1H, J = 8.8 Hz, H-
6’), 7.48 (d, 1H, J = 8.8 Hz, H-7’), 7.69 (s, 1H, H-2’), 7.87 (m, 1H, H-4’), 8.02 (d, 1H, J = 5.4 Hz, 
H-4’’), 8.15 (s, 1H, H-2’’), 8.28 (s, 1H, H-5), 8.35 (d, 1H, J = 5.4 Hz, H-5’’). Anal. Calcd for: 
C21H17ClN4OS: C, 61.68; H, 4.19; N, 13.70. Found: C, 61.42; H, 4.08; N, 13.47. 
3-[2-(5-Bromo-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-7-chloro-1-methyl-1H-pyrrolo[2,3-
c]pyridine  (49g)  
Conditions: reflux for 2 h. Yellow solid; yield: 98%; mp: 249-250 °C; 1H NMR (200 MHz, 
DMSO-d6) δ: 3.90 (s, 3H, CH3), 4.23 (s, 3H, CH3), 7.44 (dd, 1H, J = 1.9, 8.7 Hz, H-6’), 7.58 (d, 1H, 
J = 8.7 Hz, H-7’), 7.74 (s, 1H, H-2’), 8.04 (d, 1H, J = 5.5 Hz, H-4’’), 8.24-8.28 (m, 3H, H-2’’,H-5, 
H-5’’), 8.48 (d, 1H, J = 1.9 Hz, H-4’); 13C NMR (50 MHz, DMSO-d6) δ: 33.1 (q), 36.0 (q), 108.4 
(d), 109.0 (s), 110.4 (s), 112.8 (d), 113.8 (s), 115.3 (d), 122.8 (d), 124.9 (d), 126.0 (s), 128.8 (s), 
131.9 (d), 133.0 (s), 133.3 (s), 135.3 (d), 135.8 (s), 137.0 (d), 148.1 (s), 161.5 (s). Anal. Calcd for: 
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C20H14BrClN4S: C, 52.47; H, 3.08; N, 12.24. Found: C, 52.23; H, 2.94; N, 12.11. 
7-Chloro-3-[2-(5-fluoro-1-methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-
c]pyridine  (49h)  
Conditions: reflux for 1 h. Yellow solid; yield: 95%; mp: 284-285 °C; 1H NMR (200 MHz, 
DMSO-d6) δ: 3.91 (s, 3H, CH3), 4.24 (s, 3H, CH3), 7.18 (td, 1H, J = 2.5, 9.3, 11.7 Hz, H-6’), 7.61 
(dd, 1H, J = 4.4, 9.3 Hz, H-7’), 7.75 (s, 1H, H-2’), 8.02-8.07 (m, 2H, H-4’, H-4’’), 8.22 (d, 1H, J = 
5.6 Hz, H-5’’), 8.28 (s, 1H, H-2’’), 8.35 (s, 1H, H-5). Anal. Calcd for: C20H14ClFN4S: C, 60.53; H, 
3.56; N, 14.12. Found: C, 60.29; H, 3.30; N, 14.27. 
7-Chloro-3-[2-(5-fluoro-1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-c]pyridine 
(49i)  
Conditions: reflux for 3 h. Yellow solid; yield: 82%; mp: 284 -285 °C; IR 3399 (NH) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 4.25 (s, 3H, CH3), 7.11 (td, 1H, J = 2.5, 9.2, 11.7 Hz, H-6’), 7.53 
(dd, 1H, J = 4.6, 9.2 Hz, H-7’), 7.75 (s, 1H, H-2’’), 8.02 (d, 1H, J = 2.5 Hz, H-4’), 8.06 (d, 1H, J = 
5.5 Hz, H-4’’), 8.22 (d, 1H, J = 5.5 Hz, H-5’’), 8.25 (d, 1H, J = 2.9 Hz, H-2’), 8.35 (s, 1H, H-5), 
11.93 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ: 36.6 (q), 105.2 (d, JC4’-F = 24.3 Hz), 108.2 
(d), 110.5 (s), 110.7 (d, JC6’-F = 26.0 Hz), 113.4 (d, JC7’-F = 9.6 Hz), 115.1 (s), 115.2 (d), 124.5 (s, 
JC3a-F = 10.8 Hz), 128.7 (d),  128.9 (s), 132.9 (s), 133.2 (s), 133.4 (s), 135.8 (d), 137.0 (d), 137.5 (s), 
148.1 (s), 159.7 (s, JC5’-F = 254 Hz). Anal. Calcd for: C19H12ClFN4S: C, 59.61; H, 3.16; N, 14.63. 
Found: C, 59.37; H, 2.90; N, 14.83. 
7-Chloro-3-[2-(5-fluoro-1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine  (49j)  
Conditions: reflux for 2 h. Yellow solid; yield 66%; mp: 281-282 °C; IR 3418, 3557 (NH) cm-1; 
1H NMR (200 MHz, DMSO-d6) δ: 7.12 (td, 1H, J = 2.5, 9.2, 11.7 Hz, H-6’), 7.53 (dd, 1H, J = 4.6, 
9.2 Hz, H-7’), 7.83 (s, 1H, H-2’), 8.00 (dd, 1H, J = 2.5, 11.7 Hz, H-4’), 8.08 (d, 1H, J = 5.6 Hz, H-
4’’), 8.24-8.29 (m, 2H, H-5, H5’’), 8.32 (d, 1H, J = 2.8 Hz, H-2’’), 11.95 (bs, 1H, NH), 12.45 (bs, 
1H, NH). Anal. Calcd for: C18H10ClFN4S: C, 58.62; H, 2.73; N, 15.19. Found: C, 58.51; H, 2.47; N, 
14.94. 
tert-Butyl 3-[4-(7-chloro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indole-1-
carboxylate  (50a)  
Conditions: reflux for 2 h. Yellow solid; yield: 84%, mp: 225-226 °C; IR 3417 (NH), 1736 (CO) 
cm-1; 1H NMR (200 MHz, DMSO-d6) δ: 1.69 (s, 9H, 3xCH3), 7.44-7.53 (m, 2H, H-5’, H-6’), 8.02 
(s, 1H, H-2’), 8.09 (d, 1H, J = 5.5 Hz, H-4’’), 8.16-8.21 (m, 1H, H-7’), 8.23 (d, 1H, J = 5.5 Hz, H-
5’’), 8.35-8.36 (m, 2H, H-2’’, H-5), 8.47-8.51 (m, 1H, H-4’), 12.48 (bs, 1H, NH); 13C NMR (50 
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MHz, DMSO-d6) : 27.6 (3xq), 84.9 (s), 110.4 (d), 112.2 (s), 114.9 (s), 115.0 (d), 121.3 (d), 123.8 
(d), 123.9 (d), 125.4 (d), 125.6 (d), 126.6 (s), 129.8 (s), 129.9 (d), 131.4 (s), 133.8 (s), 135.0 (s), 
137.5 (d), 148.6 (s), 149.3 (s), 159.9 (s). Anal. Calcd for: C23H19ClN4O2S: C, 61.26; H, 4.25; N, 
12.42. Found: C, 61.02; H, 4.06; N, 12.13.  
tert-Butyl 3-[4-(7-chloro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1,3-thiazol-2-yl]-5-methoxy-1H-
indole-1-carboxylate (50b)   
Conditions: reflux for 1 h. Yellow solid; yield: 77%; mp: 312-313 °C; IR 3418 (NH), 1650 (CO) 
cm-1; 1H NMR (200 MHz, DMSO-d6) δ: 1.68 (s, 9H, 3xCH3), 3.92 (s, 3H, OCH3), 7.09 (dd, 1H, J = 
2.4, 9.1 Hz, H-6’), 7.99-8.07 (m, 4H, ArH), 8.30-8.35 (m, 3H, ArH), 12.47 (bs, 1H, NH); 13C NMR 
(50 MHz, DMSO-d6) : 27.6 (3xq), 55.1 (q), 84.7 (s), 103.2 (d), 110.2 (d), 112.2 (s), 114.5 (d), 
114.8 (s), 115.2 (d), 115.8 (d), 125.9 (d), 127.5 (s), 129.5 (s), 130.0 (d), 131.6 (s), 133.7 (s),  136.9 
(d), 137.2 (s), 148.5 (s), 149.2 (s), 156.1 (s), 160.2 (s). Anal. Calcd for: C24H21ClN4O3S: C, 59.93; 
H, 4.40; N, 11.65. Found: C, 59.66; H, 4.61; N, 11.50. 
tert-Butyl 5-bromo-3-[4-(7-chloro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indole-
1-carboxylate  (50c)  
Conditions: reflux for 3 h. Yellow solid; yield 77%, mp: 241-242 °C; IR 3559 (NH), 1748 (CO) 
cm-1; 1H NMR (200 MHz, DMSO-d6) δ: 1.67 (s, 9H, 3xCH3), 7.60 (d, 1H, J = 8.6 Hz, H-6’), 7.98 
(s, 1H, H-2’), 8.04-8.07 (m, 2H, H-2’’, H-7’ ), 8.19 (d, 1H, J = 5.3 Hz, H-4’’), 8.29-8.33 (m, 2H, H-
4’, H-5’’), 8.65 (s, 1H, H-5), 12.45 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 27.6 (3xq), 
85.3 (s), 110.5 (d), 112.0 (s), 114.1 (s), 114.9 (d), 116.8 (d), 123.8 (d), 126.8 (d), 127.9 (d), 128.4 
(s), 129.5 (d), 129.8 (s), 129.9 (s), 131.4 (s), 133.8 (s), 134.0 (s), 137.4 (d), 148.3 (s), 149.3 (s), 
159.4 (s). Anal. Calcd for: C23H18BrClN4O2S: C, 52.14; H, 3.42; N, 10.57. Found: C, 52.03; H, 
3.55; N, 10.32. 
tert-Butyl 3-[4-(7-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-1,3-thiazol-2-yl]-1H-indole-
1-carboxylate   (50d)  
Conditions: reflux for 2 h. Yellow solid; yield: 91%; mp: 279-280 °C; IR 1736 (CO) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 1.69 (s, 9H, 3xCH3), 4.24 (s, 3H, CH3), 7.44-7.54 (m, 2H, H-5’, H-
6’), 7.96 (s, 1H, H-2’), 8.07 (d, 1H, J = 5.5 Hz, H-4’’), 8.16-8.20 (m, 1H, H-7’), 8.20 (d, 1H, J = 5.5 
Hz, H-5’’), 8.34 (s, 1H, H-2’’), 8.37 (s, 1H, H-5), 8.48-8.52 (m, 1H, H-4’); 13C NMR (50 MHz, 
DMSO-d6) δ: 27.6 (3xq), 36.6 (q), 84.9 (s), 110.2 (s), 110.4 (d), 114.9 (s), 115.0 (d), 115.1 (d), 
121.4 (d), 123.8 (d), 125.5 (d), 125.6 (d), 126.6 (s), 128.9 (s), 132.8 (s), 133.3 (s), 135.0 (s), 135.7 
(d), 137.4 (d), 148.6 (s), 149.6 (s), 159.9 (s). Anal. Calcd for: C24H21ClN4O2S: C, 62.00; H, 4.55; N, 
88 
 
12.05. Found: C, 61.73; H, 4.41; N, 11.94. 
tert-Butyl 3-[4-(7-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-1,3-thiazol-2-yl]-5-methoxy-
1H-indole-1-carboxylate  (50e)  
Conditions: reflux for 1 h. Yellow solid; yield: 92%; mp: 212-213 °C; IR 1723 (CO) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 1.68 (s, 9H, 3xCH3), 3.91 (s, 3H, OCH3), 4.21 (s, 3H, CH3), 7.08 (d, 
1H, J = 9.0 Hz, H-6’), 7.89-8.06 (m, 4H, ArH), 8.27-8.29 (m, 3H, ArH). Anal. Calcd for: 
C25H23ClN4O3S: C, 60.66; H, 4.68; N, 11.32. Found: C, 60.45; H, 4.89; N, 11.56. 
tert-Butyl 5-bromo-3-[4-(7-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-1,3-thiazol-2-yl]-
1H-indole-1-carboxylate (50f)   
Conditions: reflux for 3 h. Yellow solid; yield: 91%; mp: 257-258 °C; IR 1727 (CO) cm-1; 1H 
NMR (200 MHz, DMSO-d6) δ: 1.69 (s, 9H, 3xCH3), 4.22 (s, 3H, CH3), 7.63 (dd, 1H, J = 1.9, 8.9 
Hz, H-6’), 7.91 (s, 1H, H-2’), 8.03 (d, 1H, J = 5.5 Hz, H-4’’), 8.09 (d, 1H, J = 8.9 Hz, H-7’), 8.18 
(d, 1H, J = 5.5 Hz, H-5’’), 8.27 (s, 1H, H-2’’), 8.35 (s, 1H, H-5), 8.61 (d, 1H, J = 1.9 Hz, H-4’). 
Anal. Calcd for: C24H20BrClN4O2S: C, 53.00; H, 3.71; N, 10.30. Found: C, 53.27; H, 3.97; N, 
10.16. 
Synthesis of indolyl-thiazolyl-pyrrolo[2,3-c]pyridines (51a-f)  
To a suspension of appropriate derivatives 50a-f (0.78 mmol) in DCM (10 mL) trifluoacetic acid 
(1.1 mL) was added. The reaction was heated at reflux for 24 h. The mixture was neutralized with 
saturated aqueous sodium hydrogen carbonate solution. The solvent was dried (Na2SO4), 
evaporated under reduced pressure and the residue recrystallized with ethanol to afford derivatives 
51a-f. 
 
7-Chloro-3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine (51a)  
Green solid; yield: 93%; mp: 271-272 °C; IR 3556, 3394 (NH) cm-1; 1H NMR (200 MHz, 
DMSO-d6) δ: 7.21-7.31 (m, 2H, H-5’, H-6’), 7.48-7.55 (m, 1H, H-7’), 7.81 (s, 1H, H-2’), 8.08 (d, 
1H, J = 5.5 Hz, H-4’’), 8.20 (d, 1H, J = 2.8 Hz, H-2’’),  8.27-8.35 (m, 3H, H-5, H-4’, H-5’’), 11.82 
(bs, 1H, NH), 12.41 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 108.0 (d), 110.4 (s), 112.2 (d), 
112.5 (s), 115.3 (d), 120.2 (d), 120.8 (d), 122.4 (d), 124.2 (s), 126.8 (d), 129.4 (d), 129.8 (s), 131.4 
(s), 133.9 (s), 136.6 (s), 137.5 (d), 148.6 (s), 162.5 (s). Anal. Calcd for: C18H11ClN4S: C, 61.62; H, 
3.16; N, 15.97. Found: C, 61.47; H, 3.40; N, 15.82. 
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7-Chloro-3-[2-(5-methoxy-1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-c]pyridine  (51b)  
Yellow solid; yield: 62%; mp: 223-224 °C; IR 3555, 3379 (NH) cm-1; 1H NMR (200 MHz, 
DMSO-d6) δ: 3.90 (s, 3H, OCH3), 6.89 (dd, 1H, J = 2.5, 8.8 Hz, H-6’), 7.42 (d, 1H, J = 8.8 Hz, H-
7’), 7.80 (s, 1H, H-5), 7.89 (d, 1H, J = 2.5 Hz, H-4’), 8.07 (d, 1H, J = 5.6 Hz, H-4’’), 8.15 (d, J = 
2.9 Hz, H-2’), 8.35 (d, 1H, J = 2.8 Hz, H-2’’), 8.39 (d, 1H, J = 5.6 Hz, H-5’’),  11.72 (bs, 1H, NH), 
12.51 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 55.1 (q), 101.6 (d), 107.7 (d), 110.1 (s), 
112.4 (s), 112.7 (d), 113.0 (d), 115.4 (d), 124.7 (s), 127.2 (d), 129.6 (d), 129.8 (s), 131.5 (s), 131.7 
(s), 133.7 (s), 137.0 (d), 148.3 (s), 154.7 (s), 162.9 (s). Anal. Calcd for: C19H13ClN4OS: C, 59.92; H, 
3.44; N, 14.71. Found: C, 59.68; H, 3.33; N, 14.56.  
3-[2-(5-Bromo-1H-indol-3-yl)-1,3-thiazol-4-yl]-7-chloro-1H-pyrrolo[2,3-c]pyridine (51c)  
Yellow solid; yield: 98%; mp: 265-266 °C; IR 3395, 3124 (NH) cm-1; 1H NMR (200 MHz, 
DMSO-d6) δ: 7.37 (dd, 1H, J = 1.9, 8.6 Hz, H-6’), 7.51 (d, 1H, J = 8.6 Hz, H-7’), 7.84 (s, 1H, H-
2’’), 8.08 (d, 1H, J = 5.6 Hz, H-4’’), 8.24-8.28 (m, 2H, H-5, H-5’’), 8.32 (d, 1H, J = 2.9 Hz, H-2’), 
8.53 (d, 1H, J = 1.9 Hz, H-4’), 12.02 (bs, 1H, NH), 12.48 (bs, 1H, NH); 13C NMR (50 MHz, 
DMSO-d6) : 108.3 (d), 110.0 (s), 112.5 (s), 113.4 (s), 114.3 (d), 115.2 (d), 112.6 (d), 124.9 (d), 
126.0 (s), 128.2 (d), 129.6 (d), 129.8 (s), 131.6 (s), 133.8 (s), 135.3 (s), 137.1 (d), 148.6 (s), 161.9 
(s). Anal. Calcd for: C18H10BrClN4S: C, 50.31; H, 2.35; N, 13.04. Found: C, 50.55; H, 2.09; N, 
12.88.  
7-Chloro-3-[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-c]pyridine (51d)  
Green solid; yield: 75%; mp: 210-211 °C; IR 3397 (NH) cm-1; 1H NMR (200 MHz, DMSO-d6) 
δ: 4.25 (s, 3H, CH3), 7.22-7.30 (m, 2H, H-6’, H-5’), 7.48-7.54 (m, 1H, H-7’), 7.75 (s, 1H, H2’’), 
8.06 (d, 1H, J = 5.5 Hz, H-4’’), 8.18 (d, 1H, J = 2.8 Hz, H-2’), 8.26 (d, 1H, J = 5.5 Hz, H-5’’), 8.33 
(s, 1H, H-5), 8.36-8.39 (m, 1H, H-4’), 11.82 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 36.6 
(q), 108.0 (d), 110.4 (s), 110.6 (s), 112.2 (d), 115.3 (d), 120.3 (d), 120.8 (d), 122.4 (d), 124.2 (s), 
126.7 (d), 128.9 (s), 132.9 (s), 133.4 (s), 136.6 (s), 135.2 (d), 137.6 (d), 148.0 (s), 162.5 (s). Anal. 
Calcd for: C19H13ClN4S: C, 62.55; H, 3.59; N, 15.36. Found: C, 62.31; H, 3.45; N, 15.21. 
7-Chloro-3-[2-(5-methoxy-1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-c]pyridine  
(51e)  
Orange solid; yield: 73%; mp: 184-185 °C; IR 3383 (NH) cm-1; ; 1H NMR (200 MHz, DMSO-
d6) δ: 3.89 (s, 3H, OCH3), 4.22 (s, 3H, CH3), 6.88 (dd, 1H, J = 2.5, 8.8 Hz, H-6’), 7.41 (d, 1H, J = 
8.8 Hz, H-7’), 7.69 (s, 1H, H-2’’), 7.87 (d, 1H, J = 2.4 Hz, H-4’), 8.02 (d, 1H, J = 5.5 Hz, H-4’’), 
8.11 (d, 1H, J = 2.9 Hz, H-2’), 8.28 (s, 1H, H-5), 8.36 (d, 1H, J = 5.5 Hz, H-5’’), 11.67 (bs, 1H, 
90 
 
NH); 13C NMR (50 MHz, DMSO-d6) δ: 36.6 (q), 55.1 (q), 101.7 (d), 107.6 (d), 110.2 (s), 110.5 (s), 
112.6 (d), 113.0 (d), 115.5 (d), 124.7 (s), 127.1 (d), 128.9 (s), 131.5 (s), 133.1 (s), 133.4 (s), 134.9 
(d), 137.3 (d), 148.0 (s), 154.6 (s), 162.8 (s). Anal. Calcd for: C20H15ClN4OS: C, 60.83; H, 3.83; N, 
14.19. Found: C, 60.59; H, 3.72; N, 13.94. 
3-[2-(5-Bromo-1H-indol-3-yl)-1,3-thiazol-4-yl]-7-chloro-1-methyl-1H-pyrrolo[2,3-c]pyridine 
(51f)  
Green solid; yield: 99%; mp: 273-274 °C; IR 3378 (NH) cm-1; 1H NMR (200 MHz, DMSO-d6) 
δ: 4.24 (s, 3H, CH3), 7.37 (dd, 1H, J = 1.9, 8.6 Hz, H-6’), 7.50 (d, 1H, J = 8.6 Hz, H-7’), 7.75 (s, 
1H, H-2’’), 8.04 (d, 1H, J = 5.5 Hz, H-4’’), 8.24-8.29 (m, 3H, H-2’, H-5, H-5’’), 8.50 (d, 1H, J = 1.8 
Hz, H-4’), 12.02 (bs, 1H, NH); 13C NMR (50 MHz, DMSO-d6) : 36.6 (q), 108.4 (d), 110.0 (s), 
110.5 (s), 113.4 (s), 114.3 (d), 115.3 (d), 117.8 (s), 122.5 (d), 125.0 (d), 125.9 (s), 128.2 (d), 128.9 
(s), 133.1 (s), 133.3 (s), 135.2 (d), 137.2 (d), 148.1 (s), 162.0 (s). Anal. Calcd for: C19H12BrClN4S: 
C, 51.43; H, 2.73; N, 12.63. Found: C, 51.19; H, 2.60; N, 12.47. 
 
BIOLOGY 
Drugs Preparation 
To obtain stock solutions of compounds 45a-l, 46a-d, 47a-d, 48a-d and 49a-j, 50a-f, 51a-f, each 
compound was initially dissolved in DMSO in order to obtain 50mM solution, stored at +4°C, and 
diluted in complete culture medium immediately before use at the appropriate concentration. 
Human Tumour Cell Lines. 
Human diffuse malignant peritoneal mesothelioma (DMPM) cell lines (STO and MesoII) were 
established from surgical specimens of patients who underwent surgery at Fondazione IRCCS 
Istituto Nazionale dei Tumori of Milan, as previously described [32].  
 
Human Tumour Cell Lines Growth Conditions 
Cells were maintained in the logarithmic growth phase as a monolayer in DMEM F12 
supplemented with 10% heat-inactivated fetal bovine serum in a humidified incubator at 37°C with 
a supply of 5% CO2/95% air atmosphere. Cell lines were tested fortnightly for the absence of 
Mycoplasma and periodically monitored for DNA profile of short tandem repeats analysis by the 
AmpFISTR Identifiler PCR amplification kit (Applied Biosystems). 
 
Evaluation of the Antiproliferative Potential of Nortopsentin Derivatives 
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After harvesting in the logarithmic growth phase, 4x10
3
 cells were plated in 96-well flat-
bottomed microtiter plates (EuroClone) for 24 hours and then treated with varying concentrations of 
different derivatives (0.01-50 μM) for 72 hours. Control cells received vehicle alone (0.1% DMSO). 
All studies were performed in eight replicates and repeated at least three times independently. 
At the end of drug exposure, the antiproliferative potential was determined by the CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (MTS; Promega), according to the manufacturer’s 
protocols. Briefly, 20µl of CellTiter 96® AQueous One Solution Reagent were added into each 
well of the 96-well assay plates containing the samples in 100 µl of culture medium. The plates 
were then incubated at 37°C for 3 hours in a humidified, 5% CO2 atmosphere. Optical density was 
read at 490 nm on a microplate reader (POLARstar OPTIMA, BMG Labtech GmbH) and the results 
were expressed as a percentage, relative to DMSO-treated cells. 
Dose-response curves were created and IC50 values (i.e., concentrations able to inhibit cell growth 
by 50%) were determined graphically from the curve for each compound obtained after 72 hour 
exposure of cells to Nortopsentin derivatives. 
 
Viability assay in vitro 
Nortopsentin analogues, prepared as described above, were dissolved in dimethyl sulfoxide 
(DMSO) (all reagents and chemicals were from Sigma Chemical Co (St. Louis, MO), unless 
indicated) and then diluted in culture medium to have a DMSO concentration not exceeding 0.1%. 
HCT-116 and Caco-2 cell lines were purchased from American Type Culture Collection, Rockville, 
MD, USA and DMEM supplemented with 10% fetal, 10% fetal bovine serum (FBS), penicillin 
(100 U/mL), streptomycin (100 g/mL) and gentamicin (5 μg/mL). Cells were maintained in log 
phase by seeding twice a week at a density of 3 x 10
8 
cells/L in humidified 5% CO2 atmosphere, at 
37 °C. In all experiments, HCT-116 cells were made quiescent through overnight incubation before 
treatment with tested compounds or vehicle alone (control cells), while Caco-2 cells were treated 15 
days after confluence, at which time the cells are differentiated in normal intestinal-like cells [50]. 
No differences were found between cells treated with DMSO 0.1% and untreated cells in terms of 
cell number and viability. Cytotoxic activity of the nortopsentin derivatives 45k and 51c was 
determined by the colorimetric assay based on the reduction of 3-(4,5-dimethyl-2-
thiazolyl)bromide-2,5-diphenyl-2H-tetrazolium (MTT) to purple formazan by mitochondrial 
dehydrogenases. Briefly, HCT-116 and Caco-2 lines cells were seeded at 2 × 10
4
 cells/well in 96-
well plates containing 200 μL RPMI. When appropriated, monolayer cultures were treated for 24 h 
with various concentrations (5-100 M) of the drugs. Then cells were washed with fresh medium 
and 50 μL FBS-free medium containing 5 mg/mL MTT added. Cells were incubated 2 h at 37 °C, 
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then medium was discarded by centrifugation, formazan blue formed in the cells dissolved in 
DMSO, and absorbance measured at 570 nm in a microplate reader (Bio-RAD, Hercules, CA). 
Formazan of control cells was taken as 100% viability. GI50 was calculated by the curve of percent 
viability versus concentration. Each experiment was repeated at least three times in triplicate.  
 
Cell cycle analysis 
Cell cycle stage was analyzed by flow cytometry. HCT-116 cells (5.0 x 10
4 
cells/cm
2
) were seeded 
in triplicate in 24-wells culture plates. After an overnight incubation, the cells were washed with 
fresh medium and incubated with compounds 45k and 51c in RPMI for 24 h. Then cells were 
harvested by trypsinization. Aliquots of 1x10
6
 cells were washed with PBS and incubated in the 
dark in a PBS solution containing 20 μg/ml propidium iodide (PI) and 200μg/ml RNase, for 30 min, 
at room temperature. Then samples of at least 1.0 x 10
4 
cells were subjected to fluorescence-
activated cell sorting (FACS) analysis by Epics XL™ flow cytometer using Expo32 software 
(Beckman Coulter, Fullerton, CA). 
 
Measurement of phosphatidylserine (PS) exposure 
The apoptosis-induced PS externalization to the cell surface was measured by flow cytometry by 
double staining with Annexin V-Fluorescein isothiocyanate (Annexin V-FITC)/propidium iodide 
(PI). Annexin V binding to phosphatidylserine is used to identify the earliest stage of apoptosis. PI, 
which does not enter cells with intact membranes, is used to distinguish between early apoptotic 
cells (Annexin V-FITC positive and PI negative), late apoptotic cells (Annexin V-FITC/PI-double 
positive) or necrotic cells (annexin V-FITC negative and PI positive).  After 24 h treatment, HCT-
116 cells were harvested by trypsinization and adjusted at 1.0 x 10
6
 cells/mL with combining buffer 
according to the manufacturer instructions (eBioscience, San Diego, CA). One hundred μL of cell 
suspensions were added to a new tube, and incubated with Annexin V-FITC and PI solution at room 
temperature in the dark for 15 min. Then samples of at least 1.0 x 10
4 
cells were subjected to FACS 
analysis using appropriate 2-bidimensional gating method. 
 
Measurement of mitochondrial transmembrane potential 
Changes of mitochondrial transmembrane potential (m) were assessed by flow cytofluorometry, 
using the cationic lipophilic dye 3,3'-dihexyloxacarbocyanine iodide(3) (DiOC6) (Molecular 
Probes, Inc.) which accumulates in the mitochondrial matrix. Changes in mitochondrial membrane 
potential are indicated by a reduction in the DiOC6-induced fluorescence intensity. After 24 h 
treatment, HCT116 cells were incubated with DiOC6 at a 40 nmol/L final concentration, for 15 min 
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at 37 °C. After centrifugation, cells were washed with PBS and suspended in 500 L PBS. 
Fluorescent intensities were analysed in at least 1x10
4
 cells for each sample. 
 
Morphology  
To analyse cell morphology, cells were fixed with methanol for 10 min and then stained with 
Giemsa (10% in PBS) for 15 min followed by washing with distilled water. Cell images were 
captured using Zeiss, AxioCam, AxioSkop microscope, (West Germany) with 40x lenses.  
 
Quantification of acidic vesicular organelles (AVO) by acridine orange (AO) staining  
AO is a fluorescent molecule used either to identify apoptotic cell death or autophagy. It can 
interact with DNA emitting green fluorescence or accumulate in acidic organelles where it is 
protonated forming aggregates that emit bright red fluorescence [41]. Briefly, cells were stained 
with AO solution (5 g/mL) for 15 min. Then they were washed, re-suspended in PBS and 
subjected to FACS analysis. The green (510-530 nm, FL-1) and red (650 nm, FL-3) fluorescence of 
AO with blue (488 nm) excitation, was determined over 10,000 events.  
 
Statistics 
 Results are given as means and their standard deviations. Three independent observations were 
carried out for each experiment, replicated three times. Statistical comparisons were made using a 
one-way ANOVA, followed by Bonferroni’s test. P<0.05 was considered statistically significant. 
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SYNTHESIS OF NAPHTHALENE DIIMIDE DERIVATIVES AS G-QUADRUPLEX 
LIGANDS  
(UCL, SCHOOL OF PHARMACY) 
INTRODUCTION 
During the second year of my PhD, I spent 7 months at the University College of London, School 
of Pharmacy, Biomolecular Structure Group (BMSG), under the supervision of Professor Stephen 
Neidle, where I carried out a project based on the synthesis of naphtalene diimides, potential ligand 
of G-quadruplex DNA. 
The DNA, the center of genetic information in the cell, is one of the most important targets of 
several anticancer drugs. Drugs that interact with this receptor are generally very toxic to normal 
cells, so a perfect chemotherapeutic DNA - interactive, should be a non-peptide molecule that can 
diffuse through the membrane without being degraded and that have as target a specific sequence of 
appropriate size of nitrogenous bases. The development of alkylating agents that react covalently 
with the nitrogenous bases of the DNA, as antitumor agents is strongly dependent on the discovery 
and development of the double-stranded DNA and its associated processes. Unluckily, numerous of 
these drugs are highly cytotoxic and non-selective. For this reason, significant efforts have been 
directed toward the discovery of new agents with improved selectivity and reduced cytotoxicity [1].  
In addition to the typical right-handed double helix proposed by Watson and Crick, DNA can 
assume other biologically significant structures, such as the G-quadruplex structure. The G-
quadruplex sequences are noncanonical secondary structures, rich in guanine d(TTAGGG), present 
in different regions of the eukaryotic genome, such as telomeres or the regulatory regions of many 
genes. These structures play important roles in the regulation of many biological events in the body 
and in recent decades have become valid targets for the development of new anticancer drugs.  
The nucleic acid sequences show a high propensity to self-association in planar quartets (G-
quartets) to form four filaments structures called G-quadruplex (or G-tetrads or G4-DNA), reported 
for the first time by Davis and co. in 1962 [1, 2].  
G-quadruplex structures are formed when four guanine are distributed in a planar arrangement 
through Hoogsteen hydrogen bondings and the structure is stabilized by the presence of a 
monovalent cation (usually K 
+
 or Na 
+
), which is at the center of the tetrad and it is coordinated 
with the lone pairs of the O6 of each guanine. Four hydrogen bonds are formed for each pair of 
guanines through N1, N2, N7 and O6 atoms (Fig.1). 
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Figure 1. A possible G-quadruplex monomeric structure (a) and the hydrogen-bonding arrangement 
in the G-quartet (b). 
The space between the G-tetrads can coordinate cations of these dimensions because the two planes 
of the tetrads are coated by eight oxygen atoms of the carbonyl groups (with a strong negative 
electrostatic potential) which create a central channel with a negative charge inside of the stack of 
G-tetrad (Fig.2) [1, 3, 4].  
 
Figure 2. G-quadruplex ion channel. 
 
The G-quadruplex crystal structure shows that the quartet can be considered as a square aromatic 
surface, whose dimensions are much larger than the base pairs of Watson-Crick (Fig.3), and this 
difference is the base for the design of new G-quadruplex-specific ligands [1, 5].  
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Figure 3. Comparison of the dimensions of duplex and G-quadruplex DNA structures. a) The 
double helix and its base pair surface. b) The quadruplex structure and the G-quartet surface.  
 
In general, structural polymorphism arises mostly from the nature of the loop, such as variations of 
strand stoichiometry, strand polarity, glycosidic torsion angle, and the location of the loops that link 
the guanine strands. Meanwhile, the solution environment, such as the presence of metal ions, 
ligands, or molecular crowding conditions, may influence the topology of quadruplex. G-
quadruplex structures are made up of one, two, or four DNA strands, which can run parallel or 
antiparallel, and the DNA sections which are involved in the quadruplex, form loops. Loops can be 
diagonal, lateral or propeller (or chain-reversal) depending on the number of G-quartets comprising 
the stem of a quadruplex and on loop length (Fig. 4) [6].  
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Figure 4. The major experimentally observed topologies for human telomeric DNA quadruplex 
sequences.  
 
G-quadruplexes can be folded from a single G-rich sequence intramolecularly or by the 
intermolecular association of two (dimeric) or four (tetrameric) separate strands [1]. The 
heterogenecity of the G-quadruplex sequences also depends on the conformation of the guanine 
(syn or anti) [4, 7, 8]. 
G-Quadruplex sequences are present in specific regions of the genome with key biological contexts. 
These include: 
 the ends of telomeric DNA [4],  
 promoter regions of several oncogenes and in a number of genes involved in cellular 
proliferation. Examples reported are c-myc [4], c-kit [9], K-ras [10], RET oncogenes [11], 
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androgen receptor [12] and HSP90 genes [13], the platelet-derived growth factor (PDGF) 
[14] and vascular endothelial growth factor (VEGF) [15], 
 5’-untranslated RNA sequences [16]. Examples of genes containing such sequences include 
the estrogen receptor [17], the MT3 matrix metalloprotease gene [18], and the Bcl2 gene 
[19]. 
The therapeutic concept developed is that the stabilization of quadruplex sequences with a small 
molecule can cause inhibition of transcription (in the case of the quadruplex promotor) or 
translation (5’quadruplex-UTR) of the gene involved, and that this could, therefore, confer a 
therapeutic advantage if the gene is critically involved in the maintenance of the malignant 
phenotype or metastatic disease [20]. 
 
DNA G-quaduplex as target for a therapeutic strategy was initially developed for telomeric DNA 
and the inhibition of telomerase enzyme.  
Telomeric DNA is non-coding DNA sequence present at the ends of the chromosomes of eukaryotic 
cells, which is essential for the preservation of genome stability [1].  
The role of the telomeric DNA-protein complex is to protect the ends of chromosomes from 
degradation and unwanted chromosomal fusions [20, 21, 22].  
Telomers are specialized complexes consisting of a repetitive sequence in double-stranded length of 
about 10-15 Kb and ending with a single strand of 200 nucleotides at the 3' rich in guanine which 
protrudes beyond the double-stranded region [4].  
The single-stranded DNA can be recognized as damage so it is not usually exposed to the cell 
environment, but it is folded on the double-stranded region leading to the formation of a large 
telomeric loop, called T-loop. The 3'end of the strand invades the adjacent duplex DNA, forming a 
region of single-stranded DNA called D-loop. The loops are associated with a large number of 
proteins, called shelterins, which help the stabilization of the secondary structure of the T-loop. 
These proteins include the complex of telomere repeat binding factor 1 and 2 (TRF1 and TRF2) that 
binds to double-stranded telomeric DNA; the protection protein of telomeres 1 (POT1) that binds 
the single-stranded 3' rich in guanine. There are three other proteins (TIN2, TPP1 and RAP1) which 
protect the integrity of telomeres and help in the development of T and D-loop (Fig. 5) [4, 21]. The 
role of the shelterin complex is to regulate telomeric DNA responses to potentially lethal damage 
events and the length of telomeric DNA. 
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Figure 5.  (a) View of the shelterin complex, (b) T and D-loops structures, (c) Schematic 
representation of the associated proteins and their mutual interactions.   
 
Due to the inability of the DNA polymerase replication system to replicate the whole length of the 
ends of telomeric DNA in somatic cells, in the absence of any compensating mechanism, telomeric 
DNA in normal cells is progressively reduced to 50-100 nucleotides during each round of cellular 
replication. When telomeres becomes critically short, they reach a critical point, called the 
“Hayflick limit” and cells go into a state of senescence with a consequent up regulation of proteins 
p21(WAF) and p16 
INK4a
, increased phosphorylation of the proteins p53 and pRB (retinoblastoma), 
and subsequent cellular apoptosis (Fig. 6) [1, 6, 20, 23, 24]. 
T-Loop  
D-Loop  
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Figure 6. Structures and biological roles of telomers. 
 
In tumor cells, the telomeres are maintained at a constant length by the activation of the enzyme 
telomerase (enzyme-dependent RNA or reverse transcriptase) (Fig. 6) that compensates for the 
shortening, adding the sequence TTAGGG at the end of telomeric DNA, resulting in a stabilization 
of the genomic DNA and inducing uncontrolled cell proliferation. This enzyme reverses the 
behavior of telomeric DNA in somatic cells, causing cellular immortality. This is the reason why 
the activity of telomerase is closely related to the proliferation of some types of tumor cells [25].  
The enzyme telomerase is not significantly expressed in normal somatic cells, suggesting the 
existence of a large therapeutic window for inhibitors of telomerase. 
Telomerase enzyme complex is a reverse transcriptase formed by two principal subunits, a catalytic 
domain (hTERT) and an RNA domain (hTR), containing a single stranded RNA template, scaffold 
for DNA retrosynthesis. The catalytic subunit adds deoxynucleotide triphosphates to the 3’ single 
stranded telomeric overhang (Fig. 7) [6].   
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Figure 7. Telomerase complex.  
 
The relation between tumor and telomerase enzyme was proved by a great number of studies on 
cancer cell lines concluding that approximately 80-85% of human cancers express significant levels 
of active form of telomerase. So telomerase has been identified as one of the essential factors 
required in order to transform a normal cell in an immortalized one [6] and the inhibition of this 
enzyme has gained significant consideration for new, more selective and less toxic anticancer 
strategies [26].  
 
The therapeutic potential of the G-quadruplex sequences has led to an increase in the number of 
studies in which ligand molecules have been used as stabilizers of the G-quadruplex DNA. Several 
compounds that interact with G-quadruplex have been described in the literature [4].  
The key characteristics common to these ligands include aromatic flat wide surface suitable for  
stacking interactions with the terminal of a G-quadruplex DNA, the presence of cationic charges 
and basic groups (often amino groups which can be protonated at physiological pH) and chains 
hydrophilic side which interact with the grooves of the DNA.  
These compounds are chemically different, some of these derive from natural sources, such as 
telomestatin, while others have synthetic origin, such as phenanthrolines, triazines, acridines as 
BRACO 19, perylene diimides, anthraquinones, cationic porphyrins, fluoroquinolones, carbazole 
derivatives and naphthalene dimiides (ND). 
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Telomestatin 1 is a macrocyclic compound containing a pentaoxazole ring system and a thiazoline 
ring isolated from Streptomyces anulatus. It showed exceptional quadruplex-binding and telomerase 
inhibitory activity [27]. Telomestatin 1 induced the formation of basket type G-quadruplex 
structures in the telomeric region, damaged the telomeric replication and inhibited the growth of 
cancer cells [28]. Studies shown that telomestatin, like synthetic compounds as BRACO19 8, acted 
not only by the inhibition of the catalytic activity of telomerase, but also by the uncapping of the 3’ 
strand of telomeres [4, 29]. 
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Porphyrins are considered to be ideal ligands of the G-quadruplex due to their extended conjugation 
that allows an optimal level of tetrads stacking.  
The porphyrin compound TMPyP4 (tetra-(N-methyl-4-pyridyl)porphyrin) 2 is a G-quadruplex 
ligand that has been used in a large number of studies. It has been reported to show anti-cancer 
activity in MX-1 mammary tumors and PC-3 human prostate carcinomas. Data in vitro and in vivo 
showed that TMPyP4 2 binded tightly to the quadruplexes and reduced c-myc expression in cell-
free system and in cells. However, this compound is able to bind equally well to many other 
quadruplexes such as human telomeric ones and the double DNA [30].  
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A bis-amide derivative of telomestatin, S2T1-6OTD 3, binded preferentially to a 22-mer from the c-
myc promoter region, showed a weak affinity for a human telomeric sequence and did not exhibit 
affinity for duplex DNA. It was observed that this compound inhibit transcription, cause significant 
reduction in c-myc mRNA and protein expression in childhood medulloblastoma (MB) cells [31].  
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Quarfloxin 4 (CX-3543) is a fluoroquinolone derivative that has reached Phase II clinical trials for 
the treatment of neuroendocrine tumors and carcinoids [4]. It was initially suggested by Hurley, that 
quarfloxin 4 is highly selective for the G-quadruplex, and in particular for the G-quadruplex of the 
c-myc promoter [32]. It is now believed that it works by destroying the interaction between the 
protein nucleolin and the ribosomal DNA quadruplex (rDNA), a critical interaction for the rRNA 
biogenesis that is overexpressed in some tumor cells. The blocking of this interaction can lead to the 
inhibition of the synthesis of the ribosome and apoptosis of tumor cells [33].  
 
N
O
F
O
N
H
O
N
N N
N
 
Quarfloxin 
4 
Substituted amido-anthraquinones 5 were the first class of molecules with activity quadruplex-
mediated telomerase inhibitors [34].  
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The key features, including the anthraquinone core and the side chains terminating with cationic 
end-group are important for the interaction with the G-quadruplex DNA and inhibition of 
telomerase. From the telomerase inhibitor data it was possible to deduce a set of structural 
characteristics important for the activtity [35]:  
 Two side-chains; 
 The best side-chain length is –(CH2)2-3-; 
 The amido group; 
 Piperidine or pyrrolidine cationic end-group; 
 The cationic group. 
Examples of known anthraquinones include the anti-tumor agent doxorubicin (Adriamycin) 6, and 
the antitumor antibiotic daunorubicin 7. 
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                                           6                                                        7 
                                 Doxorubicin (Adriamycin)                  Daunorubicin 
 
The acridine derivative BRACO 19 8, similarly to the telomestatine, causes a rapid senescence at 
the level of the tumor cells and activates the same response that occurs following the double-strand 
break of the DNA. This involves, in particular, the activation of the ATM pathway, the kinase 
p16
INK4a
 and the pro-apoptotic protein p53. This response is a consequence of the displacement of 
proteins bounding to single-stranded 3’telomeric sequence, in particular hPOT1.  
Protein hPOT1 interacts with the telomeric protein TPP1, helping the elongation of the telomere by 
telomerase. The displacement of this protein therefore results in an alteration of the function of 
telomerase [36]. In vivo activity against a human tumor xenograft was also found, where the 
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cytotoxic agent taxol was used to produce tumor regression and BRACO-19 8, given after 
debulking, was able to suppress tumor regrowth [38].  
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A number of recent studies have employed the naphthalene diimide (ND) core system as a 
quadruplex-binding motif, due to its combination of chemical accessibility and extended planar 
surfaces suggestive of favorable quadruplex-binding. Most of these published studies have focused 
on mono-di- or trisubstituted compounds. Some tri- and tetra-substituted naphthalene diimides (Fig. 
8) showed exceptional ligand properties for G-quadruplex DNA with stabilizing value for G-
quadruplex DNA, in classical and competition FRET assays, twice higher than those obtained with 
acridine compound BRACO19 8, and significantly greater than effects produced by TMPyP4 2 and 
telomestatine 1. These compounds were able to inhibit the telomerase activity in the TRAP assay, 
they showed antiproliferative activity against MCF7 and A549 cell lines, and they were localized in 
the nucleolus of MCF7 cells [38].  
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Figure 8. Some tri- and tetra-substituted naphthalene diimides.  
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Then, a series of tetrasubstituted naphthalene diimide compounds, in particular with N-
methylpiperazine end groups, were synthesized (Fig. 9). They showed high affinity and selectivity 
for telomeric G-quadruplex DNA F21T (tm values from 23.8 to 28.3 °C) and low affinity for 
duplex DNA T-loop sequence (tm values from 0.1 to 1.3 °C). These compounds presented 
extraordinary activity in a panel of cancer cell lines, including the pancreatic cell lines MIA Paca-2, 
PANC-1 and HPAC, with IC50 values of 0.1-0.2 M. They were significantly less toxic to the 
normal human fibroblast cell line WI38 than to the panel of cancer cell examined [39].   
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Figure 9. Naphthalene diimides with N-methyl piperazine end-group.  
 
In particular, a pancreatic cancer xenograft model of one of these compounds (9) revealed a 
significant antitumoral activity. After an intraperitoneal (ip) administration, 50% reduction in tumor 
volume and high inhibition of telomerase activity (in MCF7 breast carcinoma) it was observed [40].  
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In the cocrystal structures [41] was observed that the charged nitrogen atom of the N-methyl 
piperazine ring of compound 9 is in proximity to a phosphate oxygen group through hydrogen 
bonds. The N-methyl piperazine ring next to the side chain indirectly interacts with a phosphate 
group, through a network of water molecules in the groove.  
The four positive charges of this compound have been modulated through the replacement of the 
two N-methyl piperazine groups with weaker N-basic groups, with the purpose to increase the 
pharmacological properties of the series of naphathlene diimides without compromising the 
interaction with the G-quadruplex DNA. It has been suggested that a slight decrease of the cationic 
nature of the naphthalene diimides could increase the cellular uptake and the potential distribution 
in the tumor, while maintaining the affinity for DNA G-quadruplex [42].  
In particular, two morpholine groups were introduced, which not only reduce the overall molecular 
weight of the molecule but they are less basic groups relative to the N-methyl piperazine protonated 
ring, with a pK value of 8.5 compared to that for the latter of 9.2.  
The series was further explored with ND compounds having a diversity of noncharged end-groups 
as methoxy groups, furan, tetrahydrofuran or tetrahydropyran 12a-h (Fig. 10) [42]. 
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Figure 10. Molecular structure of tetrasubstituted naphthalene diimides.  
High-throughput fluorescence resonance energy transfer (FRET) is a melting technique used to 
evaluate the ability of these compounds to stabilize a human telomeric quadruplex sequence.  
In table 1 the Tm values (°C) for a duplex DNA, a human telomeric quadruplex sequence and two 
HSP90 quadruplex sequences are reported. With the exception of tetra-N-methyl-piperazine 
compound 9 [39], only derivatives with morpholine rings revealed significant stabilization of G-
quadruplex DNA, and also some binding to the duplex DNA sequence. The dimethoxy compound 
12e exhibited a very slight interaction with the telomeric quadruplex but a greater stabilizing effect 
on HSP90 promoter sequences, with Tm values of 23.8 and 29.0 °C. Compounds with furan, 
pyranose and acyclic ether rings (12b,c,e) did not show any effect on telomeric quadruplex or 
duplex stability. All the morpholine compounds determined high Tm values in the telomeric 
quadruplex, with values comparable to that reported for compound 9. Nevertheless, compounds 12f 
and 12g, in which the linker to the morpholine group is n = 2-(CH2)n-, exhibited higher selectivity 
for quadruplex DNA over duplex DNA compared to compounds with n = 3 (Tab. 1). 
 
Table 1. ΔTm Values (°C) for a Duplex DNA (T-loop), a Human Telomeric Quadruplex Sequence 
(htel), and Two HSP90 Quadruplex Sequences at a 1 μM Ligand Concentration (with 60 mM K+ at 
pH 7.4)
a
 
Compd T-loop Htel HSP90A HSP90B 
9 1.3 28.3 36.3 32.0 
12a 0.2 22.7 27.1 21.0 
12b 0.3 0.2 0.9 1.1 
12c 0.2 0.1 0.7 0.8 
12d 4.9 26.6 33.1 28.6 
12e 0.0 0.5 29.0 23.8 
12f 0.8 27.0 33.9 29.1 
12g 1.7 24.7 30.6 27.6 
12h 8.1 27.8 31.9 31.1 
aESDs are ±0.1 °C, estimated from multiple readings. 
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The SRB (Sulforodamine) assay was used to assign the antiproliferative activity of naphthalene 
diimide derivatives (Tab. 2). After 96 hours exposure to 2-fold serial dilutions of each compound in 
a panel of cancer cell lines together with a normal fibroblast line, it was observed that compound 
12a resulted devoid of significant antiproliferative activity in all the cancer cell lines, with the 
exception of MIA PaCa-2 and A549 lines, even though compunds 12b, 12c, 12e showed IC50 
values in the range of 1-8 M. In particular, compound 12c reveled up to 10-fold selectivity for the 
renal carcinoma cell line 786-0. Instead, the morpholine compound 12d and 12h, with a n = 3-
(CH2)n-linkers to the morpholine group, exhibited a potent activity in the MIA PaCa-2 pancreatic 
carcinoma and A549 lung adenocarcinoma cell lines, showing IC50 values between 10-20 nM.  
 
Table 2. Growth Inhibition data for Compounds 12a-h and 9 using a panel of cancer cell lines and a 
normal human fibroblast line (WI-38), Measured by the SRB Assay for 96 h exposure and 
expressed as IC50 Values in μM. 
 
Compd A549 RCC4 MIA-PaCa-2 786-0 MCF-7 WI-38 
12° 5.57 ± 0.31 >10 5.65 ± 0.14 >10 >10 >10 
12b 2.41 ± 0.01 3.11 ± 0.06 2.83 ± 0.01 1.10 ± 0.03 2.61 ± 0.06 6.84 ± 0.05 
12c 2.92 ± 0.01 8.38 ± 0.50 2.50 ± 0.01 1.20 ± 0.03 3.12 ± 0.13 12.65 ± 0.11 
12d <0.01 ± 0.005 0.56 ± 0.05 0.01 ± 0.01 0.32 ± 0.01 0.07 ± 0.007 0.23 ± 0.01 
12e 2.54 ± 0.01 10.51 ± 0.14 2.79 ± 0.09 7.17 ± 0.41 5.62 ± 0.15 3.32 ± 0.50 
12f 1.55 ± 0.02 1.75 ± 0.18 0.04 ± 0.01 0.63 ± 0.06 0.17 ± 0.01 0.61 ± 0.02 
12g 4.93 ± 0.05 5.10 ± 0.70 n/a 1.48 ± 0.17 0.18 ± 0.03 1.17 ± 0.11 
12h <0.01±0.006 0.28 ± 0.06 0.01±0.01 n/a 0.03 ± 0.01 2.46 ± 0.02 
9 0.11 ± 0.02 n/a 0.11 ± 0.02 n/a 0.17 ± 0.03 9.0 ± 3.2 
The panel of cancer carcinoma cell lines used includes: A549 (lung), RCC4, and 786-0 (renal), MIA PaCa-2 (pancreatic), and MCF-7 
(breast).  
 
Considering the interesting results shown, during the 7 months at the Biomolecular Structure Group 
(BMSG), I initially synthesized again compound 12d (100 mg), already published by this research 
group [42], in order to obtain a higher quantity sufficient for more biophysical studies (FRET) using 
other human G-quadruplex sequences, biological studies (SRB assay) in other cancer cell lines and  
mouse xenograft studies, in MIA PaCa-2 cells that were explanted into the mouse flank. However 
resulted related to mouse xenograft studies cannot be shown for publication reasons. 
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Then I was involved in a project related to the design, the synthesis and the evaluation of the 
antitumor activity of a series of new trisubstituted naphthalene diimide derivatives (13), obtained 
with a different panel of amines. The differences in the amines have provided diversity in the 
library, enabling the exploration of the effects of differing end groups and side-chain lengths. 
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RESULTS AND DISCUSSION: CHEMISTRY 
 
The synthetic pathway for the synthesis of compound 12d involves three steps (Scheme 1) [42]. 
Commercial isochromeno-[6,5,4,def]-isochromene-1,3,6,8-tetraone 14, dissolved in fuming 
sulphuric acid, was brominated using dibromoisocyanuric acid 15 in hot sulphuric acid solution (40 
°C). The yellow solid obtained 16 was used without purification for the next step [43]. In the second 
step, the dibrominated naphthalene anhydride 16 and 3-morpholino propylamine 17 were 
solubilized in acetic acid and heated at 130 °C for 30 minutes under microwave waves. The 
obtained semisolid was purified using reverse phase HPLC and compound 18 was isolated in 32% 
of yield. Then compound 18 was subjected to amination in order to introduce two more amino 
groups and to obtain tetra-substitute derivative 12d.  
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Di-brominated compound 18 and N-methylpiperazine propylamine 19 were solubilized in NMP (N-
methyl-2-pyrrolidinone) and the reaction mixture was heated at 130 °C for 30 minutes under 
microwave irradiation. After purification with reverse phase HPLC, it was possible to isolate tetra-
substituted ND 12d in 18% of yield.  
 
Scheme 1. Synthetic route to prepare the tetra-substituted naphthalene diimide derivative 10d. 
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Tri-substituted naphthalene diimides 13a-j were obtained from the monobromo precursor 22, using 
commercially available amines 19, 23-31 (Tab. 3). 
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Table 3. Amines 19, 23-31. 
Amine Amine Amine Amine Amine 
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A representative 3 steps synthesis is outlined in scheme 2.   
 
Scheme 2. Synthetic route to prepare the tri-substituted naphthalene diimide derivatives 13a-j. 
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13f n = 1, R = piperidine
13g n = 1, R = phenol
13h n = 1, R = morpholine
13i n = 1, R = tetrahydrofuran
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The first step involved the synthesis of the mono-brominated derivative 21. Isochromeno-
[6,5,4,def]-isochromene-1,3,6,8-tetraone 14 was treated with dibromo hydantoin (DBH) 20 in 
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sulfuric acid at room temperature for 24 h. After crystallization with N,N-dimethylformamide the 
desired compound 21 was obtained in good yield (83%) [44] (Scheme 3).  
 
 Scheme 3. 
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The monobromo percursor 21 was subjected to amination using 3-morpholino-propylamine 17 in 
acetic acid under microwave irradiation. Derivative 22 was isolated in low yield (20%) (Scheme 4).  
 
Scheme 4. 
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The final step involved a secondary amination of the mono-brominated derivative 22 with several 
amines 19, 23-31 to obtain different tri-substituted naphthalene diimides 13a-j from low to good 
yields (8-60%) (Scheme 5).  
Scheme 5. 
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13a  n = 2, R = N-Me-piperazine
13b n = 1,  R N-Me-piperazine
13c n = 1, R = pyrrolidine
13d n = 1, R = pyridine
13e n = 3, R = pyrrolidine
13f n = 1, R = piperidine
13g n = 1, R = phenol
13h n = 1, R = morpholine
13i n = 1, R = tetrahydrofuran
13j n = 1, R = diethylamine
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RESULTS AND DISCUSSIONS: BIOLOGY 
The ability of tetra-substituted compound 12d and tri-substitute compounds 13a-j to stabilize 
human telomeric quadruplex was assessed by FRET (Fluorescence Resonance Energy Transfer) 
assay modified to be used as a high-throughput screen in a 96-well format. This technique evaluate 
the distance-dependent interaction between the electronic excited states of two molecules in which 
excitation was transferred from a donor molecule to an acceptor molecule through non-radiative 
dipole–dipole coupling, resulting in the return of the donor to its ground state causing a fluorescent 
emission (Fig. 11) [45]. 
 
 
Figure 11. Schematic representation of FRET technique. 
 
The FRET efficiency (E) is the quantum yield of the energy transfer transition and it was described 
in the empirical Förster equation. The efficiency depends on the distance between the donor and the 
acceptor (r) (typically in the range of 10–100 Å), with an inverse 6th power law due to the dipole-
dipole coupling mechanism:  
1 + (r/R0)
6
1
E =
 
R0 is the Förster distance of this pair of donor and acceptor, i.e. the distance at which the energy 
transfer efficiency is 50%. 
DNA can be synthesized with its 3’ and 5’ ends tagged with fluorescent dyes, at the 5’ end 6- 
carboxyfluorescein (FAM) 32 as the donor, and tetramethyl-6-carboxyrhodamine (TAM) 33 at the 
3’ end as the acceptor, using 6 carbon linkers. 
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When nucleotides are folded in the G-quadruplex structure, the fluorophores are closer in space and 
the FRET efficiency is high. Using this property, by increasing the temperature while measuring the 
fluorescence intensity, melting experiments could be done on DNA and the melting temperature of 
the labelled oligonucleotides could be monitored to screen the G-quadruplex stabilising ability of 
small molecules [46]. The experiment was performed with different sequences of labelled DNA, 
including G-quadruplexes DNA sequences (F21T, Hsp90A, Hsp90B, Kras21, Kras32, Bcl-2) and 
the duplex DNA sequence (T-Loop). The FRET probe sequences were diluted from stock to the 
correct concentration (400 nM) in a 60 mM potassium cacodylate buffer (pH 7.4) and then annealed 
by heating to 85 °C for 10 min, followed by cooling to room temperature in the heating block (3-3.5 
h).The Tm values obtained for all the derivatives (at 1μM concentration) were reported in the table 
4.  
Table 4. Tm values (C) for FRET analyses of compounds 13a-j at 1μM concentrations with a 
series of G-rich sequences: hTel (F21T), Hsp90A, Hsp90B (Heat Shock Protein 90), Tloop (duplex 
DNA). Esds are from triplicate measurements and average 0.3 C.  Compound 12d is the di-
morpholino-di-N-methyl-piperazine naphthalene diimide derivative highlighted in Micco et al J. 
Med. Chem., 2013 [42]. 
 
Tm values (C) 
Compd F21T Hsp90A Hsp90B Kras21 Kras32 Bcl-2 Tloop 
13a 14.3 19.8 16.5 9.8 6.1 15.8 0.8 
13b 12.3 18.1 15.0 11.0 6.1 15.1 0.4 
13c 11.8  15.7 12.7 11.0 9.6 13.3 0.6  
13d <2 2.5 <2 3.0 1.5 2.8 0 
13e 15.9 20.6 16.9 11.7 6.6 16.1 0.2 
13f 9.8 9.1 8.7 4.8 2.2 5.9 0.6 
13g 6.0 11.0 9.4 2.4 1.5 5.8 1.5 
 13h 1.4 3.9 6.8 3.4 1.2 4.2 0 
13i <2 2.7 4.5 0.7 0.2 2.4 0 
13j 9 15.7 13.8 6.1 3.0 10.0 0.1 
12d 26.6 33.1 28.6 22.5 19.8 26.4 4.9 
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Table 4 shows that all the compounds exhibited significant telomeric quadruplex stabilization and a 
general preference for G-quadruplex DNA over duplex DNA. The best results were obtained with 
compounds 12d, 13a and 13e. In particular, the tetra-substituted derivative 12d exhibited the best 
telomeric quadruplex stabilization with Tm values equal to 26.6 °C for F21T, 33.1 °C and 28.6 °C 
for Hsp90A and B, 22.5 °C for Kras21, 19.8 °C for Kras32, 26.4 °C for Bcl-2, as well as some 
binding to the duplex DNA sequence, with Tm values equal to 4.9 °C.  
Tri-substituted naphthalene diimide 13a, containing a N-methylpiperazine ring, showed good Tm 
values for quadruplex DNA sequences (14.3 °C for F21T, 19.8 °C and 16.5 °C for Hsp90A and B, 
9.8 °C for Kras21, 6.1 °C for Kras32, 15.8 °C for Bcl-2) , and a low Tm value for duplex DNA 
(0.8 °C).  
Tri-substituted naphthalene diimide 13e, containing a pyrrolidine ring, showed instead good Tm 
values for quadruplex DNA sequences (15.9 °C for F21T, 20.6 °C and 16.9 °C for Hsp90A and B, 
11.7 °C for Kras21, 6.6 °C for Kras32, 16.1 °C for Bcl-2) , and a small Tm value for duplex DNA 
(0.2 °C).  
In general for all tri-substituted compounds the stabilization of the duplex DNA sequence (T-Loop) 
was not significant at the biologically relevant concentrations employed (1M).  
 
The antiproliferative activity of all compounds was assessed using the SRB (sulforhodamine) assay, 
against a panel of cancer and non-cancer cell lines (referred to as normal fibroblast cell line, WI38). 
The cancer-derived cell lines studied were A549 (human lung adenocarcinoma), MCF7 (human 
breast adenocarcinoma), Mia PaCa-2 and Panc1 (pancreatic cancer) and ALT (Alternative 
Lengthening of Telomeres). The experiment was based on a 96 hours exposure to 2-fold serial 
dilutions of each compound in order to evaluate the IC50 value of each of them.  
The assay used is the sulforhodamine B colorimetric assay (SRB). It is based on the ability of the 
purple dye SRB 34 to interact with the basic amino acid residues of cellular proteins. This molecule 
is UV active and the quantification of the dye bound to the cells at 540 nm is an indirect measure of 
the amount of viable cells. 
34
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O
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Cells were seeded in a 96-well plate and incubated for 24 hours, and then with different 
concentrations of ligand for 96 hours. The supernatant was removed and the remaining cells were 
fixed with trichloroacetic acid and stained with sulforhodamine B.  
The results obtained were adjusted by the negative control (cells without ligand and without SRB) 
and normalized by the positive control (cells only with SRB) to obtain the rate of viable cells. The 
IC50 values were calculated as the concentration responsible for a 50% decrease of cell viability.  
The results obtained are shown in table 5. 
 
Table 5. Short-term 96 h IC50 values (in μM) for compounds 13a-j and 12d in a cancer cell line 
panel, comprising MCF7 (breast), A549 (lung cancer), Mia-PaCa2/Panc1 (pancreatic cancer), ALT 
(Alternative Lengthening of Telomeres) and WI38 (lung fibroblast) cell lines. Esds average 0.25 
μM. Compound 12d is the di-morpholino-di-N-methyl-piperazine naphthalene diimide derivative 
highlighted in Micco et al J Med Chem, 2013 [42]. 
 
IC50 (M) 
Compd A549 MCF7 MiaPaCa2 Panc1 ALT WI38 
13a 0.067 0.357 0.059 0.045 0.224 1.83 
13b 0.086 0.316 0.048 0.046 0.085 1.49 
13c 0.024 0.159 0.012 0.022 0.093 1.19 
13d 0.130 1.070 0.220 0.340 1.29 2.24 
13e 0.026 0.222 0.036 0.033 0.089 1.22 
13f 0.198 1.110 0.108 0.084 0.535 5.33 
13g 2.18 >25 0.206 0.220 10.874 17.65 
13h 0.146 1.03 0.139 0.808 0.71 1.88 
13i 0.825 3.33 1.085 0.909 2.67 5.53 
13j 0.092 1.538 0.059 0.163 0.451 1.65 
12d 0.019 0.070 0.011 0.003 0.063 0.230 
 
As shown in the table 5, with the exception of compound 13g that did not show a significant 
antiproliferative activity in all cell lines, all other compounds were found to be cytotoxic for almost 
all the tumor cell lines, with the IC50 values in the micro-, submicro- and nano molar range. 
In particular, the most active compounds were found to be the tetra-substituted 12d and the tri-
substituted compounds 13b, 13c and 13e.  
The tetrasubstituted 12d with n = 3-(CH2)n-linkers to the morpholine group, showed particularly 
potent activity in the MIA PaCa-2 pancreatic carcinoma (0.011 M), A549 lung adenocarciona 
(0.019 M) and panc-1 pancreatic cell lines (0.003 M).  
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Compound 13c with n = 1-(CH2)n-linkers to the pyrrolidine ring, showed a particular selectivity 
against MIA PaCa-2 cell lines (0.012 M) and compound 13e with n = 3-(CH2)n-linkers to the 
pyrrolidine ring, exhibited selectivity against A549 cells (0.026 M).  
The small library of tri-substituted naphthalene diimides reported here shows a wide range of 
antiproliferative activity in this particular panel of cancer cell lines.  
 
In conclusion, tri-substituted derivatives 13a-j and the tetra-substituted derivative 12d have good G-
quadruplex stabilization ability and a low duplex DNA affinity. They inhibit cancer cell growth at 
low micro molar/high nano molar levels, suggesting that these correlated compounds may have 
potential as drug-like quadruplex targeting agents. 
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EXPERIMENTAL DATA 
General Methods 
All reagents, solvents and chemicals were purchased from Sigma-Aldrich UK, Alfa Aesar, 
Lancaster Synthesis, Flurochem, TCI and Fluka. Column chromatography was performed using 
BDH silica gel (BDH 153325P). Preparative HPLC was carried out with a Gilson apparatus 
combing a 322 pump and UV/VIS-155 detector with detection 280nm, using a C-18 5 (100 mm x 
20 mm) column (201022272) (W), YWC, Japan at a flow of 20 mL/min. Water and methanol 0.1% 
formic acid were used as HPLC solvents. NMR spectra were recorded at 400 or 500 MHz (
1
H NMR 
and 
13
C) on a Bruker spectrometer in CDCl3 (with 0.05% TMS Cambridge Isotope Laboratories 
USA), DMSO-d6 or D2O. NMR multiplicity abbreviations are s (singlet), bs (broad singlet), d 
(doublet), t (triplet) and m (multiplet). Coupling constants J are given in hertz (Hz). FRET 
biophysical testing was done using different DNA sequences: F21T, Hsp90A, Hsp90B, T-loop, 
KRas21, KRas32. The DNA sequences were purchased from Eurofins, MWG Synthesis, GmbH 
Germany.  
CHEMISTRY 
Synthesis of 4,9-dibromoisochromeno[6,5,4-def]isochromene-1,3,6,8-tetrone  (16) [43] 
In a round bottom flask to a solution of dibromoisocyanuric acid 15 (2.14 g, 7.46 mmol) dissolved 
in concentrated sulphuric acid (40 mL) a solution of isochromeno [6,5,4,-def]isochromene-1,3,6,8-
tetraone 14 (2 g, 7.46 mmol) dissolved in fuming sulphuric acid (80 mL) was added dropwise, over 
a period of 4 hours at 40 °C. The reaction mixture was stirred further for 1 h at 40 °C. After cooling 
at room temperature, the reaction mixture was poured onto ice affording a yellow precipitate. The 
precipitate was filtered using a sinter funnel under vacuum. The yellow product obtained was dried 
under vacuum and used without purification for the next step.  
 
4,9-dibromo-2,7-bis[3-(morpholin-4-yl)propyl]benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-
tetrone (18) [47] 
In a microwave reaction vessel compound 16 (0.13 g, 0.31 mmol) and 3-morpholino-propylamine 
17 (0.93 mmol, 0.14 mL) were suspended in acetic acid (5 mL) and refluxed for 30 minutes at 130 
°C under microwave irradiation.  This reaction was also carried out in a round bottom flask and it 
was stirred at 130 °C for 5 h. After cooling at room temperature, the solution was concentrated in 
vacuum and purified using reverse phase HPLC. Compound 18 was obtained as a red semi-solid 
(32% yield). 
1
H NMR (400 MHz, D2O)  2.27-2.24 (m, 4H, ArH), 3.31-3.29 (m, 4H, ArH), 3.40-
3.44 (m, 4H, ArH), 3.63-3.66 (m, 4H, ArH), 3.89-3.95 (m, 4H, ArH), 4.18-4.25 (m, 8H, ArH), 8.30 
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(s, 1H, ArH), 8.75 (s, 1H, ArH); 
13
C NMR (100 MHz, D2O )  21.7 (t), 38.5 (t), 51.7 (t), 54.7 (t), 
63.7 (t), 123.4 (d), 124.5 (s), 126.7 (d), 128.2 (s), 138.5 (s), 161.5 (s).  
Synthesis of 4,9-bis{[3-(4-methylpiperazin-1-yl)propyl]amino}-2,7-bis[3-(morpholin-4 
yl)propyl]benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone (12d) [42]  
Compound 18 (0.2 g, 0.295 mmol), 1 (3-aminopropyl)-4-methyl-piperazine (1.18 mmol, 0.20 mL) 
19 and NMP (2 mL) were suspendend in a microwave reaction vessel. After bubbling nitrogen 
through the solution, the tube was capped and heated at 130 °C for 30 minutes under microwave 
irradiation. After cooling at room temperature, the solvent was concentrated in vacuo and the crude 
mixture was purified by preparative HPLC. Compound 12d was obtained as blue oil (12% yield). 
1
H NMR (400 MHz, CDCl3) 1.99-1.88 (m, 8H, 4xCH2), 2.30 (s, 6H, 2xCH3), 2.53-2.44 (m, 30H, 
15xCH2), 3.57 (q, 4H, J = 6.8 Hz, 2xCH2), 3.61 (t, 8H, J = 4.4 Hz, 4xCH2), 4.24 (t, 4H, J = 6.8 Hz, 
2xCH2), 8.12 (s, 2H, ArH),t, J = 5.4 Hz, 2xNH); 
13
C NMR (100 MHz, CDCl3) 23.6 
(q), 25.6 (t), 37.8 (t), 40.3 (t), 44.5 (t), 51.7 (t), 52.5 (t), 53.6 (t), 54.6 (t), 55.5 (t), 65.9 (t), 100.9 (s), 
117.3 (d), 120.1 (s), 124.8 (d), 148.1(s), 162.1(s), 165.1 (s).
 
Synthesis of 4-bromoisochromeno[6,5,4-def]isochromene-1,3,6,8-tetrone (21) [44]  
In a single-necked round bottom flask isochromeno [6,5,4,-def]isochromene-1,3,6,8-tetraone 14 (0.8 
g, 2.98 mmol) was solubilized in concentrated sulphuric acid (6 mL) at room temperature. Dibromo 
hydantoin 20 (0.47 g, 1.64 mmol, 0.55 equ.) was added in portions over a period of 2 h and the 
reaction mixture was stirred at room temperature for 24 h. The reaction mixture was poured into ice 
affording a yellow precipitate. The solid was filtered and recrystallized from DMF to obtain the 
pure product as light yellow solid (83% of yield). Analytical and spectroscopic data are reported 
elsewhere [35].  
Synthesis of 4-bromo-2,7-bis[3-(morpholin-4-yl)propyl]benzo[lmn][3,8]phenanthroline-
1,3,6,8(2H,7H)-tetrone (22) [47] 
In a microwave reaction vessel 21 (0.13 mg, 0.31 mmol) and 3-morpholino-propylamine 17 (3 eq., 
0.93 mmol, 0.136 ml) were suspended in acetic acid (4.5 mL) and refluxed for 30 minutes at 125 °C 
under microwave irradiation.  After cooling at room temperature, the solution was concentrated and 
purified using reverse phase HPLC. Compound 22 was obtained as a red solid (20% yield).  
1
H NMR (400 MHz, CDCl3)  2.10 (q, 4H, J = 7.3 Hz, 2xCH2), 2.83-2.77 (m, 12H, 6xCH2), 3.76-
3.73 (m, 8H, 4xCH2), 4.28 (q, 4H, J = 7.2 Hz, 2xCH2), 8.75 (d, 1H, J = 7.6 Hz, ArH), 8.80 (d,1H, J 
= 7.6 Hz, ArH), 8.91 (s, 1H,ArH);
13
C NMR (100 MHz, CDCl3)  23.3 (t), 23.4 (t), 38.8 (t), 39.1 
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(t), 52.5 (t), 55.5 (t), 55.6 (t), 65.3 (t), 65.4 (t), 123.9 (d), 125.7 (s), 125.9 (d), 126.0 (d), 126.8 (s), 
128.7 (s), 128.8 (s), 130.7 (s), 131.7 (s), 138.4 (s), 161.2 (s), 161.9 (s), 162.0 (s), 162.6 (s). 
 
General procedure  
Synthesis of 4-{[3-(4-methylpiperazin-1-yl)propyl]amino}-2,7-bis[3-(morpholin-
4yl)propyl]benzo[lmn][3,8] phenanthroline-1,3,6,8(2H,7H)-tetrone (13a)  
Compound 22 (0.15 g, 0.25 mmol), 1(3-aminopropyl)-4-methyl-piperazine 19 (0.085 mL, 0.5 
mmol) and NMP (N-methyl-2-pyrrolidinone) (2 mL) were suspendend in a microwave reaction 
vessel. After bubbling nitrogen through the solution, the tube was capped and heated at 130 °C for 
25 minutes under microwave irradiation. After cooling at room temperature, the solvent was 
concentrated and the crude mixture was purified by reverse phase HPLC. Compound 13a was 
obtained as red oil (31% yield). 
1
H NMR (400 MHz, CDCl3) 2.09-1.98 (m, 6H, 3xCH2), 2.80-
2.62 (m, 21H, 9xCH2, 1xCH3), 3.17 (bs, 4H, 2xCH2), 3.69 (t, 6H, J = 5.0 Hz, 3xCH2), 3.749 (t, 4H, 
J = 4.5 Hz, 2xCH2), 4.23 (q, 4H, J = 6.73 Hz, 2xCH2), 8.23 (s, 1H, ArH), 8.31 (d, 1H, J = 7.8 Hz, 
ArH), 8.61 (d, 1H, J = 7.8 Hz, ArH), t J = 5.7 Hz,); C MNR (100 MHz, CDCl3)  
23.61 (q), 23.67 (t), 26.2 (t), 38.2 (t), 38.8 (t), 41.2 (t), 43.3 (t), 50.2 (t), 52.5 (t), 52.7 (t), 53.0 (t), 
54.5 (t), 55.7 (t), 65.5 (t), 65.7 (t), 99.9 (s), 119.4 (d), 119.7 (d), 123.4 (d), 124.6 (s), 126.1 (s), 
127.9 (s), 129.5 (s), 131.4 (s), 152.3 (s), 163.0 (s), 163.1 (s), 163.3 (s), 166.0 (s).  
 
Synthesis of 4-{[2-(4-methylpiperazin-1-yl)ethyl]amino}-2,7-bis[3-(morpholin-4 
yl)propyl]benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone (13b)  
Compound 22 (0.073 g, 0.12 mmol), 2-(4-methyl-piperazin-1-yl) ethylamine 23 (0.036 mL, 0.24 
mmol) and NMP (2 mL) were reacted according to General Procedure. Compound 13b was 
obtained as a red oil (12% yield). 
1
H NMR (400 MHz, CDCl3)  2.06-1.94 (m, 4H, 2xCH2), 2.53 
(bs, 4H, 2xCH2), 2.58-2.68 (m, 11H, 4xCH2 and 1xCH3), 2.85-2.89 (m, 6H, 2xCH2), 3.05 (bs, 4H, 
2xCH2), 3.61-3.63 (t, 4H, J = 4.4 Hz, 2xCH2), 3.66-3.72 (m, 6H, 3xCH2), 4.26 (q, 4H, J =8.2 Hz, 
2xCH2), 8.21 (s, 1H, ArH), 8.34 (d, 1H, J = 7.8 Hz, ArH), 8.64 (d, 1H, J = 7.8 Hz, ArH), 10.79 (t, 
1H, J = 4.9 Hz, NH); 
13
C NMR (100 MHz, CDCl3)  24.0 (q), 38.3 (t), 39.1 (t), 40.2 (t), 43.7 (t), 
50.4 (t), 52.9 (t), 53.1 (t), 53.6 (t), 55.8 (t), 56.0 (t), 56.1 (t), 66.1 (t), 66.4 (t), 100.3 (s), 119.5 (d), 
120.0 (d), 123.6 (s), 124.7 (d), 126.3 (s),128.0 (s), 129.5 (s), 131.4 (s), 152.1 (s), 163.0 (s), 163.1 
(s), 163.4 (s), 165.9 (s).  
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Synthesis of 2,7-bis[3-(morpholin-4-yl)propyl]-4-{[2-(pyrrolidin-1-
yl)ethyl]amino}benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone (13c)  
Compound 22 (0.15 g, 0.25 mmol), 1-(2-aminoethyl)pyrrolidine 24 (0.063 mL, 0.5 mmol) and 
NMP (2 mL) were reacted according to General Procedure. The crude mixture was purified by 
column chromatography (DCM/MeOH/NH3). Compound 13c was obtained as red oil (16% yield). 
1
H NMR (400 MHz, CDCl3) 2.04 (m, 8H, 4xCH2), 2.68-2.78 (m, 12H, 6xCH2), 3.19 (t, 4H, J = 
6.3 Hz, 2xCH2), 3.32 (t, 2H, J = 6.6 Hz, 1xCH2), 3.71 (t, 4H, J = 4.6 Hz, 2xCH2), 3.76 (t, 4H, t, J = 
4.6 Hz, 2xCH2), 4.01 (q, 2H, J = 6.5 Hz, 1xCH2), 4.22 (t, 4H, t, J =6.8 Hz, 2xCH2), 8.14 (s, 1H, 
ArH), 8.29 (d, 2H, J = 4.1 Hz, ArH), 8.56 (d, 1H, J = 7.8 Hz, ArH),tJ = 5.7 Hz, NH); 
13
C NMR (100 MHz, CDCl3) 23.3 (t), 23.6 (t), 23.7 (t), 38.2 (t), 38.8 (t), 40.0 (t), 52.6 (t), 52.7 
(t), 53.9 (t), 54 (t), 55.7 (t), 55.2 (t), 65.5 (t), 65.8 (t), 100.7 (s), 119.1 (d), 119.4 (d), 123.5 (s), 124.9 
(s), 126.1 (d), 128.0 (s), 129.2 (s), 131.4 (s), 151.8 (s), 162.7 (s), 162.8 (s), 163.2 (s), 165.9 (s).  
 
Synthesis of 2,7-bis[3-(morpholin-4-yl)propyl]-4-{[2-(pyridin-2-
yl)ethyl]amino}benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone (13d)  
Compound 22 (0.15 g, 0.25 mmol), 2-(2-pyridyl)ethyl amine 25 (0.06 mL, 0.5 mmol) and NMP (2 
mL) were reacted according to General Procedure. Compound 13d was obtained as a red oil (8% 
yield). 
1
H NMR (400 MHz, CDCl3)  1.90-1.96 (m, 4H, 2xCH2), 2.49-2.58 (m, 12H, 6xCH2), 3.22 
(t, 2H, J = 7.2Hz, 1xCH2), 3.57 (t, 4H, J = 4.8 Hz, 2xCH2), 3.61 (t, 4H, J = 4.4 Hz, 2xCH2), 3.99 (q, 
2H, J = 6.8 Hz, 1xCH2), 4.16-4.20 (m, 4H, 2xCH2), 7.11-7-13 (m, 1H, ArH), 7.14 (s, 1H, ArH), 
7.56-7.61 (m, 1H, ArH), 8.20 (s, 1H, ArH), 8.26 (d, 1H, J = 7.82 Hz, ArH), 8.56 (m, 2H, ArH), 
10.21 (t, 1H, J = 4.9 Hz, NH); 
13
C NMR (100 MHz, CDCl3) 23.2 (t), 24.2 (t), 37.6 (t), 37.7 (t), 
38.5 (t), 39.2 (t), 42.8 (t), 53.2 (t), 53.3 (t), 56.2 (t), 66.4 (t), 66.5 (t), 100.1 (s), 119.8 (d), 121.9 (d), 
123.5 (s), 123.6 (d), 124.5 (s), 126.2 (d), 128.0 (d), 129.5 (d), 131.3 (s), 136.8 (d), 149.7 (s), 152.3 
(s), 157.8 (s), 163.0 (s), 163.1 (s), 163.4 (s), 166.1 (s).  
 
Synthesis of 2,7-bis[3-(morpholin-4-yl)propyl]-4-{[4-(pyrrolidin-1-
yl)butyl]amino}benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone (13e)  
Compound 22 (0.10 g, 0.17 mmol), 4-(1-pyrrolidinyl)-1-butylamine 26 (0.051 mL, 0.33 mmol) and 
NMP (2 mL) were reacted according to General Procedure. Compound 13e was obtained as a red 
oil (15% yield). 
1
H NMR (400 MHz, CDCl3) 1.75-1.84 (m, 12H, 6xCH2), 2.32 (d, 8H, J = 4.0 
Hz, 4xCH2), 2.38-2.42 (m, 4H, 2xCH2), 2.54 (d, 6H, J = 6.8 Hz, 3xCH2), 3.44-3.52 (m, 10, 5xCH2), 
4.18 (bs, 4H, 2xCH2), 8.09 (s, 1H, ArH), 8.23 (d, 1H, J = 7.8 Hz, ArH), 8.54 (d, 1H, J = 7.8 Hz, 
ArH), 10.03 (t, 1H, J = 5.36 Hz, NH); 
13
C NMR (100 MHz, CDCl3)  23.2 (t), 23.4 (t), 23.7 (t), 
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23.8 (t), 26.7 (t), 38.3(t), 38.9 (t), 42.4 (t), 52.7(t), 52.8 (t), 53.3 (t), 54.7 (t), 55.8 (t), 55.9 (t), 65.7 
(t), 66.0 (t), 100.2 (s), 119.50 (d), 119.6 (d), 123.6 (s), 124.7 (d), 126.3 (s), 128.1 (s), 129.5 (s), 
131.5 (s), 152.3 (s), 162.9 (s), 163.1 (s), 163.4 (s), 166.2 (s).  
 
Synthesis of 2,7-bis[3-(morpholin-4-yl)propyl]-4-{[2-(piperidin-1-
yl)ethyl]amino}benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone (13f)  
Compound 22 (0.10 g, 0.17 mmol), 1-(2-aminoethyl)piperidine 27 (0.05 mL, 0.33 mmol) and NMP 
(2 mL) were reacted according to General Procedure. Compound 13f was obtained as a red oil (12% 
yield). 
1
H NMR (400 MHz, CDCl3) 1.52-1.55 (m, 2H, CH2), 1.69-1.75 (m, 4H, 2xCH2), 1.93-
2.02 (m, 4H, 2xCH2), 2.51-2.62 (m, 12H, 6xCH2), 2.68 (bs, 4H, 2xCH2), 2.87 (t, 2H, J = 6.5 Hz, 
1xCH2), 3.61 (t, 4H, J = 4.5 Hz, 2xCH2), 3.67 (t, 4H, J = 4.5 Hz, 2xCH2), 3.78 (q, 2H, J = 6.2 Hz, 
CH2), 4.25 (q, 4H, J = 8.6 Hz, 2xCH2), 8.18 (s, 1H, ArH), 8.30 (d, 1H, J = 7.8 Hz, ArH), 8.61 (d, 
1H, d, J = 7.8 Hz, ArH), 10.24 (t, 1H, t, J = 5.0 Hz, NH); 
13
C NMR (100MHz, CDCl3) 23.8 (t), 
24.2 (t), 25.2 (t), 38.5 (t), 39.1 (t), 39.9 (t), 40.0 (t), 53.1 (t), 53.2 (t), 54.3 (t), 56.2 (t), 56.8 (t), 66.4 
(t), 66.5 (t), 100.3 (s), 119.5 (d), 119.8 (s), 123.6 (d), 124.5 (d), 126.2 (s), 128.0 (s), 129.5 (s), 131.3 
(s), 152.0 (s), 162.9 (s), 163.1 (s), 163.4 (s), 165.9 (s).  
 
Synthesis of 4-{[2-(4-hydroxyphenyl)ethyl]amino}-2,7-bis[3-(morpholin-4-
yl)propyl]benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone [13g]  
Compound 22 (0.14 g, 0.23 mmol), tyramine-hydrocloride 28 (0.08 g, 0.46 mmol), NMP (2 mL) 
and triethylamine (0.46 mmol, 0.065 mL) were suspendend in a microwave reaction vessel. After 
bubbling nitrogen through the solution, the tube was capped and heated at 130 °C for 25 minutes 
under microwave irradiation. After cooling at room temperature, the solvent was concentrated in 
vacuo and the crude mixture was purified by column chromatography on a silica gel (DCM, MeOH, 
NH3). Compound 13g was obtained as red oil (23% yield). 
1
H NMR (400 MHz, DMSO-d6)  1.75-
1.82 (m, 4H, 2xCH2), 2.31-2.44 (m, 12H, 6xCH2), 2.90 (t, 2H, J = 6.7 Hz, CH2), 3.41-3.44 (m, 8H, 
4xCH2), 3.70 (d, 2H, J = 5.8, 1xCH2), 4.02 (bs, 4H, 2xCH2), 6.71-6.73 (m, 2H, ArH), 7.14-7.16 (m, 
2H, ArH), 7.84 (s, 1H, ArH), 8.02 (d, 1H, J = 7.7 Hz, ArH), 8.31 (d, 1H, d, J = 7.7 Hz, ArH), 9.86 
(s, 1H, OH); 
13
C NMR (100 MHz, CDCl3) 24.3 (t), 24.6 (t), 29.7 (t), 35.2 (t), 38.4 (t), 44.9 (t), 
53.4 (t), 53.5 (t), 56.2 (t), 56.4 (t), 66.6 (t), 66.8 (t), 116.0 (d), 116.1 (d), 119.5 (s), 120.2 (s), 124.6 
(d), 126.2 (s), 130.2 (d), 131.3 (d), 145.4 (s), 152.8 (s), 155.3 (s), 163.0 (s), 163.2 (s), 163.5 (s), 
165.7 (s). 
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Synthesis of 4-{[2-(morpholin-4-yl)ethyl]amino}-2,7-bis[3-(morpholin-4-
yl)propyl]benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone [13h]  
Compound 22 (0.06 g, 0.1 mmol), 4-(2-aminoethyl) morpholine 29 (0.03 mL, 0.2 mmol), NMP (1 
mL) were reacted according to General Procedure. The crude mixture was purified by column 
chromatography (DCM/MeOH). Compound 13h was obtained as red oil (23% yield). 
1
H NMR (500 
MHz, CDCl3) 1.89-1.98 (m, 4H, 2xCH2), 2.41-2.45 (m, 8H, 4xCH2), 2.51 (q, 4H, J = 6.9 Hz, 
2xCH2), 2.59 (t, 4H, J = 4.5 Hz, 2xCH2), 2.80 (t, 2H, J = 6.2 Hz, 1xCH2), 3.56 (t, 4H, J = 4.5 Hz, 
2xCH2), 3.62 (t, 4H, J = 4.5 Hz, 2xCH2), 3.68 (q, 2H, J = 5.9 Hz, 1xCH2), 3.78 (t, 4H, J = 4.5 Hz, 
2xCH2), 4.24-4.30 (m, 4H, 2xCH2), 8.21 (s, 1H, ArH), 8.33 (d, 1H, J = 7.8 Hz, ArH), 8.64 (d, 1H, J 
= 7.8 Hz, ArH), 10.34 (t, 1H, J = 4.5 Hz, NH); 
13
C NMR (100 MHz, CDCl3) 
ttttttttttt
tts(dsddss)s)
ss), sss 
 
Synthesis of 2,7-bis[3-(morpholin-4-yl)propyl]-4-[(tetrahydrofuran-2-
ylmethyl)amino]benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone [13i]  
Compound 22 (0.06 g, 0.1 mmol), racemic tetrahydrofurfurylamine 30 (0.021 mL, 0.21 mmol), 
NMP (1 mL) were reacted according to General Procedure. The crude mixture was purified by 
column chromatography (DCM/MeOH). Compound 13i was obtained as red oil (17% yield). 
1
H 
NMR (500 MHz, CDCl3) 1.26-1.77 (m, 4H, 2xCH2), 1.94-2.18 (m, 8H, 4xCH2), 2.43-2.51 (m, 
10H, 5xCH2), 3.64-3.56 (m, 8H, 4xCH2), 3.74-4.0 (m, 2H), 4.25-4.28 (m, 4H, 2xCH2), 8.27 (s, 1H, 
ArH), 8.34 (d, 1H, J = 7.7 Hz, ArH), 8.65 (d, 1H, J = 7.7 Hz, ArH), (s, 1H, NH); 13C NMR 
(100 MHz, CDCl3) 24.4 (t), 24.6 (t), 25.9 (t), 29.2 (t), 38.7 (t), 39.3 (t), 47.3 (t), 53.6 (t), 56.5 (t), 
56.6 (t), 66.9 (t), 67.0 (t), 68.6 (t), 100.2 (t), 119.5 (d), 120.0 (d), 123.7 (s), 124.5 (d), 126.2 (s), 
127.9 (s), 129.5 (s), 131.2 (s), 152.5 (s), 163.1 (s), 163.2 (s), 163.4 (s), 166.2 (s). 
 
Synthesis of 4-{[2-(diethylamino)ethyl]amino}-2,7-bis[3-(morpholin-4-
yl)propyl]benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetrone [13j]  
Compound 22 (0.024 g, 0.04 mmol), 2-diethylamino ethylamine 31 (0.08 mmol, 0.011 mL,), NMP 
(1 mL) were reacted according to General Procedure. The crude mixture was purified by column 
chromatography (DCM/MeOH/NH3). Compound 13j was obtained as red oil (60 % of yield). 
1
H 
NMR (500 MHz, CDCl3) 1.08-1.11 (m, 6H, 2xCH3), 1.90-2.98 (m, 4H, 2xCH2), 2.43-2.54 (m, 
12H, 6xCH2), 2.67 (q, 4H, J = 6.6 Hz, 2xCH2), 2.86 (t, 2H, J = 6.0 Hz, 1xCH2), 3.57 (t, 4H, J = 4.4 
Hz, 2xCH2), 3.61-3.65 (m, 6H, 3xCH2), 4.23-4.30 (m, 4H, 2xCH2), 8.21 (s, 1H, ArH), 8.31 (d, 1H, 
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J = 7.8 Hz, ArH), 8.62 (d, 1H, J = 7.8 Hz, ArH),(t, 1H, J = 4.9 Hz, NH); 13C NMR (100 
MHz, CDCl3) : 11.8 (q), 24.4 (t), 24.5 (t), 38.6 (t), 39.3 (t), 47.1 (t), 51.6 (t), 53.5 (t), 53.56 (t), 
56.5 (t), 66.9 (t), 100.1 (s), 119.4 (d), 120.2 (d), 123.7 (s), 124.3 (d), 126.2 (s), 127.8 (s), 129.6 (s), 
131.2 (s), 152.1 (s), 163.1 (s), 163.2 (s), 163.5 (s), 165.9 (s).  
 
BIOPHYSICAL STUDIES: FRET ASSAY 
The ability of the naphthalene diimide compounds to stabilize DNA sequences was investigated 
using a fluorescence resonance energy transfer (FRET) assay modified to be used as a high-
throughput screen in a 96-well format. Several quadruplex sequences were studied (including the 
human telomeric G-quadruplex DNA sequence 5'-FAM-d(GGG[TTAGGG]3)-TAMRA-3' and the 
duplex sequence 5'-FAM-dTATAGCTATA-HEG-TATAGCTATA-TAMRA-3' (HEG linker: [(-
CH2-CH2-O-)6.  
The labelled oligonucleotides have attached to them the donor fluorophore FAM: 6-
carboxyfluorescein and the acceptor fluorophore TAMRA: 6-carboxytetramethylrhodamine. The 
FRET probe sequences were diluted from stock to the correct concentration (400 nM) in a 60 mM 
potassium cacodylate buffer (pH 7.4) and then annealed by heating to 85 °C for 10 min, followed 
by cooling to room temperature in the heating block. The compound was stored as a 10 mM stock 
solution in DMSO; final solutions (at 2 × concentration) were prepared using 10 mM HCl in the 
initial 1:10 dilution, after which 60 mM potassium cacodylate buffer (pH 7.4) was used in all 
subsequent steps. The maximum HCl concentration in the reaction volume (at a ligand 
concentration of 20 µM) is thus 200 µM, well within the range of the buffer used. Relevant controls 
were also performed to check for interference with the assay. 96-Well plates (MJ Research, 
Waltham, MA) were prepared by aliquoting 50 µl of the annealed DNA into each well, followed by 
50 µl of the compound solutions. Measurements were made on a DNA Engine Opticon (MJ 
Research) with excitation at 450–495 nm and detection at 515–545 nm. Fluorescence readings were 
taken at intervals of 0.5 °C in the range 30–100 °C, with a constant temperature being maintained 
for 30 s prior to each reading to ensure a stable value. Final analysis of the data was carried out 
using a script written in the program Origin 7.0 (OriginLab Corp., Northampton, MA). The 
advanced curve-fitting function in Origin 7.0 was used for calculation of ΔTm values. All 
determinations were performed in triplicate or better. Esds in ΔTm are ± 0.1 °C. 
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IN VITRO CELL ASSAY 
Cell culture and cytotoxicity testing. Human cancer cell lines and the somatic human cell line WI-
38 (lung fibroblast) were purchased from ATCC. Cell lines were maintained in appropriate medium 
supplemented with 10 % foetal bovine serum (Invitrogen, UK), 2 mM L-glutamine (Invitrogen, 
Netherlands), and other components as specified by the suppliers. Cell lines were maintained at 37 
°C, 5% CO2 and routinely passaged. Drugs were dissolved in DMSO and filtered through 0.22 µm 
pore-size filter units before addition to cell line appropriate media. Cellular growth inhibition was 
measured using the sulforhodamine B (SRB) assay in 96 well plates as described previously [39, 
48]. Fifty percent inhibitory concentrations (IC50) were determined by taking the mean absorbance 
at 540 nm for each drug concentration expressed as a percentage of the absorbance of untreated 
control wells. For qRT-PCR analysis, Mia PaCa-2 cells were seeded to a density equivalent to that 
used for IC50 determinations in T75 culture flasks and grown for 24 h in 10 ml DMEM to allow 
attachment before addition of compounds to the culture medium. Following compound exposure, 
cells were washed twice in PBS, harvested by trypsinisation, collected by centrifugation (300 g, 5 
min, 4°C) and re-suspended in RLT buffer (Qiagen). Samples were homogenised using 
QIAshredder spin columns and stored at -80 °C prior to RNA extraction. Three biological replicates 
were performed on separate days. 
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DISCOVERY OF NEW G-QUADRUPLEX BINDING CHEMOTYPES 
 (SCHOOL OF PHARMACY, UCL) 
 
INTRODUCTION 
During the months spent at the UCL School of Pharmacy, I have been involved in a collaboration 
concerning the synthesis of new G-quadruplex binding chemotypes, which was object of a 
publication [1]. In particular, I have dealt with the high-throughput 96-well FRET (Fluorescence 
Resonance Energy Transfer) assay of some acyclic furan- and thiophene based compounds (1-6), in 
order to evaluate the ability to stabilize G-quadruplex sequences.  
  
G-quadruplexes are high-order nucleic acid arrangements involving a core - stacked guanine-
quartets (G-quartets) [2]. The targeting of quadruplex DNA sequences in telomers and in oncogene 
promoter regions is emerging as a novel approach to anticancer therapy, mainly because the 
existence of quadruplex DNA with nucleic acid motifs distinct from double stranded DNA has been 
validated at genomic level [3].  
A large number of small molecules have been reported as G-quadruplex binding ligands [4, 5, 6].  
Only few small molecules that interact with G-quadruplex DNA have achieved in vivo studies in 
models of human cancer, such as quarfloxacin, a fluoroquinolone derivative which has reached 
clinical trials [7].  
 
RESULTS AND DISCUSSIONS 
Thirty-eight members of a large chemical library from the anti-parasitic drug discovery programme 
at Georgia State University (several hundred compounds) [8, 9] with very different scaffolds and 
functional groups, were screened using a high-throughput 96-well FRET (Fluorescence Resonance 
Energy Transfer) assay [10]. G4 stabilization was initially evaluated using dual-labelled F21T 
(human telomeric 21-mer) and c-KIT2 (a tyrosine kinase oncogene) G-quadruplex sequences, as 
well as a duplex DNA sequence (T-loop). The ten most active compounds were subsequently 
screened against an expanded panel of fluorescently-labelled promoter G4-forming sequences, with 
Hsp90A, Hsp90B (heat shock protein 90 promoter sequences), Kras21 (in the promoter of the k-
RAS oncogene) and AR, a G-quadruplex sequence recently identified in the promoter of the 
androgen receptor (involved in prostate cancer development) [11]. Six acyclic furan- and thiophene-
based compounds 1-6 showed high Tm values (>15 °C) (Fig. 1).    
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Figure 1. Structures of compounds 1-6, a control compound 7 and tetra-substituted naphthalene 
diimide 10d.  
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Table 1.  FRET G4 stabilization (Tm at 1 M in °C). Compound 7, a negative control, is a para 
analogue of the mono-furan compounds. Compound 10d is a tetra-substituted naphthalene diimide 
derivative used here as a G4 control [12]. 
 
Compd Mol. Wt F21T c-KIT2 Hsp90A Hsp90B Kras21R AR T-Loop 
1 384.5 22.3 16.8 27.7 23.7 19.6 15.4 <2 
2 364.4 20.4 16.3 26.0 22.0 18.5 13.8 <2 
3 330.5 17.6 17.8 21.2 18.1 15.1 11.9 2.2 
4 372.5 18.0 13.9 22.5 19.1 15.9 10.2 <2 
5 412.5 22.6 18.5 26.6 22.7 18.3 14.7 <2 
6 350.3 18.6 n/a 20.6 16.2 13.4 10.1 <2 
7 302.5 14.4 12.2 19.0 15.7 16.6 9.9 3.4 
10d 830.6 26.6 22.0 33.1 28.6 n/a 15.9 4.9 
 
All six compounds showed potent G-quadruplex stabilizing properties, as demonstrated by the large 
Tm values for the selected G-quadruplex sequences. In particular, the bis-phenyl-mono-furan 
compounds 1 and 5 had very high Tm values, widely comparable to those reported for tetra-
substituted naphthalene dimmides [12]. The tri-furan compound 2 is much more active in stabilizing 
the G-quadruplex than the polyfuran compound 6. 
Generally, F21T and the two Hsp90 G-quadruplex sequences have been most stabilized by 
compound 1-6.  
Comparing the stabilizing properties against AR G-quadruplex sequence of compounds 1-6 with the 
tetra-substituted naphthalene diimides alredy published [11], it is possible to observe that compound 
1-6 exhibited only moderate Tm values, which are generally lower than with the other G-
quadruplexes. Compounds 1-6 produced slightly reduced but still significant stabilization of c-KIT2 
and Kras21 G-quadruplexes, suggesting that these compounds have the ability to act simultaneously 
on multiple G-quadruplex sequences (G4-poly-targeting). In general for all the compounds the 
stabilization of the duplex DNA sequence (T-Loop) was not significant at the biologically relevant 
concentrations employed (1M) and compounds 1 and 5 exhibited a particular selectivity for G-
quadruplexes versus duplex DNA. A control compound 7, an established duplex DNA minor 
groove binder, also showed a significant stabilization, although with higher effects on the duplex 
DNA.  
In conclusion, these compounds are structurally-simple, chemically readily accessible with MW 
<400 Da. They have G-quadruplex stabilisation ability comparable to those previously observed 
with polycyclic heteroaromatic compounds [12] (such as compound 8, showed in Table 1), but with 
low duplex DNA affinity. 
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EXPERIMENTAL DATA 
 
CHEMISTRY 
Synthesis was performed at Georgia State University. 
 
BIOPHYSICAL STUDIES: FRET ASSAY 
The ability of the compounds to stabilize DNA sequences was investigated using a fluorescence 
resonance energy transfer (FRET) assay modified to be used as a high-throughput screen in a 96-
well format. Several quadruplex sequences were studied (including the human telomeric G-
quadruplex DNA sequence 5'-FAM-d(GGG[TTAGGG]3)-TAMRA-3' and the duplex sequence 5'-
FAM-dTATAGCTATA-HEG-TATAGCTATA-TAMRA-3' (HEG linker: [(-CH2-CH2-O-)6.  
The labelled oligonucleotides have attached to them the donor fluorophore FAM: 6-
carboxyfluorescein and the acceptor fluorophore TAMRA: 6-carboxytetramethylrhodamine. The 
FRET probe sequences were diluted from stock to the correct concentration (400 nM) in a 60 mM 
potassium cacodylate buffer (pH 7.4) and then annealed by heating to 85 °C for 10 min, followed 
by cooling to room temperature in the heating block. The compound was stored as a 10 mM stock 
solution in DMSO; final solutions (at 2 × concentration) were prepared using 10 mM HCl in the 
initial 1:10 dilution, after which 60 mM potassium cacodylate buffer (pH 7.4) was used in all 
subsequent steps. The maximum HCl concentration in the reaction volume (at a ligand 
concentration of 20 µM) is thus 200 µM, well within the range of the buffer used. Relevant controls 
were also performed to check for interference with the assay. 96-Well plates (MJ Research, 
Waltham, MA) were prepared by aliquoting 50 µl of the annealed DNA into each well, followed by 
50 µl of the compound solutions. Measurements were made on a DNA Engine Opticon (MJ 
Research) with excitation at 450-495 nm and detection at 515-545 nm. Fluorescence readings were 
taken at intervals of 0.5 °C in the range 30-100 °C, with a constant temperature being maintained 
for 30 s prior to each reading to ensure a stable value. Final analysis of the data was carried out 
using a script written in the program Origin 7.0 (OriginLab Corp., Northampton, MA). The 
advanced curve-fitting function in Origin 7.0 was used for calculation of ΔTm values. All 
determinations were performed in triplicate or better. Esds in ΔTm are ± 0.1 °C. 
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